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too much on one poor little brain that is almost non-existent already. (...)
Of course, if I can really do it it will be rather priceless ...”
– Dorothy Crowfoot Hodgkin (1910 - 1994)
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1. Theoretical Background and Methods
1

Theoretical Background and Methods
1.1. X-ray diffraction
The discovery of X-rays and the subsequent detection of diffraction of X-rays by crystals
by Max von Laue mark the beginning of crystallography (Eckert, 2012). Using X-ray
diffraction (XRD), the first crystal structure was solved by William Henry Bragg and his
son William Lawrence Bragg in 1915 (Bragg, 1962). The Bragg equation (Equation 1.1)
describes the interference of light waves with a point lattice.
dmin =
λ
2 sin θ (1.1)
Macromolecular crystallography evolved into the primary method for determining
macromolecular structures and provides insight to the function of proteins and their
complex assemblies through detailed structure models.
Still, the availability of well diffracting crystals remains a prerequisite. X-ray radiation
interacts with matter through an oscillating electric field vector which interacts with
electrons by polarization. As a result of this interaction the electrons emit electromagnetic
waves of the same frequency. Superposition of this electromagnetic waves give rise to
interference. This diffraction phenomena results in a diffraction pattern as a sum of all
scattering events. One has to keep in mind that electrons are not located at grid points
in a lattice but moving around atomic nuclei which are distributed in the crystal in an
ordered fashion.
The diffraction pattern is recorded in the form of Bragg reflections hkl with specific
intensities. The intensities of all unique reflections are used to reconstruct the electron
density of the molecule that gave rise to the diffraction pattern. All scattering contributions
of each atom in all unit cells to a reflection are described in the form of a structure factor.
The amplitude of the structure factor of a reflection is used to reconstruct the electron
density in the crystal by calculating the Fourier summation. The Fourier transformation
needs both the amplitudes and the phases of the experiment to reconstruct the electron
density. Since only the amplitudes are measured during XRD, the phases must be
3
recovered – this phenomenon is known as the phase problem.
A comprehensive overview of the fundamentals of crystallography is provided by
Giacovazzo et al. (2011), Massa (2009), Borchardt-Ott (2012), and Rupp (2011).
1.1.1. Anomalous diffraction
Friedel pairs are reflections related by inversion through the origin (North, 1965). The
intensities of a Friedel pair of reflections (hkl and h¯k¯l¯) are approximately equivalent and
their phase is opposite, known as Friedel’s law.
Absorption and subsequent re-emission of X-ray photons coupled with ionisation of the
atom is known as anomalous scattering. Anomalous scattering generates anomalous
differences in the structure factor amplitudes of symmetry related reflections. Due to
the anomalous scattering contribution, Friedel’s law breaks down and the reflections are
forming Bijvoet pairs with different amplitudes.
The anomalous differences can be utilized for experimental phasing of crystal struc-
tures. The absorption of X-ray radiation decreases with increasing wavelength. At a
given wavelength the mass absorption coefficient is higher for heavier elements than for
light elements. This correlation is used in the structure determination of macromolecular
structures (Rossmann, 1961). Heavy elements or metals can be incorporated into the
crystal to facilitate anomalous diffraction at shorter wavelength that are experimentally
more easy to access (Garman and Murray, 2003). For some biomolecules intrinsic ele-
ments can be used, such as phosphorus in deoxyribonucleic acid (DNA) or ribonucleic
acid (RNA) and sulfur in proteins (North, 1965). Hendrickson and Teeter (1981) solved
the structure of Crambin solely from anomalous signal of intrinsic sulfur atoms. Other
methods for the incorporation of anomalous scatterers are co-crystallization or soaking
of the crystal with suitable compounds (Taylor, 2010).
1.2. Quality indicators in X-ray diffraction1
Collecting accurate intensities for all Bragg reflections hkl is a critical objective of any
XRD experiment. Various quality indicating parameters have been established over the
years to evaluate the XRD experiment.
1The definitions in this chapter are based on the collection as presented in the International Tables for
Crystallography, Volume F (Arnold et al., 2012).
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1.2. QUALITY INDICATORS IN X-RAY DIFFRACTION
1.2.1. Quality indicators in general
Both random error and systematic error influence the measured intensities. It is the goal
of early data processing to separate the true signal from the noise. Relative random
errors can be reduced by increasing exposure time. Systematic errors are approximately
proportional to measured intensities.
Systematic errors can occur due to technical or macroscopic aspects of the experiment,
e.g. beam instability in flux or direction, due to the shutter or vibration of the crystal in
the cryo-stream. Also radiation damage, absorption of the loop or detector issues such
as overloads or shadows can add to the systematic error. These are only a few of the
possible problems adding to the observed overall error and are only partially under the
control of the experimenter.
Random error is the chance that not the most likely number of diffraction events was
observed. This is due to the fact that diffraction events follow a Poisson distribution.
One has to distinguish between accuracy and precision when evaluating the errors
influencing the measured intensities. Precision quantifies the average deviation of a
series of measurements from its mean value. It can be understood as the internal
consistency of the signal. Accuracy describes the deviation of the collected values
from the true values. Accuracy is generally more important than precision. While low
precision yields imprecise results, low accuracy leads to wrong results. The goal of the
experimenter is the optimization of both accuracy and precision.
To describe the quality of a data set, numerous quality indicators have been defined
over the time and their convenience is often dependent on the intent of their use. Many
indicators of data quality are dependent on estimates for the standard uncertainties
(ss.u.s) and therefore on the methods for estimating them. All initial estimates of the
s.u.s of each intensity observation are generally underestimated by integration programs
(Evans and Murshudov, 2013). It should be noted that most quality indicators can only
describe the precision of the collected signal and not the accuracy (Diederichs, 2016).
Since the accuracy is not available for direct evaluation, the minimization of undetected
errors is significant for data collection and processing.
In the following sections the most commonly used quality indicator, and those used in
this thesis are discussed.
Determination of the resolution
Early definitions of the resolution of a data set were subjective and dependent on the
experimenter, like the nominal resolution dmin. Here, the limit is defined as a fraction of
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the unique reflections, e.g. 70%, that are above a threshold, for example set at three
times their s.u.s. Another definition is the midpoint of the resolution range of the shell at
which the mean signal-to-noise ratio falls below 2.
The true resolution dtrue is given as the minimum distance between two objects in a
crystal that permits their images in the resulting electron density map to be resolved.
When two equivalent atoms are represented by Gaussians, they can be considered
resolved when the electron density value drops to zero at midpoint between them2.
A consistent use of the resolution of data sets is favorable since it is often used to
determine the resolution cutoff, not only during model refinement but integration as well.
In this work the resolution of a data set is defined by quality indicators that are
discussed in the following sections. The resolution is used to define the point to which
diffraction images are integrated during data processing.
1.2.2. Data quality of unmerged intensities
Crystallographic residual index factors (R-factors) are widely used as a measure of data
or model quality (Einspahr and Weiss, 2012).
Merging R factor
The merging R factor Rmerge describes the spread of the individual intensity measure-
ments Ii of a reflection hkl around the mean intensity 〈I(hkl)〉 of this reflection.
Rmerge =
∑
hkl
∑
i |Ii(hkl)− 〈I(hkl)〉|∑
hkl
∑
i Ii(hkl)
(1.2)
The sums run over all observed unique reflections (hkl) and over all individual obser-
vations i of a given reflection.
Rmerge is dependent on the multiplicity of a data set (Diederichs and Karplus, 1997,
Weiss, 2001, Weiss and Hilgenfeld, 1997). The Rmerge will be higher with a higher
multiplicity of the data set. This conflicts with the statistical expectations, that averaged
intensities values should be more precisely determined. Therefore, the merging R
factor proved not useful as general data quality indicator for diffraction data (Evans and
Murshudov, 2013, Weiss, 2001). Nonetheless, Rmerge ≥ 0.6 – 0.8 has been used to
determine the resolution cutoff for a long time (Karplus and Diederichs, 2012).
2This is not a reasonable criteria for atoms in molecules as they are found in real crystals.
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Redundancy independent merging R factor
The precision of the individual intensity measurement is better described with the
redundancy independent merging R factor (Rrim or Rmeas). The Rrim is independent from
the number of observations of the individual reflection.
Rmeas = Rrim =
∑
hkl{ N(hkl)N(hkl)−1}1/2 ·
∑
i |Ii(hkl)− 〈I(hkl)〉|∑
hkl
∑
i Ii(hkl)
(1.3)
〈I(hkl)〉 describes the mean of the N(hkl) individual measurements Ii(hkl) of the
intensity of a reflection hkl. Rrim should be substituted for the conventional Rmerge
(Diederichs and Karplus, 1997, Weiss, 2001, Weiss and Hilgenfeld, 1997).
Mean signal-to-noise ratio
As a measure of the overall precision of a data set, the mean signal-to-noise ratio
〈I/σ(I)〉 (mean I/σ(I)) finds broad application. It describes the statistical significance
of a measured intensity and for all reflections the averaged intensity as a multiple of
the s.u.s. There are two definitions of 〈I/σ(I)〉 that find application in macromolecular
crystallography:
〈I(hkl)〉
σ[I(hkl)] =
〈I(hkl)〉
[( 1N )|Ii(hkl)− 〈I(hkl)〉|2]1/2
and
〈I(hkl)〉
σ〈I(hkl)〉 =
〈I(hkl)〉
[( 1N )
∑
i σi(hkl)2]1/2
.
(1.4)
The first definition describes the ratio of the mean intensity 〈I(hkl)〉 to the root mean
squared (r.m.s.) scatter of the individual reflections about that mean. It does not take
into account multiplicity or redundancy of reflections.
The second definitions describes the average of all observations of the reflection
(hkl). Here σi(hkl) describes the experimental s.u. of the individual measurement and
σ〈I(hkl)〉 is the propagation-of-error combination.
The mean signal-to-noise ratio of the outer resolution shell is often used to define the
nominal resolution of a data set. Furthermore, this is used as indicator for the highest
resolution shell that should be used for refinement (Wang, 2010). It is common practice
to define mean I/σ(I) ∼ 2 as integration limit during data reduction. The indicator is
depending on σ(I), which can be mis-estimated (Evans, 2006, 2011).
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Asymptotic signal-to-noise ratio
A visual representation of the data quality is a plot of I/σ(I)asymptotic against the resolution.
ISa is the highest observed asymptotic signal-to-noise ratio of a data set (Diederichs,
2010). The sigmoidal curve reaches an upper limit that can serve as a guide for the data
quality. The limit should be as high as possible and is sensitive to systematic errors –
instrument errors manifesting themselves in the data set. The sensitivity for systematic
error arises from the approximate independence of random error for very high values
(Diederichs, 2016). The measure is nearly independent from counting statistics, provided
radiation damage is negligible. Maximizing ISa should be the goal of data processing
and is an indicator of a good data set in general. Diederichs (2016) suggested that an
ISa ∼ 30 is as high as can be achieved from a charge-coupled device (CCD) detector
and indicates a good data set.
1.2.3. Precision of averaged reflections
Precision-indicating merging R factor
Especially to describe the precision of the averaged intensity measurements, the Rpim
was introduced analogous to Rrim.
Rpim =
∑
hkl{ 1N(hkl)−1}1/2 ·
∑
i |Ii(hkl)− 〈I(hkl)〉|∑
hkl
∑
i Ii(hkl)
(1.5)
The Rpim accounts for the increase in precision of the intensities when merging more
observations. Decreasing with increasing redundancy, the Rpim is also a useful statistic
for the estimation of data quality for anomalous diffraction data sets (Weiss, 2001).
Correlation coefficient
The Pearson correlation coefficient was adapted as a measure of data quality in the
form of CC1/2 (Diederichs and Karplus, 2013, Evans and Murshudov, 2013, Karplus
and Diederichs, 2012). This precision indicator describes the correlation between two
random subsets of the merged intensities (Evans, 2006). CC1/2 is independent of
estimated standard deviations of intensities and does not suffer an increase through
most systematic errors (Diederichs, 2016, Diederichs and Karplus, 2013). It has been
suggested to integrate and process raw data up to a CC1/2 of 10% and deposit it with
the final structure (Diederichs, 2016, Karplus and Diederichs, 2015). Including all data
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until a CC1/2 ∼ 20% can improve the solution and resulting model quality (Wang, 2010)
compared to data truncated at cutoff limit given by Rmerge.
1.2.4. Data quality of the anomalous signal
The presence and accuracy of anomalous signal is of special interest for anomalous
scattering phasing procedures. When averaging multiple data sets from a single crystal
or from multiple crystals (MCA), the quality of the merged data set is often the crucial
criterion for the success of the structure solution (Akey et al., 2014). In difficult cases only
the use of high-multiplicity data from multiple samples was effective for the solution of the
anomalous scatterers’ substructure (Akey et al., 2014, Liu et al., 2012). It has become
common practice to use the peak wavelength alone to collect data for single-wavelength
anomalous diffraction (SAD) phasing (Rice et al., 2000). The efficiency of merging with
respect to the anomalous signal is therefore often the crucial step for further success
(Akey et al., 2014). The quality of the averaged measurements can be evaluated by
indicators specific for the anomalous signal.
Anomalous merging R factor
The anomalous R factor Ranom is used to describe the anomalous signal strength.
Ranom =
∑
hkl |I(hkl)− I(h¯k¯l¯)|∑
hkl〈I(hkl)〉
(1.6)
with 〈I(hkl)〉 = 12 [I(hkl) + I(h¯k¯l¯)]. The ratio between Rpim and Ranom has been
suggested as an indicator of the strength of the anomalous signal of a data set (Panjikar
and Tucker, 2002). When the ratio of the precision indication R value and the anomalous
merging R value (Rpim/Ranom) exceeds 1.5, the substructure solution with the anomalous
differences becomes achievable (Weiss, 2001).
Anomalous correlation coefficient
With a better understanding of factors influencing the quality of the data, the anomalous
correlation coefficient CCanom was introduced (Zwart, 2005).
CCanom =
∑(x− 〈x〉)(y − 〈y〉)
[∑(x− 〈x〉)2∑(y − 〈y〉)2]1/2 , (1.7)
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where x and y are the anomalous differences [I(hkl)− I(h¯k¯l¯)] in the two data sets
and 〈x〉 and 〈y〉 are their averages. Also called Pearson’s CC, CCanom of 30 or higher
is regarded as a good indicator for an adequate anomalous signal. A resolution cutoff
for anomalous phasing has been suggested at CCanom of 10 (Schneider and Sheldrick,
2002). Choosing an adequate cutoff for structure solution can be critical for its success
(Sarma and Karplus, 2006).
1.3. Data collection and processing
1.3.1. Data collection
XRD images collected on hybrid pixel detectors, such as the Dectris Pilatus and Eiger
detectors, have different characteristics when compared to CCD detector images (Hülsen
et al., 2006). Hybrid pixel detectors have fast readout times and no readout noise. Fine
φ-slicing was suggested as strategy for these single photon counting detectors (Mueller
et al., 2012).
Using this strategy, the accuracy of strong reflections should improve and the mosaicity
can be calculated more accurately (Hülsen et al., 2006, Kraft et al., 2009). For data
collection with Pilatus detectors, an oscillation range of ∆φ of 0.1 – 0.2◦ per image is
commonly used. The Eiger detector installed at the SLS PXI X06SA undulator beamline
is the next generation of single photon counting detectors. With an even shorter dead
time and faster frame rates, the detector allows data collection with an ultra-fine φ-slicing
method (Casanas et al., 2016). With this detector, data is commonly collected with an
oscillation range of ∆φ of 0.04 – 0.1◦ per image.
1.3.2. Data reduction and scaling
All frames collected at synchrotron undulator beamlines were processed using the XDS
software (Kabsch, 2010). XDS control files were provided by the corresponding beamline.
These control files contain all parameters needed for the integration and command the
steps the program performs.
XDS determines the initial detector background, strong reflections for indexing, unit cell
dimensions, crystal orientation, and the active detector area in the first steps. The next
step is the integration of all frames and thereby the estimation of all reflection intensities.
In a last step, corrections are applied, the reflections are scaled, and statistics are
generated. For all steps output files are written that can be reviewed manually or by
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using XDSgui3. The correction step provides an output file with an overview of the most
common data quality indicators.
Optimization of data integration
For optimization, all data are re-processed as suggest by the XDSwiki4, by Mueller et al.
(2012) and Diederichs (2016). First, space group and cell parameters are inspected
and transferred into the XDS control file. High and low resolution cutoff can be adjusted
depending on the statistics and result files provided by XDS. The integration is performed
without merging the Bijvoet pairs.
For each new integration cycle some files need to be renamed and parameters
transferred to the XDS control file. The output file containing the latest geometry
description is recycled with each iteration, so that the newest file is used by XDS.
This results in more reliable statistics and a better anomalous signal. Next, the beam
divergence and mosaicity are updated in the XDS control file. These values are refined
with each run of XDS and can lead to better R-factors, if recycled (Diederichs, 2016).
The integration and correction step in XDS are repeated at least three times. The
output file of the correction step is inspected between each cycle. Optimization should
improve the overall statistics of ISa, mean I/σ(I), and CC1/2. ISa is used as indicator for
systematic error and CC1/2 is used to evaluate the precision of the merged intensities.
The precision of the unmerged intensities is evaluated using Rrim and mean I/σ(I).
The error model estimation is validated via χ2 as a function of resolution and intensity.
A value close to one over the resolution range indicates a good fit of the error model.
When an anomalous scatterer is present, the values of ’SigAno’ (anomalous signal-to-
noise ratio, d”/σ(d”)) and ’AnomalCorr’ (CCanom) are also inspected.
During the repeated integration cycles a high resolution cutoff is applied. The cutoff is
either chosen as the edge of the detector surface or at the resolution where CC1/2 falls
below 30 % (Karplus and Diederichs, 2012).
For SAD data, or in general when an anomalous signal is present, the integration is
repeated with a focus on the absorption correction. It was reported that the anomalous
signal is better described when the absorption correction was applied (Akey et al., 2014).
This is tested by comparing the resulting statistics of the correction step, once performed
with absorption correction and once without.
3W. Brehm, K. Diederichs and M. Hoffer, https://sourceforge.net/projects/xdsgui/.
4University of Konstanz, https://strucbio.biologie.uni-konstanz.de/xdswiki/index.php/Optimisation.
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Scaling
The programs PHENIX_scale_and_merge (Adams et al., 2010), XPREP5 and XSCALE
(Kabsch, 2010) were used to process the datasets. If the aforementioned programs
were used for scaling, the scaling option intrinsic to XDS during the correction step was
not employed. XSCALE and PHENIX_scale_and_merge both scale and merge the data
sets in one step (see Section 1.4). XPREP is a multi purpose program and does not
scale the intensities before data averaging. The script XDS2SAD6 is used to convert the
XDS data file into the input format for the program SADABS7. SADABS is used to scale
the raw data and convert it to the appropriate format for XPREP. Averaging of equivalent
reflections is performed by iterative improvement of weights of the intensities. Friedel
pairs are treated as non-equivalent reflections when anomalous signal is present.
1.4. Multi crystal averaging
1.4.1. XSCALE
The program XSCALE scales and averages reflections obtained from XDS. When
the single scans are associated with a crystal name, the program can perform zero
dose extrapolation to correct for radiation damage (Diederichs et al., 2003). This
option was used whenever more than one data set was obtained from one crystal.
The output file provides a wealth of information to evaluate the quality of the merging.
Parameters such as ISa for the whole data set and CC1/2, mean I/σ(I), CCanom, R-value
or anomalous density by resolution were reviewed. Some options already available in
XDS are implemented in XSCALE as well, such as scaling and absorption correction.
1.4.2. PHENIX_scale_and_merge
PHENIX_scale_and_merge uses local scaling and a multi-step merging approach (Akey
et al., 2016). During averaging of equivalent reflections from multiple data sets, the
Friedel pairs are excluded and their accuracy is optimized in a separate step. The weight
of anomalous differences is optimized by comparing the anomalous differences from
individual data sets with those of the merged dataset. Optionally, outlier data sets can
be excluded. However, this option was not used in this thesis. The data quality of
5G.M. Sheldrick, Bruker AXS Inc., Madison, Wisconsin, USA, 2003.
6G.M. Sheldrick, www.shelx.uni-goettingen.de.
7G.M. Sheldrick, Bruker AXS Inc., Madison, Wisconsin, USA.
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the merged file is evaluated by the value of CCanom against different resolution cutoffs,
reported as CCcumulative. The values for CCcumulative at a resolution of 6.0 Å are used as
an indicator for the data quality in this work.
1.4.3. XPREP
XPREP is a command line program used for analysis and preparation of data which is
also capable of merging and scaling. After space group determination, the scaling factors
are determined by least-squares optimization of equivalent reflections and outliers in
the data set are down-weighted. Data quality can be reviewed by various data statistic
tables and plots, including the anomalous signal-to-noise ratio ( d”/σ(d”)).
1.4.4. SHELXC
SHELXC (Sheldrick, 2010) was designed as a data-preparation program for structure
solution coming from an integration or scaling program. The development version of
the program capable of averaging data sets assigns low weighting factors to data sets
disagreeing with other data sets, yielding the combined data set with the highest internal
consistency. Data quality can be reviewed in the log file giving tables over-viewing data
quality indicators such as CC1/2, CCanom for each data set and mean I/σ(I), CCanom,
d”/σ(d”), χ2, Rpim, and Ranom by resolution.
1.5. Evaluation of the anomalous signal
It has been common practice to average the reflections of multiple data sets to improve
data precision and phasing. In recent years the advantage of using intrinsic anomalous
scatterers in macromolecules has been discussed (Rice et al., 2000). Especially the
possibility of using sulfur atoms in proteins is an attractive alternative of heavy metal
soaking or modification with e.g. selenomethionine (SeMet). To enhance the anomalous
signal of intrinsic scatters, data from many crystals can be merged (Liu et al., 2012,
2013). The CFOM (combined figure of merit) value of a successful run of the data set
with SHELXD (Schneider and Sheldrick, 2002) and the averaged anomalous density
calculated from ANODE (Thorn and Sheldrick, 2011) can be used to evaluate the quality
of a merged data set.
SHELXD employs direct methods and integrated Patterson to determine the marker-
atom substructure (Schneider and Sheldrick, 2002). Correct solutions are identified
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by correlation coefficients which are combined to the CFOM value. SHELXD takes all
anomalous scatters present into account for the calculation of CFOM.
ANODE calculates the phases of the marker atom substructure from the native phases
obtained from the structure. With these phases a heavy-atom density map is computed
and the averaged anomalous density at specific atomic positions is calculated. ANODE
requires the structure and files prepared from the reflections, which are produced by
SHELXC or XPREP.
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Poly(rA) – Quality indicators for data
merging enhancing the anomalous signal
In 1961, A. Rich, D. Davies, F. Crick and J. Watson proposed a parallel double helix
ribonucleic acid (RNA) structure for poly(rA) on the basis of diffuse fiber diffraction
photographs (Rich et al., 1961). Over 50 years later the suggested structure was
confirmed via single crystal X-ray diffraction (XRD) experiments (Safaee et al., 2013)
(Figure 2.1). The formation of a right-handed, parallel nucleic acid duplex was shown
to be thermodynamically favorable (Pattabiraman, 1986). The proposed model of the
parallel double-helix of poly(rA) was expected to be stabilized by N1 protonation.
2.1. Introduction
The XRD structure of the poly(rA) parallel double helix was described by Safaee et al.
(2013). The double helix in the structure of (rA)11 is comprised of ten base pairs and one
unpaired nucleotide at each terminal end. The A-A base pairing is characterized by the
involvement of Watson-Crick and Hoogsteen faces of adenine (Holbrook and Kim, 2004,
Rich et al., 1961). The first X-ray crystal structure with a parallel double helical structure
is the cytidylyl-3’,5’-adenosine (CpA) proflavine complex (Westhof and Sundaralingam,
1980). In this structure a base pairing pattern mediated by four hydrogen bonds was
described. The parallel duplex of (rA)11 displays the same A-A base pairing.
Crystal structures of (deoxy)ribonucleic acid oligomers can be solved by standard
methods of macromolecular crystallography. Molecular replacement with an plausible
search model and the use of heavy atoms introduced into the structure are common
techniques. Direct methods can be employed for small oligomers when well diffracting
crystals are available. Dauter and Adamiak (2001) reported the successful structure
solution of a DNA oligomer by phasing with the anomalous signal of intrinsic phosphorus.
Phosphorus single-wavelength anomalous diffraction (SAD) phasing remains the sim-
pler choice for sample preparation but does not find broad application (Reyes et al.,
2009). The need for accurate measurements of the reflections amplitudes to determine
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(a)
(b)
Figure 2.1.: The parallel, right-handed double stranded helix of r(A)11. (a) The A-A base pairing driving the
formation of the poly(rA) duplex. Four hydrogen bonds are formed including the phosphate
groups of the RNA backbone. (b) The r(A)11 duplex in ball-and-stick representation. The parallel
duplex is comprised of ten base pairs and one nucleotide overhanging at each end.
the anomalous signal is a prerequisite. The average ratio of Bijvoet difference of phos-
phorus for data collected from DNA crystals is higher as that of sulfur atoms in proteins
(Dauter and Adamiak, 2001). Still, data redundancy and adequate data reduction play
a vital role in the phasing success of deoxyribonucleic acid (DNA) oligomers via the
intrinsic anomalous signal (Dauter and Adamiak, 2001).
2.2. Aim of this work
The availability of highly ordered Poly(rA) crystals evoked the hope for charge density
studies on the structure. With this objective, XRD measurements were carried out with
the available crystals. In total 37 data sets were collected from eight crystals with a
resolution of up to 0.7 Å. Since the analysis of charge density proved infeasible, the
focus was shifted to use the data for multi crystal averaging studies.
The collected data are evaluated under different aspects concerning the data quality
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and suitable indicators are discussed. XRD data was averaged in a multi-dataset from
one crystal (MDS) approach as well as in a multi-crystal approach (MCA). The results of
this study aimed at evaluating quality indicators for data averaging.
Furthermore, the program SHELXC by G. M. Sheldrick was extended to include
an option allowing the averaging of multiple data sets. The data collected of Poly(rA)
provided a suitable test set for the alpha test version of SHELXC with the new feature.
The data sets of Poly(rA) are evaluated by different criteria to select which data sets
are suitable for multi crystal averaging. Results of these evaluation can provide useful
indicators for the implementation of the averaging function in SHELXC.
Additionally, the diffraction data was evaluated for an anomalous signal from the
intrinsic phosphorus atoms. Even when the experimental setup was not chosen with a
focus on phosphorus-SAD (P-SAD), significant signal was observed. The influence of
data processing and averaging on the anomalous signal is evaluated. The systematic
averaging of selected data sets to maximize the anomalous signal is discussed to enable
P-SAD phasing.
2.3. Materials and methods
2.3.1. Data collection
Crystals of r(A)11 forming a parallel double helix were obtained by Jingwei Xie and
Nozhat Safaee in the laboratory of Prof. Gehring1. The crystals were of large size and
diffracted to high resolution – an improvement over the crystals available when the
structure was initially solved by Safaee et al. (2013).
The crystals were measured at undulator beamlines at DESY (german electron
synchrotron, PetraIII P11) and SLS (swiss light source, PXII X10SA, PXI X06SA) at
100 K. Due to one long cell axis of 163 Å and the intent to collect data for charge
density studies, a short wavelength was chosen for data collection. The XRD data were
collected at the wavelengths 0.6359 Å, 0.6525 Å, 0.796 Å, and 0.7293 Å. The beamline
P11 at DESY (PetraIII) allowed measurements at an energy of 19.5 keV, the beamlines
X10SA (PXII) and X06SA (PXI) at SLS allowed a high energy limit of 19.0 keV and
17.5 keV, respectively. PetraIII P11 and PXII X10SA were equipped with Dectris Pilatus
6M detectors and PXI X06SA with a Dectris Eiger 16M detector. All beamlines were
outfitted with single φ rotation axis goniometers.
1Department of Biochemistry, McGill University, 3649 promenade Sir-William-Osler, Montreal, Canada.
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Table 2.1.: Overview of the data collection from Poly(rA) crystals. The scans are given by number (#)
of the data set and sorted by beamline and crystal.
# crystal scan beamline wavelength [Å] dda [mm] rotation [◦] slicing [◦]
1 A1 1 P11 0.6525 300 90 0.2
2 2 P11 0.6525 200 180 0.2
3 3 P11 0.6525 180 180 0.2
4 4 P11 0.6525 180 180 0.2
5 5 P11 0.6525 300 180 0.2
6 A3 1 P11 0.6525 300 180 0.2
7 2 P11 0.6525 180 180 0.2
8 3 P11 0.6525 200 180 0.2
9 A4 1 P11 0.6525 155 180 0.2
10 2 P11 0.6525 300 180 0.2
11 3 P11 0.6525 200 180 0.2
12 4 P11 0.6525 230 180 0.2
13 5 P11 0.6525 250 180 0.2
14 6 P11 0.6525 250 180 0.2
15 B3 1 X10SA 0.6359 200 360 0.1
16 2 X10SA 0.6359 400 180 0.1
17 3 X10SA 0.6359 250 180 0.1
18 B4 1 X10SA 0.6359 180 180 0.1
19 2 X10SA 0.6359 400 180 0.1
20 3 X10SA 0.6359 200 180 0.1
21 C3 1 X10SA 0.6358 200 180 0.1
22 2 X10SA 0.6358 400 360 0.1
23 3 X10SA 0.6358 180 180 0.1
24 4 X10SA 0.6358 180 180 0.1
25 5 X10SA 0.6358 200 180 0.1
26 6 X10SA 0.6358 190 180 0.1
27 C2 1 X10SA 0.6358 350 180 0.1
28 2 X10SA 0.6358 200 360 0.1
29 3 X10SA 0.6358 180 180 0.1
30 4 X06SA 0.7293 300 180 0.1
31 5 X06SA 0.7293 140 180 0.1
32 6 X06SA 0.7293 140 180 0.1
33 C1 1 X06SA 0.7293 300 180 0.1
34 2 X06SA 0.7293 135 180 0.1
35 3 X06SA 0.7293 135 180 0.1
36 4 X06SA 0.7293 140 180 0.1
37 5 X06SA 0.7293 135 180 0.1
a dd = detector distance.20
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In total, 37 data sets were measured from eight crystals, an overview of the data
collection settings is depicted in Table 2.1. Further data collection information is available
in Appendix A.1. Between three and six scans were collected per crystal, depending on
the overall size and orientation. The crystals were translated along the goniometer axis
for each new scan.
2.3.2. Integration and processing
All frames were integrated using XDS software (Kabsch, 2010). Diffraction images
obtained from the PI X06SA beamline with the Dectris Eiger 16M detector were first
processed using the script H5ToXds provided by Dectris. The script enables XDS to
read the Eiger detector frame format H5. Data integration was performed as described
in Section 1.3.
Pilatus detectors are known to suffer from errors in count-rate correction for every
strong pixels. This was corrected by flagging all reflections with intensities higher than
one tenths of the maximum count rate as overloads. Diffraction images collected on
Dectris Pilatus 6M detectors were processed with and without overload correction. The
overload correction is evaluated only for images taken with the Pilatus detectors, since
the Eiger detector is less effected by this problem.
For optimization, all data were re-processed as suggest by Diederichs (2016) and
Mueller et al. (2012). The optimization procedure is described in Section 1.3.
2.3.3. Anomalous Signal
Special attention was extended to the anomalous signal of the data sets. At each
step during the processing of all data different criteria were evaluated to maximize the
anomalous signal.
During data processing, the anomalous signal was optimized to achieve high anoma-
lous correlation (CCanom) to high resolution. Akey et al. (2014) reported the positive
influence of the strict absorption correction on the anomalous signal strength. Using
this correction resulted in a significantly better anomalous signal and allowed structure
solution with S-SAD (Akey et al., 2014). Therefore, integration applying the correction
was performed and compared to data sets processed without the correction.
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2.3.4. Data averaging studies
Measurements of different crystals were selected and merged using various criteria.
The goal was to achieve the best possible anomalous signal of the anomalous scatterer
phosphorus. The maximization of the phosphorus signal should facilitate substructure
solution via P-SAD. The output of the program ANODE was used as primary indicator of
the strength of the anomalous signal. It evaluates the averaged anomalous density of a
specified element and calculates the anomalous density at the corresponding atomic
positions.
The individual φ-scans of all crystals were evaluated for their data quality and different
quality indicators were selected to rank the data. All data sets were compiled into lists,
which where sorted by different criteria such as ISa, mean I/σ(I), resolution, crystal,
or beamline. Starting with the data sets ranked best in each category, successively
more data was combined into a merged data set. Studies by Terwilliger et al. (2016)
on merging from the best to the worst data set concluded that adding the worst data
degraded the accuracy of the anomalous differences. Here, successively more data sets
were combined until the overall quality of the merged data could not be improved upon.
The influence of the program used for the averaging of the reflections was evaluated
further. In the interest of comparing the averaging capabilities of the development version
SHELXC, the merged files were compared to those of other averaging programs.
2.4. Results and discussion
2.4.1. Evaluation of data quality
Influence of radiation damage
The unit cell parameters were evaluated for changes in their size to exclude radiation
damage as source for systematic error. When crystals suffer from radiation damage, an
increase in the unit cell dimensions can be noticed (Teng and Moffat, 2000). In Figures
2.2 and A.1 the cell axis for each crystal are plotted against the scan number. The unit
cell axis should increase with the scan number if radiation damage is present.
The changes in the unit cell dimension are negligible for all crystals. The crystal C2
was measured at two different beamlines and displays the largest deviation over the
range of all measurements. While some measurements show a slight increase in the
unit cell parameters, the changes are below 1%. To further evaluate possible radiation
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Figure 2.2.: Change of unit cell axis c in consecutive measurements by crystal.
damage, the χ2 values were be reviewed (data not shown). Overall no radiation damage
was found to influence the measurement.
Correction for overload
All measurements were studied for the influence of overloads on data quality. Data sets
with and without possible overload pixels factored in were obtained during integration
with XDS. The results were compared with a focus on the mean I/σ(I) values calculated
by XRPEP, the anomalous signal indicators Ranom calculated by PHENIX, and average
anomalous density of the phosphorus atoms calculated by ANODE. The results are
presented in Figures 2.3, 2.4 and A.2.
For most measurements, the mean I/σ(I) values decrease when the integration is
corrected for overload pixels (see Figure 2.3). The decrease in the mean I/σ(I) was
the highest in data set 6. Without overload correction the mean I/σ(I) was 9.57 and
decreased to 7.30 with the adjustment applied.
In the case of data set 2 the adjustment of the overload rescued the mean I/σ(I) value
from 0.98 to 4.65. A similar increase in the mean I/σ(I) can be observed for measurement
8 (from 1.33 to 4.76). An increase can be due to a more accurate description of the
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reflection profiles or more accurate error estimation.
Overall, the comparison reflects the general expectation that when the overload is
considered the mean I/σ(I) can decrease. Only data sets experiencing strong reflections
suffering from overload effects or of a similar intensity should be affected by the adjust-
ment. A decrease in the mean I/σ(I) is not necessarily tantamount to a decrease in data
quality.
More importantly, the average anomalous density at the position of the phosphorus
atoms increased or remained unchanged in almost all data sets after applying the
correction (Figure 2.4). For data set 2, 6 and 7 the change was most significant: Without
the overload correction no anomalous signal was detectable at all phosphorus positions.
When the correction was applied during data reduction, the averaged anomalous signal
was not only detectable, but unexpectedly strong for a single measurement. The
reverse is true for measurement 15. Here, a very weak averaged anomalous density for
phosphorus was reported for the data without overload correction and no signal when
the overload correction was applied.
Overall, the overload correction has a positive influence on the anomalous signal
strength. For all integrations the overload correction was performed from this point
forward.
Correction for absorption
The option to apply an absorption correction during data reduction is available in XDS.
Akey et al. (2014) reported that the absorption correction influenced the anomalous
signal strength. In their study the structure could only be solved via anomalous phasing
after the absorption correction had been applied. Here, data sets integrated with and
without strict absorption correction are compared.
The influence of the absorption correction was evaluated via the indicators ISa, CCanom
and d”/σ(d”). Figure 2.5 displays the CCanom values for each data set at one specific
resolution. A full table of the data and figures with the other indicators is available
in Section A.1.3. For nearly all data sets the absorption correction influenced the
anomalous signal significantly. A value of CCanom of 10 or higher is considered significant
(Schneider and Sheldrick, 2002). Ten data sets displayed values below this criteria
before the absorption correction and only four afterwards. Overall, the employment of
the absorption correction leads to higher values for CCanom.
In conclusion, the absorption correction has a positive influence on the anomalous
signal strength. The strict absorption correction was performed during data reduction for
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all further studies.
Comparison of data quality indicators
ISa One of the strongest indicators of systematic error is the asymptotic signal-to-noise
(ISa) value of the unmerged intensity data. The ISa value should be above 30 for a
good measurement (Diederichs, 2016). The ISa will decrease when systematic error
compromise the measurement. ISa of all single measurements is plotted in Figure 2.6
as calculated by XDS.
Figure 2.6.: The limit of the asymptotic signal-to-noise ratio (ISa) is plotted for the individual data sets. The
ISa was calculated by XDS.
For nearly one third of the individual measurements the ISa is clearly above 30,
indicating high data quality. From all measurements conducted at the PetraIII undulator
beamline P11 only one single data set (#10) achieved an ISa above 30. On the other
hand, data acquired from the crystals C3 and C4 display the highest ISa values. Contrary
to expectation, the measurements collected with a Dectris Eiger detector, #30–37, were
not generally better than those collected at a Dectris Pilatus detector (#1–28). While
the crystals B3–B4 and C3–C2 (#27–29) were all collected at the same beamline, the
individual measurements were made at two different times. The measurements #15–20
were collected earlier than the measurements #21–29. The large difference in the ISa
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when comparing the two different collection dates might arise due to a difference in
beamline specifics leading to different systematic errors.
In conclusion, the best and worst measurements when comparing solely the ISa were
collected at the SLS undulator beamline PX10SA. In general, data sets from one crystal
display similar ISa values.
Resolution limit Over the years, different limits for the integration or resolution cutoff
have been suggested (see Chapter 1). Frames were in general integrated up to the edge
of the detector or to the resolution at which CC1/2 reached 30%. The different common
cutoff criteria are compared in Figure 2.7.
The more conservative resolution limits of Rmeas ≤ 0.8 and mean I/σ(I) ≥ 2 suggest
cutoff at higher resolution than CC1/2 ≥ 30%. For nearly all measurements the difference
is ∼ 0.1 Å. Several studies suggested that the inclusion of high resolution data beyond
the conservative limits improve the phasing result and the model quality (Liu et al., 2011,
Wang, 2010). Therefore all frames utilized in this work were integrated to the limit when
the quality indicator CC1/2 reached 30%. It has been suggested (Karplus and Diederichs,
2015) to integrate all reflections even further, to a limit of CC1/2 ≥ 10% even if this data
is not used in structure solution or refinement.
Anomalous correlation coefficient CCanom The anomalous correlation coefficient
CCanom is one of the most important indicators for the presence of an anomalous signal in
unmerged reflections. XDS reports this indicator as ’Anom Corr’ for the highest resolution
bins. The resolution to which a significant anomalous correlation can be measured is
a good indicator for the quality of the integration. One goal of the optimization of data
reduction was therefore the maximization of the resolution to which CCanom is greater
than 10%. The resolution for this indicator for all measurements of Poly(rA) is displayed
in Figure 2.8.
As discussed before, the quality indicator CCanom is a guide to the strength of the
anomalous signal. It is therefore one of the most important indicators whether the
phasing using the anomalous signal can be successful. The resolution for phasing of
nearly all datasets is better than 3 Å and lies for most data sets between 1.5–2.5 Å. This
is a surprising result, considering that the XRD experiments were conducted at short
wavelength not favorable for an anomalous signal from phosphorus.
Mean I/σ(I) Taking a closer look at the mean I/σ(I) values of the single measurements,
the best values were obtained from the crystals C3 and C2. The differences between the
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A1 A3 A4 B3 B4 C3 C2 C1
Figure 2.8.: All Poly(rA) measurements with their resolution limit for an anomalous correlation of at least
10%. The anomalous correlation was calculated by XDS.
single data sets are highlighted in Figure 2.9. The values are color-coded by beamline
and the individual crystals are marked on the abscissa.
For the measurements from crystal C2 (#27–32) a direct comparison between the two
detectors Pilatus 6M and Eiger 16M is possible. Interestingly, only one measurement
(#30) from the Eiger 16 M detector shows a significantly higher mean I/σ. All other data
sets collected at the Eiger 16 M detector show a mean I/σ comparable to the Pilatus 6M
data sets.
2.4.2. Correlation between data quality indicators and anomalous signal
strength
In advance of the averaging studies, the correlation between the quality indicators has
been evaluated. The indicators mean I/σ(I) and ISa have been consulted for the overall
quality of the data sets. Additionally the overall Ranom of each data set and the averaged
anomalous density were examined. Only data quality indicators directly correlated with
the anomalous signal strength should be considered when the further steps for structure
solution by anomalous signal are planned.
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A1 A3 A4 B3 B4 C3 C2 C1
Figure 2.9.: Single data mean I/σ(I) analysis, coded by beamline and crystal.
At first the correlation between the limit of the asymptotic signal-to-noise ratio (ISa)
and averaged anomalous density at the positions of the phosphorus atoms was analyzed
(see Figure 2.10).
No correlation can be found between the ISa and the averaged anomalous density
of the individual data sets. The indicator ISa is not applicable for the evaluation of the
strength of the anomalous signal. Interestingly, Assmann et al. (2016) reported that the
identification of outliers based on the ISa was not a reliable criteria for the rejection of
data sets. This indicates that neither the quality of the data set nor the strength of the
anomalous signal can be evaluated via the value of ISa.
It furthermore indicates that ISa can only be regarded as indicator for the presence of
systematic errors in the processed data but not as deciding factor in consecutive data
processing. When considering which data sets can be used for averaging to enhance the
anomalous signal or the overall data quality, ISa should not be considered in isolation.
Next, the correlation between the mean I/σ(I) and the strength of the anomalous
signal of the phosphorus atoms has been evaluated (see Figure 2.11). The averaged
anomalous signal at the position of the phosphorus atoms is stronger when the mean
I/σ(I) is higher. The data as presented in Figure 2.11 shows a clear correlation of both
values. This relationship is further confirmed in the correlation between the mean I/σ(I)
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Figure 2.10.: The limit of the asymptotic signal-to-noise ratio (ISa) against the averaged anomalous density
is plotted. The ISa was calculated for each data set by XDS and the averaged anomalous
density of the phosphorus atom positions was calculated by ANODE.
Figure 2.11.: The mean I/σ(I) is plotted against the averaged anomalous density. The mean I/σ(I) was
calculated for each data set by XPREP and the averaged anomalous density of the phosphorus
atom positions was calculated by ANODE.
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and Ranom (see Figure A.4). Ranom decreases with increasing mean I/σ(I). Based on
the direct correlations found, mean I/σ(I) can be an indicator of the anomalous signal
strength. Additional correlation plots of the indicators mean I/σ(I), ISa, Ranom and the
averaged anomalous density are displayed in Appendix Section A.1.4 (Figures A.4 –
A.7).
In conclusion, a clear correlation can be found between the data quality indicator mean
I/σ(I) and the strength of the anomalous signal. The correlation can be considered as
criteria when selecting data sets for averaging studies.
2.4.3. Multi crystal averaging
Selection criteria for multi crystal averaging were evaluated. The main focus is the en-
hancement of the anomalous signal of the intrinsic scatterer phosphorus. The anomalous
signal was evaluated at the atomic position of the phosphorus atoms with the program
ANODE. The averaged anomalous density for all phosphorus positions was compared.
The first selection criteria was the crystal itself. All data sets collected from one crystal
were averaged and evaluated. The consistency of these data sets is expected to be high
and the result can reflect the quality of the crystal.
The second selection criteria was the beamline at which the XRD experiments were
conducted. The XRD experiments were conducted at the synchrotron PetraIII undulator
beamline P11 (crystals A1, A3, A4) and at two different undulator beamlines at the
SLS, PX10SA and PX06SA. The data sets from crystals B3 and B4 as well as the data
sets from crystal C3 and C2 (scan 4–6) were collected at PX10SA, but not during the
same time slot. Those data sets are grouped as SLS2015 and SLS2016, respectively.
Finally the data sets from crystal C2 (scan 1–3) and C1 were collected at PX06SA. The
separation of the data sets by beamline also discriminates them by the detector that was
used for data collection (see Section 2.3.1).
The final selection criteria was the mean I/σ(I). All data sets are ranked from the
highest to the lowest mean I/σ(I) and consecutively merged. Starting with the five highest
ranked data sets, more data sets were added until no improvement of the anomalous
signal strength was measurable. ISa as criteria for multi crystal averaging was excluded
based on the report by Diederichs (2009) and Huang et al. (2015) and the results
obtained in this work.
Data sets were averaged using the programs PHENIX_scale_and_merge (Adams
et al., 2010), XPREP2 and XSCALE (Kabsch, 2010). These programs were used to
2G.M. Sheldrick, Bruker AXS Inc., Madison, Wisconsin, USA, 2003.
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compare the quality of the averaged files with the development version of SHELXC. The
results are presented in Figure 2.12 and Table A.5.
Averaging by crystal Three to six data sets – or scans – were collected per crystal,
depending on its size and orientation. The data sets collected from one crystal should
display low anisotropy, especially when radiation damage can be excluded (Sygusch
and Allaire, 1988).
The anomalous signal strength described by the averaged anomalous density for the
data sets averaged by crystal is displayed in Figure 2.12, the first eight values from
the left. The averaged data set from crystals A1 and A3 display very little anomalous
signal at the position of the phosphorus atoms. Crystals C2 and C1 show a strong
anomalous signal. The strength of the anomalous signal is depended on the program for
crystal C2. The data sets processed with XPREP performs inferior to those averaged
with XSCALE and especially PHENIX. For all other averaged data sets the results from
different merging programs are more similar in quality.
In conclusion, except for the outlier computed for crystal C2, the different programs
are treating the anomalous signal quite similar. Averaging data sets from one crystal can
result in a stronger anomalous signal, but the increase is usually minor.
Averaging by beamline Six to 23 data sets were averaged for the analysis of the
beamline and detector influence. The resulting averaged anomalous density is plotted
in Figure 2.12, the values named by beamline. The best results were obtained from
merging all data collected at the SLS beamlines, a total of 23 data sets. Data sets
averaged by PHENIX clearly display a stronger anomalous signal for the data measured
at PX06SA and PetraIII. The influence of the program is visible quite distinctly for these
data set combinations.
The averaged file for all measurements collected with the Dectris Eiger detector
(SLS2016-PX06SA) displays an anomalous signal strength comparable to the mea-
surements from beamline PX10SA (SLS2016-PX10SA and SLS2015-PX10SA). But the
quality of the anomalous signal is depended on the program used to average the data
sets.
The strongest anomalous signal was obtained when all data sets collected at SLS
beamlines were averaged (All SLS). This averaged data set contains the averaged
reflections collected in 23 scans from five crystals in total. Here the choice of the
program is not as critical, all programs generate files resulting in an averaged anomalous
signal of above 9.
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Averaging by mean I/σ(I) All data sets were ranked by the quality indicator mean
I/σ(I). The data sets were merged consecutively from the highest to the lowest mean
I/σ(I) starting with the five best.
A selection of the results are displayed on the right in Figure 2.13. In this evaluation,
the merged data sets obtained with PHENIX result in data sets with a stronger anomalous
signal. Especially for the data set containing only the best five scans, the averaged
anomalous density is above 8 when using PHENIX but below 7 for XPREP and XSCALE.
The best overall result was achieved with the best 25 data sets merged with PHENIX.
An averaged anomalous density of the phosphorus atoms of 10.7 was obtained. When
more data sets were added, the averaged anomalous density decreased slightly. The
programs XSCALE and XPREP presented their highest averaged anomalous density
when 20 data sets were merged. Again, the anomalous signal strength decreased when
more data sets were added.
The selective exclusion of weak data resulted in a better anomalous signal strength.
This result was reported by Akey et al. (2014) before. The mean I/σ(I) as best qualifier for
the anomalous signal was proposed by Dauter and Adamiak (2001). This study achieved
the best overall anomalous signal strength with the mean I/σ(I) as exclusion criteria.
Influence of data redundancy The influence of the number of data sets averaged in
the final file is evaluated. A plot of the number of scans per merged file is presented in
Figure 2.13.
The number of available measurements of individual intensities stand in direct cor-
relation with the accuracy of the resulting mean intensity (Weiss, 2001). With higher
redundancy the Bijvoet pairs and therefore the anomalous signal should be better es-
timated. This trend is reflected in the present study as well. With a small number of
contributing data sets to the merged data sets, a lower averaged anomalous density
is recorded. The averaged anomalous density increases with increasing number of
averaged data sets. When a certain signal strength is reached, the addition of more data
sets does not improve the averaged anomalous density. This has been reported before
by (Liu et al., 2012) and is confirmed by this study.
Interestingly, one outlier is present in the evaluation. For the averaged file containing
14 data sets the averaged anomalous density is, independent from the program used,
below the expected value given by the trend. This data set contains all measurements
collected from PetraIII, P11. Possible reasons for this outlier can be systematic errors
specific to the undulator beamline setup or poor quality of the crystals used for XRD.
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Figure 2.13.: The number of averaged data sets is plotted against the averaged anomalous density. The
data sets were selected by crystal, beamline or the highest value of mean I/σ(I).
SHELXC development version The development version of SHELXC capable of
multi crystal averaging could not be tested to the full extend in the course of this work.
Therefore all preliminary results will be reported at a later time. Based on the down-
weighting of outlier data sets, SHELXC will average all available data. The first results
obtained for all 37 data sets were promising. The averaged anomalous density calculated
with ANODE was in the same range with that of the other programs tested.
2.5. Conclusion and Outlook
In this work, the influence of data processing on data quality and the anomalous signal
strength is evaluated.
The strict absorption correction and the optimization of the mean I/σ(I) during data
reduction provides data sets of the best quality. The influence of data processing was
discussed before (Dauter and Adamiak, 2001, Karplus and Diederichs, 2015, Liu et al.,
2012, Wang, 2010). While ISa can be used to detect the influence of systematic errors
on the data, it is not the best indicator for the overall quality of a data set.
Furthermore, the program used to average multiple data sets can have a significant
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influence on the anomalous signal strength. Since only one set of measurements was
used in this study, a general recommendation for one single program cannot not be given,
but the results presented here suggest that a selection of merging programs should be
tested in borderline cases.
The exclusion of data sets of inferior quality can improve the anomalous signal strength.
Hereby the quality indicator mean I/σ(I) can play a significant role and other indicators
such as d”/σ(d”) or Ranom should be tested as well. The concept of multi crystal averaging
in SHELXC is based on simple down-weighting outliers. Further studies on the detection
of outliers can be conducted. Assmann et al. (2016) suggested the identification of rogue
data sets based on calculating CC1/2 between all data sets. As a result, the data sets
could be clustered by their correlation (Diederichs, 2017).
The best averaged data sets displayed an averaged anomalous density of 10.7 for
all phosphorus atoms. Although the value was not ideal, P-SAD with the anomalous
signal was attempted, but gave no substructure solution with SHELXD. Nonetheless,
significant anomalous signal is present and the improvement of multi crystal averaging
strategies could lead to a structure solution via the anomalous signal in the future. This
could be a compelling argument to use intrinsic anomalous scatterers in macromolecular
crystallography, especially for the structure solution of (deoxy)ribonucleic acid structures
(Harp et al., 2016).
Overall, the importance of data reduction and processing and the influence on the
quality of the anomalous signal strength could be demonstrated. The conclusions drawn
from this work were applied for the structure solution of cln5 (see Chapter 4).
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Enabling the refinement of high resolution macromolecular data with the program
SHELXL (Sheldrick, 2015) has been an enduring desire for more than two decades now
(Sheldrick and Schneider, 1997). With the continued development and availability of
more brilliant and better-focused X-ray radiation sources (Duke and Johnson, 2010) as
well as more sensitive detector technology (Casanas et al., 2016, Leonarski et al., 2018),
the number of macromolecular structures with a resolution of 1.7 Å or better is steadily
increasing.
The protein database (PDB) supports mmcif and pdb file format and all deposited data
are freely available. The most common refinement programs adhere to this standard
and present the resulting files in these formats as well. Access to SHELXL refinement
is limited by the necessity to convert from the most commonly used formats in macro-
molecular crystallography to the standard in small molecule refinement – ins (refinement
instructions and atomic coordinates) and hkl (reflection data) format. To bridge this gap,
the program PDB2INS was developed.
3.1. Background
The PDB archive (wwPDB) is a depository for 3D structural information of macro-
molecules, such as proteins, nucleic acids and complex assemblies (Berman et al.,
2003). Today, the wwPDB consists of four members, the Biological Magnetic Resonance
Data Bank (BMRB), the Protein Data Bank Japan (PDBj), the Protein Data Bank Europe
(PDBe), and the Research Collaboratory for Structural Bioinformatics Protein Data Bank
(RCSB PDB). It has become mandatory for publishing in relevant papers to deposit
macromolecular X-ray diffraction (XRD) models and reflection data at the web service
provided by the wwPDB (Wlodawer, 2007).
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3.1.1. Macromolecular refinement programs
Several refinement programs are available for macromolecular refinement. Some are
highly specialized for a specific problem while others can be applied to a broader range
of structures. A number of factors influence the choice of refinement program, such
as resolution or required parameterization. A more detailed discussion is available by
Tronrud (2007) and Shabalin et al. (2018).
Some popular refinement programs, such as REFMAC5 (Murshudov et al., 2011) or
PHENIX (Adams et al., 2010), are very versatile and offer a broad range of refinement
options (see Figure 3.1). The standard repertoire includes least squares, maximum likeli-
hood and phase maximum likelihood target functions with sparse matrix gradient method
as minimization algorithm. Mostly coordinate refinement with Konnert-Hendrickson-type
restraints and torsion-libration-screw (TLS) parameterization of anisotropy are included
for refinement configuration. Special minimization algorithms, refinement target functions
or restraint parameterization are implemented as well or are available in other programs.
Generalized comparisons of available programs are problematic, since the implementa-
tion of functions, parameterizations, and optimizations methods can vary significantly
from one program to the next.
Figure 3.1.: The most popular refinement programs against total numbers of deposited structures in the
PDB in March 2019.
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Depending on the resolution or stage of refinement, some programs or software suites
may offer an advantage. For a refinement with a low resolution data set (3.0 Å or lower)
or with a poor starting model, X-PLOR (Brünger, 1992), CNS (Brunger, 2007, Brünger
et al., 1998) or PHENIX are more suitable in general. These structures may benefit
from simulated-annealing molecular dynamics to increase the convergence radius or
a lower parameter count via torsion angle refinement. For structures in the resolution
range from 3.0 Å up to 1.4 Å, into which most of the published structures fall, restrained
coordinate refinement against maximum likelihood target functions usually yields good
results. These are available in most programs including REFMAC5, TNT (Tronrud,
1997, Tronrud et al., 1987), CNS or PHENIX. Atomic resolution data can benefit from
a customizable restraint model or the refinement against intensities with a blocked
least-squares algorithm as provided by SHELXL.
3.1.2. Advantages of a refinement with SHELXL
Refinement with SHELXL is particularly useful if high resolution data is available. The
program allows refinement against neutron and Laue diffraction data (Gruene et al.,
2013). When the data-to-parameter ratio is sufficiently high, anisotropic refinement
is possible. The refinement of multi-domain twinned data, including non-merohedral
twinning, is facilitated. This is beneficial since all data can be used for refinement instead
of only data of a single domain.
SHEXL enables the refinement against intensities and allows the refinement of atomic
site occupancies. Also complicated disorder can be treated flexibly and refined, including
constrained determination of occupancies. For small structures the least-squares estima-
tion of individual standard uncertainties in possible. The calculation of Rcomplete (Luebben
and Gruene, 2015) in addition to Rfree (Brünger, 1992) is implemented, providing access
to state of the art structure validation techniques.
One example of the advantages offered by SHELXL refinement of macromolecules
was published by Köpfer et al. (2014). Various websites and tutorials are available
explaining the use of SHELXL with macromolecular data, such as the CCP4 wiki1, the
SHELXL homepage2 and chapters in the SHELXL manual or in Mueller et al. (2006).
1 K. Schäfer and K. Diederichs, strucbio.biologie.uni-konstanz.de/ccp4wiki/index.php/SHELXL, Univer-
sity of Konstanz.
2 G. M. Sheldrick, shelx.uni-goettingen.de, tutorials, talks, open access papers, and overview of all
SHELX commands, University of Goettingen.
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3.1.3. File transformation to SHELXL formats
The first interface to enable easy access to SHELXL for macromolecular data was
SHELXPRO, written by Sheldrick and Schneider (1997). Designed to be self-explanatory
and easy-to-use, it was distributed for the first time with the SHELX-97 release of the
SHELX program suite. SHELXPRO reads a number of file formats, can generate inter-
atomic distance and bond angle restraints for essential amino acids, can display a variety
of plots for analytical purposes, and perform anisotropic scaling (Shakked, 1983). It is
also used to create a basic instruction (ins) file or to convert from the SHELXL output file
back to the PDB format file.
Similar features were later implemented and more conveniently accessed by other
programs like COOT (Emsley et al., 2010), XPREP3, or SHELXL itself.
COOT is capable of reading and writing SHELXL result files to display the model and
electron density maps. Other tasks were implemented in XPREP. It is capable of Rfree
flag creation, plot generation, and displaying various data tables. Several features found
their way as instructions into SHELXL, such as the generation of pdb files4.
While SHELXPRO itself became partly redundant, some functions – for instance
converting to the SHELXL compatible format – remained useful nonetheless. Gener-
ating ins (instruction) files from PDB files while adding sensible restraint commands
and renumbering residues to fit SHELXL nomenclature, for example. To address this
requirement, PDB2INS was created as a successor.
PDB2INS was designed to extend the function of converting from macromolecular file
formats to the SHELXL compatible formats. The main focus is hereby the creation of
the instruction file which is controls the refinement and contains the atomic coordinates.
Additional options were added as well as more choice for customizing data processing.
The aim is to allow easy access to refinement of macromolecular data with SHELXL for
inexperienced users while at the same time grant more directed control for advanced
users. In the end, minimal to no additional editing should be necessary before running
SHELXL with the created instruction file.
Obtaining the reflection file in SHELXL format from an mtz file was possible by the
programs MTZ2SCA and SCA2HKL by Grune (2008). The tool CIF2MTZ by Winn et al.
(2011) could be used to create an mtz file. XPREP facilitates the conversion of multiple
input formats5 to hkl files as well. For convenience, the transformation from the mmcif
3G. M. Sheldrick, Bruker AXS Inc., Madison, USA, 1997.
4The instruction WPDB was added to SHELXL prompting the program to write a pdb file directly.
5An overview of all reflection data containing input files for XPREP is given when the program is started
without any filename on the command line. The following file formats are read: sca (SCALEPACK or
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file format used by the PDB to the hkl format was introduced into PDB2INS as well. This
should limit the need for other conversion programs and allows direct access to all data
available in the PDB.
3.1.4. SHELXL file format aspects to consider
Various limitations within the SHELXL instruction format are present and have to be
taken into account when converting PDB files to SHELXL instruction files. The instruction
file contains lines of maximal 80 characters, starting with four letter keywords followed
by parameters. The keywords can contain essential information regarding the structure
and regulate the refinement which can be fine-tuned with specific parameters.
The instruction file can be segmented into three main parts. The first part contains
essential keywords which have to appear in a defined succession providing the most
basic data such as the cell, wavelength, symmetry, or elements present and their
corresponding scattering factors. Also, the type of refinement needs to be specified.
Next, additional information can be provided to guide and improve the refinement.
Parameters to allow a refinement of twinned data, keywords regulating the amount
of output files and statistics as well as specific refinement restrictions can be defined.
Additionally, restraints and constraints can be placed here as well as commands to add
riding atoms such as hydrogen.
The final part consists of the atoms present in the asymmetric unit, one line per atom,
and starts with the atom name instead of a fixed keyword in contrast to all other lines.
The atom name can not exceed four characters and needs to be unique. This stands in
stark contrast to macromolecular crystallography guidelines, were atoms of one specific
residue are expected to follow a strict repetitive naming scheme. SHELXL allows the
combination of a residue number with an atom name leading then to a unique identifier
for each atom.
SHELXL restricts the residue number to four characters, therefore limiting the size
of macromolecules that can be refined. This presented a particular challenge, since
SHELXL was capable to address residues by name and number but not chain identifiers.
Accordingly, a program writing an instruction file for SHELXL from a regular PDB file
must convert the chain identifiers into a residue number. Often one chain only contains
a few hundred amino acids and a new chain could simply be distinguished by adding a
multiple of 1000 to the residue number. A new chain would then be identified by the size
of the gap in between to consecutive residue numbers in the file. Such a work-around
HKL2000 format), HKL (XDS_ASCII.HKL file), fco (written by XD), and SHELX file formats.
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makes it harder to compare and reference the original file with the files produced after
the SHELXL refinement and still limits the size of the molecule that can be processed
by the program. In SHELX format one chain can contain up to 9999 atoms when the
numbering starts with 00016. Today, only a single character for the chain identifier is
allowed and the capitalization of letters is discriminated. In the end, the file is terminated
with an instruction specifying the format of the associated reflection file.
3.2. Aim of this work
The small molecule refinement program SHELXL can be used to refine macromolecular
XRD data of high resolution. SHELXL offers multiple advantages not implemented in
the most commonly used refinement programs in macromolecular crystallography. To
facilitate a refinement of suitable data with SHELXL, a program to set up the necessary
files in the correct format is needed.
The aim of this work is to create a program, PDB2INS, to set up all refinement files
for a SHELXL refinement from pdb files. PDB2INS is constructed as simple interface
between macromolecular files and a refinement with SHELXL. The conversion is handled
in a single program with an optional graphical user interface. Novice and expert users
alike can use PDB2INS to create all files needed for SHELXL. PDB2INS allows many
options to customize the data and adds instructions and restraints to use SHELXL to its
full potential.
3.3. Methods and Implementation
PDB2INS is available as packaged version for Windows, Linux and MacOSX from the
homepage of G. M. Sheldrick7. The source code, command line versions as well as the
graphical user interface (GUI) versions are available at https://github.com/av-luebben.
Some distributions of CCP4i/CCP4i2 also contain the command line version of PDB2INS.
6Additionally, negative residue numbers up -999 can be used.
7G. M. Sheldrick, http://shelx.uni-goettingen.de.
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3.3.1. Programs and resources
PDB2INS was written using Python 2 programing language8. The integrated devel-
opment environment (IDE) PyCharm (JetBrains, Prague, Czech Republic) as free,
academic edition was employed and the python interpreter PyInstaller9 was used to
generate stand-alone executables. All version control and publication of the code was
done using git 10 and the free academic GitHub professional version (GitHub Inc, San
Fransisco, USA), respectively. The graphical user interface of PDB2INS was written
using TKinter (Tcl/Tk), the standard graphical user interface package of python.
PDB2INS was designed to be called from a command line and can be integrated
into automated scripts. The program was tested by selected test users and using an
automated script that included downloading files from the PDB website11 or using a
pre-downloaded part of the PDB. Furthermore, SHELXL was called after a successful
PDB2INS run to perform a refinement with the created files. The program COOT
(Emsley et al., 2010) was used to visually inspect the refinement result and directly
modify selected regions.
3.3.2. Data formats
Protein Database formats
The last major changes to the pdb file format were made in 2008 resulting in Version
3.20 (Dutta et al., 2009). Since then it became mandatory not only to deposit atomic
coordinates but also the corresponding experimental diffraction data. PDB2INS is
accepting all pdb and sf-cif files in this format.
A pdb file is divided into nine major sections containing the atom coordinates in
addition to information about the source of the macromolecule, programs used during
data processing, the authors, and secondary structure features. The file is in a specific
format, each line consists of 80 characters with the first six columns indicating the record
name.
Each record name has a distinct format for the following columns and is usually
terminated with an end-of-line character. All records have to appear in a fixed order and
mandatory record types are present in all PDB entries (see Section B.1).
8Python is an multi-paradigm, interpreted programming language that is freely available at
www.python.org, Python Software Foundation, Python Language Reference, Version 2.7.
9PyInstaller Development Team, http://www.pyinstaller.org/, initiated by Giovanni Bajo.
10Junio Hamano, http://git-scm.com, initiated by Linus Torvalds.
11www.rcsb.org, member of wwPDB and EMDataResource, National Science Foundation.
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Especially the coordinate section is of interest, containing all atoms and their associ-
ated information such as name, B-factor, occupancy and coordinates.
SHELX file formats
SHELXL expects two files, the instruction file with the suffix .ins and the structure factor
file with the ending .hkl as input. The later file uses a fixed format.
The hkl file consists of lines of up to 80 characters with each line containing the data for
one hkl index and starts without preamble. While the hkl indices take up four characters
each (H,K, and L, right justified), the associated reflection (R) - either intensities or
amplitudes - and their estimated standard deviation (S) hold eight characters each.
Afterwards, four more characters are reserved for a flag (F ), such as Rfree flags or
domain association, resulting in a line structure such as:
HHHHKKKKLLLLRRRRRRRRSSSSSSSSFFFF (3.1)
The last line in the ins file will contain a specification which kind of data are present in
the reflection file. The instruction HKLF 4 stands for reflections in the form of intensities
while HKLF 3 specifies amplitudes, for example.
The ins file is more elaborate, each line either starting with a four character instruction
followed by additional parameters in free format. A list of possible instructions and a brief
summary on their use is given on the homepage of G. M. Sheldrick12. In the context
of this thesis, the ins file is described as containing three parts, the general refinement
instructions, the structure specific instructions, and the atom instructions.
The general refinement instructions contain crystallographic information, such as
experimental setup, cell dimensions, space group in form of symmetry operations, Z
value and element symbols for scattering factors to be employed. Some instructions
have to be given in a specific order and must be given at the start of the file. Also, the
refinement options as well as general restraints affecting the whole cell content such as
anisotropic refinement, weighting scheme or specifying the output files and their extent
are given here.
The structure specific instructions contain mainly geometric restraints for the molecules
in the cell, such as bond distances and angles, chiral volumes, and torsion angles.
Additionally the creation of hydrogen atoms can be achieved by specific commands
written in this section.
12 G. M. Sheldrick, http://shelx.uni-goettingen.de.
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The atom instructions are lines beginning with the atom name (up to four characters,
the first one must be a letter). This is followed by the scattering factor number, the
fractional coordinates, the side occupations factor, and the U factor, with either one
isotropic or six anisotropic components. Atom instructions might be intermittent with
instructions organizing the molecule into residues or specifying disordered parts.
3.3.3. PDB2INS layout and architecture
PDB2INS can be started from command line under Windows, Linux or MacOSX (see
Section 3.3.4). The command line version can be run in interactive mode or by using
keywords after the program name at startup. In the first mode, the user is guided through
the program by answering a series of questions. Additionally, a GUI version of the
program is available for users more comfortable with a graphical interface.
An overview of the main steps in the program from the input file (pdb) to the output
file (ins) is given in Figure 3.2. In the following some key functions of PDB2INS are
explained in more detail.
Generation of symmetry operations from the space group symbol
The number of symmetry operations in a unit cell for any space group equals the multiplic-
ity of the general position. The International Tables list for each space group all symmetry
operations and specify which function as generators (Aroyo, 2016). Generators are a
subset of the symmetry operations which will generate all symmetry elements of the
space group by consecutive pairwise combination (Dauter and Jaskolski, 2010). Sym-
metry operations are tabulated as operation O, followed by the translational component
wg in parenthesis and its location (x0, y0, z0).
O(wg)x0, y0, z0 (3.2)
In the International Tables the type of operation in combination with its orientation
is tabulated together with the corresponding matrix W . The orientation of a symmetry
operation can be derived from the location.
Taking the symmetry operations of the space group, the general positions can be
calculated from their generators (Fischer and Koch, 2006). Each generator is described
by a (3× 3) matrix W – the rotation part – and a corresponding (3× 1) column vector w
representing the translation vector. With the matrix pairs (W,w) each positional vector p
(x, y, z) can be transformed into the symmetry equivalent positional vector p′ (x′, y′, z′).
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Figure 3.2.: Schematic diagram of the core processes in PDB2INS from the input file (pdb) to the output file
(ins).
It is possible to obtain all symmetry operations for a given space group from the
generators. The symmetry operations can be extracted from the translational vector w
and the matrix W . w can be calculated from the sum of the translation component, the
intrinsic translational part wg and the location part wl.
w = wg +wl =

w1
w2
w3
 (3.3)
The location part can be acquired from matrix W , the identity matrix I, and the location.
wl = (I −W )

x0
y0
z0
 =

x′0
y′0
z′0
 (3.4)
A new pair of coordinates (W ′, w′) can be derived from two matrix pairs Wn, wn and
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Wm, wm.
W ′ = W n ∗Wm (3.5)
w′ = W n ∗wm +wn (3.6)
To obtain all possible symmetry operations from the generators, all matrix pairs have
to be multiplied with each other until no new result is obtained.
PDB2INS contains the module SPAGSYDATA, that can generate all possible co-
ordinate triplets from the space group symbol. It contains a dictionary of all non-
centrosymmetric space groups as symbol and their associated generators as lists of
matrix pairs (W,w). From this database all symmetry operations are derived by matrix
multiplication until no new matrix pair is generated (Equations 3.5 and 3.6).
Each resulting matrix pair W ′, w′ can be translated into positional vector p′.
p′ = W ∗ p+w =

W11x+W21y +W31z + w1
W12x+W22y +W32z + w2
W13x+W23y +W33z + w3
 =

x′
y′
z′
 (3.7)
These positional vectors are given in the form of SYMM instructions in the ins file.
SYMM x′, y′, z′ (3.8)
For each new symmetry operation a new line with a separate symmetry instruction
(SYMM) is created. SHELXL does not read a space group symbol and needs the SYMM
instructions as shorthand for all symmetry operations, facilitating refinement of structures
in arbitrary settings.
This module is freely available and can be used independently from PDB2INS13.
Lattice type as SHELXL command
In addition to the symmetry operation SHELXL needs the lattice type to complete a space
group assignment. The lattice type is saved in the ins file as an integer from -7 to 7. The
SHELXL code is given in Table 3.1. The code must be negative for non-centrosymmetric
space groups.
13https://github.com/av-luebben/spagsydata.
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Table 3.1.: Lattice type as input in SHELXL files.
SHELXL lattice type
1 primitive (P)
2 body-centered (I)
3 rhombohedral (obverse on hexagonal axis)
4 face-centered (F)
5 A-base-centered
6 B-base-centered
7 C-base-centered
Wavelength specific considerations
SHELXL recognizes the wavelength of the most common in-house X-ray sources. The
dispersion and absorption coefficients of the natural elements up to element 98 for the
wavelength produced by the elements Cr, Cu, Mo, Ag and In are available. For other
X-ray sources, such as synchrotron sources, SHELXL requires an instruction specifying
these parameters. The instruction is given via the keyword "DISP", followed by the
element prefixed by a "$" and afterwards defining f’, f” and µ.
DISP E f ′ f ′′ µ (3.9)
PDB2INS calculates f ′, f ′′ and µ for all wavelengths not known by SHELXL from
Kissel scattering factor tables (Roy et al., 1993). If w1 is the wavelength the data was
collected at, wb and wa are the tabulated wavelengths, the difference is given by
∆ = wb − wa. (3.10)
f ′ can be calculated from the tabulated values f ′b and f
′
a
f ′ = |f | · (f ′b − f ′a) + f ′a (3.11)
with
f = (wa − w1)∆ . (3.12)
The calculation of f ′′ and µ is achieved analogously:
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f ′′ = |f | · (f ′′b − f ′′a ) + f ′′a , (3.13)
µ = |f | · (µb − µa) + µa. (3.14)
Refinement commands
In the first part of the instruction file a number of commands regulating the refinement
and parameters are given. They largely remain the same for all data sets and can be
customized by the user during later stages of the refinement. The first three lines of the
file contain the titel (TITL), wavelength, cell (CELL) and standard deviation of the cell as
well as the Z value (ZERR). The title specifies from which file this ins file was generated,
the wavelength, cell and Z value are transferred as given in the pdb file. The cell standard
deviations are given as 0.1% from the cell length, zero for angles constrained by space
group symmetry and 0.05◦ for all other angles. These are just general estimates and do
not reflect realistic standard deviations. Adding general estimates for the cell standard
deviation is necessary since no standard deviations are included in the pdb file.
Next, the space group is stated as remark (REM), a line which is not interpreted by
SHELXL but can contain explanations or additional annotations for the user. This tool is
used on multiple occasions throughout the file. The space group is then represented by
one lattice statement (LATT) followed by lines defining symmetry operations (SYMM)
as described in Section 3.3.3. Should the data set contain neutron diffraction data,
the NEUT instruction is inserted after the symmetry operations. One line defining all
elements present in the model via the SFAC command follows and their quantity in
the same order on a separate line (UNIT). Should the wavelength not be that of an
in-house source recognized by SHELXL, the instructions establishing the absorption
and dispersion coefficients for present elements (DISP) is inserted in between these two
instructions.
To change the applied standard deviations for the geometric restraints the instruction
DEFS is given. Default values of 0.02 for DFIX, SADI and SAME, 0.1 for CHIV and
FLAT, 0.01 for DELU, and 0.04 for SIMU are used and not changed, this can be done
manually by the user if desired. The next command defines the least-squares solving
method employed by SHELXL, by default PDB2INS defines the conjugate-gradient least
squares (CGLS) algorithm with 20 cycles. When the second parameter is given as a
negative number, it uses the fraction of the reflections reserved for Rfree validation. This
parameter is set to ’-1’ so that the Rfree set as given in the hkl file is used. In later
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stages of the refinement the CGLS command might be changed to L.S., for a full-matrix
least-squares refinement. The BLOC command can be added optionally at this point to
facilitate a least-squares refinement using only parts of the asymmetric unit per cycle.
Next, the included resolution range is defined (SHEL) and the grid for Fourier synthesis
is specified (FMAP). Then follow some commands specifying the content and format
of several SHELXL output files. The extent of a list of positive Fourier peaks that
should be written to the output coordinate file is defined by the instruction PLAN. The
reflection output file (fcf ) format is defined by the command LIST and can be read
by macromolecular standard programs like COOT (Emsley et al., 2010). The refined
coordinates are written to a pdb file, also including anisotropic parameters when present,
when the command WPDB is given.
Restraints in general
A number of globally applied restraints follow the refinement instruction in the first part
of the ins file. Several restraints on atomic displacement parameters (sADPs) can be
applied when using SHELXL, especially during an anisotropic refinement. An anisotropic
refinement requires six parameters per atom for the displacement instead of just one as
is the case in an isotropic refinement. It is advisable to refine anisotropically only when
the resolution is high enough and the data-to-parameter ratio is sufficiently high.
The restraint SIMU makes anisotropic ADP of two atoms more equal, which can be
useful for disordered parts of the model when the atoms overlap. The rigid bond restraint
DELU can be used to restrain the motion of two bonded atoms to be more equal along
the bond. Another powerful restraint is RIGU, which assures that the relative motion of
two bonded atoms is perpendicular to the bond joining them. This reduces the number of
independent parameters per atom. The restraint can also be applied to 1,3 distances or
globally on all atoms, further improving the data-parameter-ratio. The constraint XNPD
defines a minimum value for all atoms’ displacement parameters, enforcing positive
definite values.
Furthermore, a number of specific restraints can be generated for the given content of
the pdb file:
• Restraints for all natural amino acids present.
• Instructions for the generation of hydrogen atoms (HFIX) for all natural amino acids
are given with ’REM’ as prefix. Removing the prefix will add the hydrogen in the
next refinement cycle as riding atoms.
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• Restraints of the most common ligands are available and added when present.
This only includes distance and angle distance restraints but not HFIX instructions.
• For all cysteine residues the distance between the sulfur atoms is calculated.
Should two sulfur atoms be closer than 3 Å, restraints for a disulfide bridge are
added.
• All amino acids are checked for their completeness. To prevent error messages in
SHELXL when restraints are employed, appropriate ’HFIX 0’ instruction are added
for incomplete amino acid side chains.
• All terminal residues of a polypeptide chain are identified by distance calculations.
Once terminal residues are recognized, the naming of the C-terminal oxygen
residues is reviewed. Other naming conventions apply for terminal residues than
for the rest of the peptide chain and the oxygen atoms are renamed if necessary.
Otherwise, only the appropriate restraints are added, including the correct HFIX
command for the N-terminal end.
• All residues showing disorder are sorted into parts. This method makes sure
the disorder is handled correctly. The user can later refine the occupation of
this residues by assigning free variables to the disordered parts. Until then the
occupations as given in the pdb file are transferred.
• Bond, angle and chiral volume restraints for proteogenic amino acids are added.
Restraints for the most common ligands were created using the GRADE server14 and
are added automatically where appropriate. Some of the more specific restraints, e.g.
for the terminal restraints, are explained in the following in more detail.
Terminal restraints
To generate the correct geometry and riding hydrogen atoms restraints, the terminal
residues have to be handled separately. The N terminus needs a different hydrogen
atom command, since it is consisting of an amine group. The C terminus is a carboxyl
group and the geometry is restraint with distance restraints.
14http://grade.globalphasing.org, Global Phasing Ltd.
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N -terminus:
C-terminus:
HFIX 33
DFIX 1.249 C OT1 C OT2
DANG 2.379 CA OT1 CA OT2
DANG 2.194 OT1 OT2
(3.15)
Terminal residues are identified by the calculation of distances to other residues (see
Algorithm 1).
Generation of fractional coordinates
PDB2INS generates the atom instruction with positions in fractional coordinate space.
Cartesian coordinates, as given in pdb files, are transformed as described before by
Grosse-Kunstleve and Adams (2002) and Lübben et al. (2015).
The angles α, β, and γ in degrees are transformed to radians α′, β′, and γ′:
α′ = α180◦ · pi, β
′ = β180◦ · pi, γ
′ = γ180◦ · pi (3.16)
All conversions can be achieved using the matrix Mcf , transforming from Cartesian to
fractional space.
M cf = M−1fc =

1
a − cos(γ
′)
a·sin(γ′) bc
cos(α′) cos(γ′)−cos(β′)
a·V ·sin(γ′)
0 1b·sin(γ′)
cos(β′) cos(γ′)−cos(α′)
b·V ·sin(γ′)
0 0 sin(γ
′)
c·V
 (3.17)

u
v
w
 = M cf ·

x
y
z
 (3.18)
where u, v, w are the coordinates in fractional space, x, y, z are the coordinates in
Cartesian space, and V is the volume of the unit cell.
V =
√
1− cos(α′2)− cos(β′2)− cos(γ′2) + 2 · cos(α′) cos(β′) cos(γ′) (3.19)
Generation of displacement parameter Uiso from atomic temperature factor
All pdb files contain the atom coordinates together with a temperature factor for the
atoms, called B-factor. When the diagonal elements of the matrix are all equal to each
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Algorithm 1: Find terminal residues in a macromolecule.
1 list: naturalAA and nonAA ;
// list of all natural amino acids or all else, respectively.
2 for each residue number in molecule do
3 if residue has smallest residue number and is naturalAA then
4 append residue to ListOfN − TerminalResidues
5 end
6 if residue has highest residue number and is naturalAA then
7 append residue to ListOfC − TerminalResidues
8 end
9 end
10 for atoms, residue in ListOfN − TerminalResidues do
11 if atomname of atom is N then
12 for atom in listofnonaminoacidresidues do
13 calculate distance between atom and N ;
14 if distance ≤ 3.0 then
15 N is not terminal residue;
16 remove residue from ListOfN − TerminalResidues
17 end
18 end
19 end
20 end
21 for each residue in ListOfC − TerminalResidues do
22 if atomname of atom is O then
// Terminal oxygen atoms can also be named OT1, OT2 or OTX
23 for atom in listofnonaminoacidresidues do
24 calculate distance between atom and O;
25 if distance ≤ 3.0 then
26 O is not terminal residue;
27 remove residue from ListOfO − TerminalResidues
28 end
29 end
30 end
31 end
59
CHAPTER 3. PDB2INS
other and the off-diagonal elements are equal to zero, the B-factor is isotropic. Only one
number is needed to describe the isotropic B factor.
Biso =

B11 0 0
0 B11 0
0 0 B11
 (3.20)
SHELXL requires the atomic displacement parameter U iso instead. PDB2INS calcu-
lates the displacement parameter via a simple conversion.
Uiso =
Biso
8 · pi2 (3.21)
Transformation of anisotropic ADP
All anisotropic ADPs are converted into fractional coordinates as established (Grosse-
Kunstleve and Adams, 2002, Lübben et al., 2015). The anisotropic ADP in Cartesian
space is represented by a matrix Uij,cart.
U ij,cart =

U11 U12 U13
U12 U22 U23
U13 U23 U33
 (3.22)
The ADP can be transformed into the matrix representation in fractional coordinates
Uij,frac using
U∗ij = M cf ·U i,j ·MTcf (3.23)
and
U ij,frac = N−1 ·U∗ij ·
(
N−1
)T
. (3.24)
The conversion matrix Mcf is defined in Equation 3.17 and the scaling factor N is
given by:
N =

1
a 0 0
0 1b 0
0 0 1c
 . (3.25)
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Handling of residues
SHELXL finds most application in the refinement of small molecule structures. Many
small molecule crystallographers use SHELXL in combination with the graphical user
interface SHELXle (Hübschle et al., 2011). In small molecule crystallography most
structures do not need to be grouped into smaller units like molecules or residues for the
refinement.
Nonetheless, SHELXL provides useful features for macromolecular crystallographers
in that respect. While one atom per line is defined by only the atom name, coordinates,
occupancy and U values, it is possible to group the atoms with specific instruction lines.
Atoms can be grouped into residues and residues can be further grouped into chains.
Before each separate entity, a line defining it as residue (RESI) can be entered, specifying
a residue name (three characters), chain ID, and residue number. For example, the
residue tyrosine in chain A with the residue number 21 can be defined by the following
line specified before the corresponding atom lines:
RESI TYR A : 21 (3.26)
It is allowed to use a residue name multiple times, but the residue number must be
unique in each chain.
Once the data is structured into residues, restraints can be globally applied to all
residues carrying the same name. This feature is especially useful when handling
macromolecular data where a chain containing a repeating sequence of amino acids can
have a standard set of restraints for all natural amino acids. For example, the following
command restraints the Cα-Cβ bond in all alanine residues:
DFIX_ALA 1.521 CA CB (3.27)
Furthermore, all atoms can be explicitly named by referring to them in the form
atom name_chainID : residue number, (3.28)
e.g. OT1_A:125 refers to atom ’OT1’ in residue 125 in chain A.
The restraints are implemented in PDB2INS as they were published by Engh and
Huber (1991). Additionally, PDB2INS contains a library of restraints for the most common
ligands in the PDB. These restraints were mainly generated using the GRADE server.
Another hurdle is the residue name accepted by SHELXL. The residue name can
be three characters long, as it is common in macromolecular crystallography, but must
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contain at least one letter. Most common residues names contain a letter, such as
amino acids or nucleobases, and do not pose a problem. But since a large number of
ligands and small molecules can be present in a crystal, some of these have a PDB
code containing only digits. These ligand PDB codes are naturally used as residue name
for identification purposes but can not be processed by SHELXL. PDB2INS recognizes
these ligands and offers the option to rename them.
Treatment of hydrogen atoms
Should neutron data be present, a specific instruction (NEUT) must be included in the
first part of the ins file. This instruction prompts SHELXL to employ neutron scattering
factors and absorption coefficients and adjusts distance restraints as well as a more
sensible treatment of hydrogen atoms. Furthermore, all hydrogen atoms already present
in the pdb file are kept and transferred to the new file by PDB2INS. This option is also
available for XRD data, but not done automatically. Iin that case it is recommended
to constrain all hydrogen with commands (HFIX) as riding atoms. Specific treatment
of hydrogen atoms in a refinement against neutron data is described in Gruene et al.
(2013).
PDB2HKL
A separate module PDB2HKL was written, since the handling of reflection data rep-
resents a challenge in macromolecular crystallography. The most common reflection
data format in macromolecular crystallography is the crystallographic file format cif or
mmcif. This should not be confused with the small molecular cif, since no consistent file
format standard is applied. A number of other file formats are in use such as mtz, sca or
HKL. In small molecular crystallography the hkl format is predominant and is used for
SHELXL refinements. There are a number of scripts and programs one can employ to
convert between different file formats. Most of them are applied automatically as part
of pipelines or with graphical user interfaces such as CCP4i2 or PHENIX. Others are
stand-alone programs such as CIF2MTZ (Winn et al., 2011), MTZ2HKL (Grune, 2008),
or XPREP. Since SHELXL only reads hkl format reflection files and one objective was to
create an easy access to macromolecular refinement with SHELXL, the utility program
PDB2HKL was written. PDB2HKL can take the crystallographic reflection data mmcif
file as it is provided by the PDB and create an hkl file suitable for SHELXL refinement.
PDB2HKL reads the ’name-sf.cif’ file and searches for keyword sets. Keyword sets as
listed in Table 3.2 are recognized. All keywords of a given keyword set must be present
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in the reflection data file to be accepted as a complete data set. Should more than
one set of reflections be present, the program selects intensities over amplitudes and
unmerged over merged data. The program will write feedback to the console, stating
which data was found and transferred into the hkl file.
Table 3.2.: Keywords recognized by PBD2INS module PDB2HKL from reflection files in mmcif format. A
set of keywords has to be complete to be accepted.
reflection type keyword set
unmerged intensities +
standard uncertainties
_refln.pdbx_I_plus, _refln.pdbx_I_minus,
_refln.pdbx_I_plus_sigma, _refln.pdbx_I_minus_sigma
merged intensities +
standard uncertainties
_refln.I_meas_au, _refln.I_meas_sigma_au
_refln.I_meas, _refln.I_meas_sigma
_refln.F_squared_meas, _refln.F_squared_sigma
_refln.intensity_meas, _refln.intensity_sigma
unmerged amplitudes +
standard uncertainties
_refln.pdbx_F_plus, _refln.pdbx_F_minus,
_refln.pdbx_F_plus_sigma, _refln.pdbx_F_minus_sigma
merged amplitudes +
standard uncertainties
_refln.F_meas_au, _refln.F_meas_sigma_au
_refln.F_meas, _refln.F_meas_sigma
Since the standard format of a reflection in the hkl file only allows seven characters
for the amplitude/intensity of the reflection, it can not exceed 9999999. Is the ampli-
tude/intensity greater than this value, the whole dataset is scaled by a factor setting it
to 9999999. Reflections where either h, k, l, reflection intensity/amplitude or estimated
standard deviation (e.s.d.) are undefined (indicated by a ’?’ character) are omitted. The
file will be terminated with a line containing all zero items.
PDB2HKL was integrated into PDB2INS and is executed as a first step. The generation
of an hkl file is optional, but the information whether amplitudes or intensities are present
in the data file is mandatory for the ins file. PDB2HKL will extract this information when
used and forward it to the main program.
3.3.4. Versions of PDB2INS
All versions are available as standalone executables for Linux, Windows and MacOSX.
The source code is published under the GNU lesser general public license and is freely
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available.
Command line use
It is possible to use PDB2INS is as an interactive command line program. The user is
guided through the creation of input files for a SHELXL refinement in a step-by-step
manner. When starting the program without any additional commands, the start screen
is visible as depicted below.
INFO: +++ starting PDB2INS. +++
########################################################################
# PDB2INS #
# by Anna V. Luebben (Darwin\_x86\_64@2018 -01 -04) #
########################################################################
Reads a PDB file and generates an .ins file for SHELXL.
The PDB file is assumed to conform to the Protein Data Bank notes
’Atomic Coordinate and Bibliographic Entry Format Description Version
3.30’. For remarks and problems please contact aluebbe@gwdg.de.
Usage:
pdb2ins <filename|@pdbcode > [options]
<filename|@pdbcode > Exact name of a file in PDB format or
a legal pdb code prefixed by ’@’.
Enter ’--help ’ for complete options list.
Enter ’q’ or ’exit ’ to exit the program.
Create .hkl file from structure factor file (cif) or PDB code? (y or n) [N]:
At first, an hkl file containing reflection data can be created from an -sf.cif file. The
format of the reflection is a necessary information for the creation of the ins file. For this
reason the program asks for a reflection data file first and extracts the format.
Successively, the program will create the hkl file and read the pdb file. For all missing
information or supplementary options the user is prompted for input. Additionally, all
relevant changes or information is given to the user using the keywords info, attention
or error.
PDB2INS will confirm that all requested files were written before terminating. The user
can end the program at any point by simply using the command ’q’ or ’exit’.
Several options can be passed to the program via command line arguments (see
Table 3.3). An overview of all options will be displayed if the program is started with the
argument ’pdb2ins - -help’. These options allow the user to control nearly all decisions
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in the program while starting it. This provides a powerful tool to use the program as part
of a script or pipeline and skip all interaction.
Table 3.3.: Options available during startup of PDB2INS prefixed by ’-’ are tabulated.
option description
w followed by the wavelength in Ångstroms to enter a wavelength manually.
h followed by a value to enter hkl format in SHELX syntax.
c followed by the six coordinates (a,b,c,alpha,beta,gamma) in Ångstroms
and Degrees to enter the cell (No spaces allowed).
s followed by the space group (No spaces allowed).
i skip user input interrupts.
a use anisotropic displacement data if available.
b create an hkl file from a PDB structure factor file (cif ) or PDB code.
d followed by a filename to specify structure factor file in cif format.
e all hydrogen atoms are transferred from the pdb file to the ins file.
o followed by a filename to specify the output filename.
r if a PDB code is given with ’@’, this option fetches the pdb file from the
PDB_REDO server.
z followed by a number specifying the Z value (number of molecules per
cell).
PDB2INS can be used in a customized, automated way. The option ’-i’ allows the
user to skip all questions when running the program and use default answers instead. In
combination with the other options these can be modified to suite the users needs.
Graphical User Interface
TKinter was used to create the GUI (see Figure 3.3). The top part of the GUI is used
to capture user input as well as select options for the file conversion. The bottom part
displays a text window either showing output from the program or an explanation for the
buttons of the top half.
At the top left corner the file name can be typed in or selected from the file structure. In
case a PDB file should be downloaded from the RCSB PDB website, the four letter PDB
code must be given prefixed with ’@’. On the right a ’Load’ button is located. Once the
file field is filled in, the Load button should be pressed to display the important information
from the file. When a PDB code was inserted, the file is downloaded beforehand. Should
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Figure 3.3.: Depiction of the PDB2INS graphical user interface developed to streamline the use of SHELXL
with macromolecular crystallography data.
one press a question mark button next to one of the fields or buttons in the top half, the
corresponding explanation will appear in the text window.
Most options of the command line program are available in the GUI, for others default
answers are used. For example hydrogen atoms are automatically transferred to the
ins file for neutron diffraction data but not for XRD data. The program will not start
until all essential information is completed in the fields above the start button. Is
information missing, the corresponding field is highlighted with a red background color.
A successful run of the program can be monitored in the text window on the bottom half,
were command line output is displayed. Also errors while running the program will be
displayed in the text window.
This graphical user interface is freely available15.
3.3.5. Refinement with SHELXL
Refinement with SHELXL can be started from the command line with the command
’shelxl name’, where name is the file name base (without extension) of the required files.
It is recommended to perform the refinement against intensities (F-squared) in conjugate
gradient (CGLS) mode. Results of the refinement can be inspected using an interactive
15http://github.com/av-luebben/PDB2INSGUI.
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graphics display program such as COOT. It is advisable to compare the models with the
respective electron density map after each refinement iteration.
Optionally, disordered side chains or sections can be modeled by using the PART
instruction. Disorder can be modeled as two-fold or multi-fold and the occupation of
each part can be refined using free variables (FVAR). Free variables in SHELXL are a
powerful concept to refine e.g. the occupancy of a single atom or a group of atoms in
a disorder. For example, in combination with the PART instruction, the occupancy of
a disordered side chain in two parts can be refined for each part individually with the
restriction that the sum of the individual occupancies must be one.
At first, it is recommended to refine all parameters isotropically to quasi convergence
and then continue with an anisotropic refinement if the resolution of the data is sufficient
(Sheldrick, 1996). An anisotropic refinement is not recommended for structures with
an overall resolution lower than 1.5 Å. The introduction of anisotropic displacement
parameters should lead to a drop in both R1 (Rcryst) and Rfree. If a drop of Rfree is not
observed, the refinement of anisotropic ADP is not sensible and should be abandoned.
The addition of hydrogen atoms can be achieved by adding appropriate commands to
the instruction file (HFIX). This commands were generated automatically by PDB2INS
during the file creation, but are not used by default. To use these instructions, the
preceding ’REM’ before the command must be removed.
As final step, a cycle of full-matrix least squares (L.S.) refinement, optionally blocked
(BLOC), can be performed to obtain standard uncertainties of all refined parameters.
3.4. Results and discussion
PDB2INS successfully generates input files for a refinement of macromolecules with
SHELXL. Multiple ways to access PDB2INS are available to all users. The program can
be used with a graphical interface (PDB2INSgui) or in an interactive mode via command
line. Also, the command line version can be used without user input in an automated
way, for example to implement PDB2INS in scripts.
PDB2INS recognizes a variety of specific PDB keywords and takes appropriate action
to translate them into SHELXL format without loss of information. The need to manually
edited the instruction file for SHELXL is reduced to a minimum or, in most cases, made
obsolete.
PDB2INS automatically introduces restraints developed in recent years in a sensible
way. Furthermore, with PDB2INS the direct access to SHELXL is possible using a PDB
code. No other programs are necessary to generate all files essential to refine with
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SHELXL when using PDB standard format files.
PDB2INS offers several advantages that have not been available before. In comparison
to SHELXPRO, the user has more control over the information the instruction file can
contain. Also, more information is extracted from the input files by default. Some
additional restraints for ligands are directly added to the instruction file for SHELXL.
Additionally, the conversion of structure factor cif files is now available directly from within
PDB2INS. Another improvement is the availability of a graphical user interface for users
not comfortable with command line programs.
3.4.1. Test of PDB2INS against protein database files
PDB2INS was tested in an automated way against data available from the PDB. Only
XRD structures deposited after 2007 and containing reflection data as well as coordinates
were selected. All data with a resolution of 1.7 Å or better where chosen as a test set,
amounting to 23 974 structures in total.
From all files tested, 95.98% were converted to the SHELXL input files without error
and could be refined successfully (see Figure 3.4). A successful refinement is assumed
when SHELXL starts with the refinement and finishes it after ten conjugate-gradient
least-squares cycles. The remaining 4.02% of files could not be processed fully. The
points of failure were investigated and are presented in this section and in Section B.2.
At several points during the test, information about problems and error messages was
collected. PDB2INS recognizes the most common complications and writes appropriate
log messages. This messages can be utilized by the user to edited the input files, if
necessary, and run PDB2INS again.
SHELXL also displays feedback when a refinement with the applied files is not possible.
Usually, this feedback can be used to correct the input files as well. Some complications
occur more frequently than others, the most common ones are listed in Table 3.4.
The test of nearly 24 000 pdb files showed that the majority of files (23 010 files,
95.68% total) could be refined with SHELXL without any problems. From the remaining
data sets (964 files, 4.02% total), 19.7% (190 files, 0.79% total) manifested an error in
PDB2INS and 80.3% (774 files , 3.23% total) in SHELXL. This does not mean that the
complication itself was caused by the program displaying the error, but that it was simply
detected while using it. An overview of the most commonly reported complications is
displayed in Figure 3.5, grouped by the reporting program.
68
3.4. RESULTS AND DISCUSSION
Ta
bl
e
3.
4.
:M
os
tc
om
m
on
co
m
pl
ic
at
io
ns
w
hi
le
us
in
g
P
D
B
2I
N
S
an
d
S
H
E
LX
L
in
su
cc
es
si
on
.
pr
og
ra
m
a
er
ro
r
de
sc
rip
tio
n
P
D
B
2I
N
S
in
co
m
pl
et
e
st
ru
ct
ur
e
fa
ct
or
fil
e
T
he
in
qu
iry
fil
e
-s
f.c
if
di
d
no
tc
on
ta
in
a
co
m
pl
et
e
se
to
fr
efl
ec
tio
n
ke
yw
or
ds
.
P
D
B
2I
N
S
on
ly
co
nv
er
ts
a
re
fle
ct
io
n
fil
e
if
a
ke
yw
or
d
se
ti
s
co
m
pl
et
e.
A
cc
ep
te
d
ke
yw
or
d
se
ts
ar
e
lis
te
d
in
Ta
bl
e
3.
2.
m
or
e
th
an
on
e
m
od
el
It
is
le
ga
lt
o
de
po
si
tm
or
e
th
an
on
e
m
od
el
in
on
e
pd
b
fil
e.
P
D
B
2I
N
S
ca
nn
ot
ha
nd
le
th
os
e
fil
es
an
d
w
ill
te
rm
in
at
e
w
ith
ou
tw
rit
in
g
a
ne
w
fil
e.
R
em
ov
in
g
al
l
bu
to
ne
m
od
el
fro
m
th
e
in
pu
tfi
le
w
ill
en
ab
le
P
D
B
2I
N
S
to
co
nv
er
tt
he
fil
e.
pr
ob
le
m
w
hi
le
ha
nd
lin
g
in
se
r-
tio
n
co
de
s
P
D
B
2I
N
S
is
ca
pa
bl
e
of
re
nu
m
be
rin
g
re
si
du
es
w
he
n
an
in
se
rt
io
n
co
de
is
us
ed
.
T
hi
s
is
ne
ce
ss
ar
y
si
nc
e
no
sp
ec
ifi
c
m
et
ho
d
of
ha
nd
lin
g
in
se
rt
io
n
co
de
s
is
av
ai
la
bl
e.
W
he
n
th
is
re
nu
m
be
rin
g
is
af
fe
ct
ed
by
co
m
pl
ic
at
io
ns
,t
he
re
si
du
e
th
at
co
ul
d
no
tb
e
re
nu
m
be
re
d
is
in
cl
ud
ed
in
th
e
er
ro
rm
es
sa
ge
.
S
H
E
LX
L
ba
d
re
si
S
H
E
LX
L
te
rm
in
at
ed
w
ith
ou
tr
efi
ne
m
en
tw
he
n
on
e
of
th
e
re
si
du
es
ha
s
a
re
si
du
e
na
m
e
co
nt
ai
ni
ng
on
ly
di
gi
ts
.
Th
is
is
al
lo
w
ed
in
pd
b
fil
es
.
P
D
B
2I
N
S
w
ill
pr
om
pt
th
e
us
er
to
ch
an
ge
th
is
re
si
du
e
na
m
es
w
he
n
ru
n
in
in
te
ra
ct
iv
e
m
od
e.
H
ow
ev
er
in
an
au
to
m
at
ed
m
od
e,
P
D
B
2I
N
S
on
ly
w
rit
es
a
w
ar
ni
ng
bu
tc
on
tin
ue
s
w
ith
ou
t
re
na
m
in
g.
re
fle
ct
io
n
hk
l
ha
s
w
ro
ng
fo
r-
m
at
O
ne
re
fle
ct
io
n
do
es
no
ta
dh
er
e
to
th
e
hk
lf
or
m
at
as
sp
ec
ifi
ed
in
S
ec
tio
n
3.
3.
2.
T
he
hk
lfi
le
ca
n
be
ed
ite
d
m
an
ua
lly
to
fix
th
is
re
fle
ct
io
n.
T
he
ne
xt
ve
rs
io
n
of
P
D
B
2I
N
S
w
ill
re
fo
rm
at
th
os
e
re
fle
ct
io
ns
ap
pr
op
ria
te
ly
.
un
kn
ow
n
el
em
en
t
Th
e
pd
b
fil
e
co
nt
ai
ns
an
el
em
en
tn
am
e
in
th
e
S
FA
C
in
st
ru
ct
io
n
lin
e
th
at
do
es
no
tc
or
re
sp
on
d
to
th
e
fir
st
98
el
em
en
ts
of
th
e
pe
rio
di
c
ta
bl
e.
M
os
tc
om
m
on
ly
,
on
e
of
th
e
el
em
en
ts
is
sp
ec
ifi
ed
as
’X
’,
an
un
kn
ow
n
el
em
en
t,
w
hi
ch
na
tu
ra
lly
do
es
no
tc
or
re
sp
on
d
to
an
y
sc
at
te
rin
g
fa
ct
or
s
in
S
H
E
LX
L.
no
m
at
ch
fo
ra
to
m
in
re
st
ra
in
t
O
ne
or
m
or
e
at
om
s
do
no
th
av
e
th
e
ap
pr
op
ria
te
re
st
ra
in
ts
sp
ec
ify
in
g
th
em
.
Th
e
us
er
ca
n
ch
ec
k
if
th
e
m
en
tio
ne
d
re
si
du
es
ar
e
na
m
ed
co
rr
ec
tly
.
a
Th
e
pr
og
ra
m
re
po
rt
in
g
th
e
er
ro
ri
s
lis
te
d
he
re
.
Th
is
do
es
no
tn
ec
es
sa
ril
y
im
pl
y
th
at
th
e
er
ro
rl
ie
s
w
ith
in
th
e
pr
og
ra
m
its
el
f.
69
CHAPTER 3. PDB2INS
Figure 3.4.: Analysis of PDB2INS test against all XRD data to a resolution of 1.7 Å deposited with reflection
data in the PDB since 2008.
(a) Errors reported by SHELXL.
(b) Errors reported by PDB2INS.
Figure 3.5.: Overview of the test results of PDB2INS against a selected part of the PDB database. Compli-
cations reported by SHELXL (a) and PDB2INS (b) are displayed with number of occurrence
(above) and percentage (below).
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The most common problem was an issue regarding the residue name. To this problem
appertain 31.7% (306 files, 1.28% total) of all failures to refine a dataset within SHELXL.
The affected data sets contain one or more residues with a residue name consisting of
only digits. These residues do not adhere to the naming convention in SHELXL but are
legal in the PDB format. PDB2INS provides the option to rename these residues while
using the interactive mode. The user is automatically informed of the expected conflict
and can immediately rename the residue.
The second most common problem was regarding an issue with the format of reflec-
tions. This problem is reported by SHELXL and occurs in 22.4% (216 files, 0.90% total)
of all failures during refinement. This complication is caused by the conversion of the
reflection from -sf.cif to hkl format in PDB2INS. Since only a single or a few reflections
are affected by this format error, it is possible to manually edit the hkl file.
Furthermore, 11.2% (108, 0.45%) of errors are caused by the inclusion of an unknown
element in the structure, often named element X. Since this element does not exist in
the periodic table of elements, SHELXL cannot assign scattering factors to the element.
This requires the users intervention to assign valid elements to the atoms in question.
All other issues are listed in more detail in Section B.2.
In conclusion, PDB2INS can facilitate an easy, direct access to a refinement of
macromolecular structures with SHELXL for nearly all of the suitable data sets. The test
was designed to bring bugs in PDB2INS to attention although it also provides evidence
of the success. Further developments in PDB2INS will improve upon this results.
3.5. Outlook
3.5.1. Possible developments in SHELXL
SHELXL allows the modeling of diffuse solvent regions using a variation of Babinet’s
principle (Moews and Kretsinger, 1975). This is implemented in a single instruction
(SWAT) and can improve the agreement of the very low angle data. The method warrants
improvement and cannot compete with implementations in other refinement programs.
The development of a better, more suitable solvent model in SHELXL is desirable.
3.5.2. Further prospects of PDB2INS
Currently the program PROSMART (Nicholls et al., 2012) can be used to generate
external restraints (Murshudov et al., 2011), which are then converted to SHELXL format
(Gruene et al., 2013). It is conceivable to extent PDB2INS with an option to derive
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restraints for a SHELXL refinement directly from a homologue structure. Restraints from
a homologue could be generated in the form of 1,4 distance restraints and applied to the
new structure. A search for the longest common substring in the amino acid sequence
can be implemented into PDB2INS. The so established sequence identity can be the
basis of the restraints.
Furthermore, the progress of the PDB and their file format system have to be taken
into account. While most refinement programs still use pdb as their standard output file
format, the PDB might change the available file format for direct download. Before long,
the pdb format will be replaced by a pdb-cif format for all coordinates and associated
information. Support for this file format can be implemented into PDB2INS as well.
A further possible addition to PDB2INS can be an interface to the GRADE server for
generating restraints. Today, only a database of the most common ligands in the PDB is
available in PDB2INS. In addition to the pre-computed restraints stored within PDB2INS,
users could be given the option to generate appropriate restraints on-the-fly. The user
can use the output from PDB2INS directly and be sure that all molecules present are
restraint appropriately. However, right now the server is available for non-interactive
scripts only upon request.
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Ceroid-Lipofuscinosis Neuronal Protein 5
Neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, is a group of rare
and severe autosomal-recessively inherited diseases involving neurodegeneration – a
progressive loss of neurons. The disease group is associated with retinopathy, cognitive
decline, myoclonic epilepsy and progressive cerebellar atrophy. The NCLs belong
to the superordinate group of lysosomal storage diseases. The inherited conditions
are characterized by the lysosomal accumulation of auto-fluorescent lipofuscin-like
lipopigments in neuronal and extra-neuronal tissues (Goebel, 1997). Earlier classified
among the amaurotic family idiocies, the term neuronal ceroid lipofuscinosis was first
used by Zeman and Dyken (1969). NCL became delimited to inherited storage disorders
with progressive decline of mental, motor, and visual functions (Dyken, 1989).
NCL associated proteins are heterogenous in their function and cellular location.
Mutations in these proteins cause common clinical and pathological features. While the
function of many NCL proteins is established, the protein structure of cln5 remained
unknown and the function poorly understood. The ceroid-lipofuscinosis neuronal protein
5 (cln5) is the focus of this work1.
4.1. Neuronal Ceroid Lipofuscinoses
4.1.1. A brief history
O. C. Stengel, a physician in Norway, first described a probable NCL in a case of four
siblings. The clinical features are compatible with the disease today classified as CLN3
disease (Stengel, 1826)2. The children displayed blindness and progressive dementia
with juvenile onset of the disorder. Later, the English neurologist F. E. Batten described
1In this work the following protein and gene nomenclature will be applied: Human gene symbols are in
uppercase letters and italicized. Disease designations are the same as the gene symbol but not italicized.
Protein symbols are in lowercase letters of the disease symbol unless named after their protein product.
The mouse gene is italicized but only the first letter is uppercase. For example: human gene: CLN5;
disease: CLN5; protein: cln5; mouse gene: Cln5.
2The original article ’Beretning om et mækeligt Sygdomstilfælde hos fire Sødskende I Nærheden af
Röraas’ was translated to ’Account of a singular illness among four siblings in the vicinity of Røraas’ and
mentioned first in (Armstrong et al., 1982).
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two cases within one family showing the neuropathology of cerebral degeneration with
ocular macular changes (Batten, 1903, 1909). Shortly after, F. Spielmeyer (1905) and
H. Vogt (1906) reported a similar disorder, which became known as Batten disease or
Batten-Spielmeyer-Vogt disease.
With a late-infantile onset, a similar disease was reported by J. Janský (1908) and M.
Bielschowsky (1913) and referred to as Janský-Bielschowsky disease (earliest mention
of CLN2). An adult-onset form with similar pathological characteristics was described by
H. Kufs in the 1920’s and 1930’s (Anderson et al., 2013, Kufs, 1925). In contrast to the
earlier described juvenile and late-onset cases, Kufs disease, or CLN4, did not progress
with loss of vision. A disease with early-onset, known as Haltia-Santavuori disease or
classic infantile, was firstly described by M. Haltia and P. Santavuori during the 1970’s
(Haltia et al., 1973).
An overview of the NCLs associated genes and their classification is displayed in
Table 4.1. Further background about NCL pathogenesis is provided in Section C.1.1.
4.1.2. Classification
While earliest cases were associated by similar pathology it became clear that the
diseases display a different age of onset and were classified thereby. Although known
by their eponyms, the expression ’Batten disease’ was often used for the juvenile-onset
disease as well as for the whole association of diseases. As causative genes were
unknown, the classification was achieved by distinctive ultrastructural patterns in addition
to age of onset (Zeman and Dyken, 1969). Later discovered forms of NCL were referred
to by their country of origin, e.g. CLN5 and CLN7 were referred to as Finnish variant and
Turkish variant, respectively (Santavuori et al., 1982, Williams et al., 1999).
At first, NCLs had been associated with the so-termed ’amaurotic family idiocies’ due
to the resemblance of clinical features with Tay-Sachs disease, the prototype of this
disease family. Zeman and Dyken (1969) revised this by designating them as inherited
storage disorders, clinically characterized by progressive decline of mental, motor, and
visual functions. Thereby a new group was created, distinctly separated and termed
neuronal ceroid lipofuscinoses in 1969 (Zeman and Dyken, 1969).
At length the nature of the storage material accumulated had been discussed and was
a contributing factor in distinguishing Tay-Sachs-type from NCL diseases (Terry and Ko-
rey, 1960). Long described as auto-fluorescent lipopigments, ceroid or lipofuscin (Zeman
and Donahue, 1963, Zeman and Dyken, 1969), the major component of the accumulated
storage bodies was identified as subunit c of mitochondrial adenosine triphosphate
synthase (ATPase) for most animal and human NCL forms (Palmer et al., 1986). The flu-
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orescence of the storage bodies is an aggregate property of non-fluorescent compounds
(Palmer et al., 1993, 2002). The ATPase is a transmembrane protein responsible for
the synthesis of adenosine triphosphate (ATP). Adjacent sphingolipid activator proteins
(ssaposins) A and D have been found as main components in infantile NCL and autoso-
mal dominant form of adult NCL (Nijssen et al., 2002, Tyynelä et al., 1993). Saposins
facilitate the catabolism of glyco-sphingolipods in lysosomes (Munford et al., 1995).
Thus, another subdivision of the NCL diseases into those accumulating subunit c of the
mitochondrial ATPase and those storing saposins A and D, is possible.
Developments in the field of genetics allowed to link the CLN3 disease to chromosome
16 (Eiberg et al., 2008). In 1995 the gene responsible for the infantile Haltia-Santavuori
disease (CLN1) was identified by a positional candidate gene approach (Vesa et al.,
1995). In the same year, the genes underlying classic late infantile Janský-Bielschowsky
disease and juvenile Spielmeyer-Sjörgen disease were identified as CLN2 and CLN3,
respectively (Lerner et al., 1995, Sleat, 1997). Due to the fast advancements in the
identification of NCL genes, a new classification based thereupon evolved (Goebel et al.,
1999, Haltia, 2003, Hofman and Peltonen, 2002, Mole, 2004, Wisniewski et al., 2001).
So far, nine genetic forms of NCL have been identified (CLN1–8, CLN10) and more
show evidence of accumulation of ceroid lipofuscin (CLN11–14).
As more forms were discovered, additional features distinguished the NCLs, for
instance specific clinical features, rate of progression, underlying cell biology, and
biochemistry. A proposed general definition is "A progressive degenerative disease
of the brain and, in most cases, the retina, in association with intracellular storage of
material that is morphologically characterized as ceroid lipofuscin or similar." (Mole et al.,
2012) With advances in gene classification and analysis, many experts suggest a primary
classification by gene and secondary classification by clinical features and age of onset
(Williams et al., 2011). Diagnosis based on clinical or phenotypical features remains
difficult, since different mutations within one gene may result in varying phenotypes
and age of onset. Therefore, a more extensive taxonomy has been recommended as a
clinical nomenclature consisting of seven axes (Williams and Mole, 2012):
1. affected gene (CLN gene symbol)
2. mutation diagnosis
3. biochemical phenotype
4. clinical phenotype
5. ultrastructural features
6. functionality
7. other remarks.
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4.1.3. Interaction and common pathways
Most of the NCLs show common pathways, but full understanding of the interactions
and mechanisms remains elusive. A common factor in the severe neurodegenerative
diseases of some NCLs is the disturbed lipid metabolism. Lyly et al. (2008) proposed
that cln1 interacts with the F1-complex of the mitochondrial ATPase. In Cln1 knockout
mice (Cln1-/-) studies, neurons show entropic α and β subunits of ATPase enriched in
plasma membrane (Getty and Pearce, 2011). It has been reported earlier that infantile
NCL patient’s fibroblasts show reduced basal ATPase activity and deficient regulation of
the enzyme (Das et al., 1999).
Components of ATPase localize to the plasma membrane of many different cell types
and may act as receptors for multiple ligands as well as participate in regulation of lipid
metabolism and cellular proliferation (Arakaki et al., 2003, Kim et al., 2004, Martinez
et al., 2003). Cln1-/- mice have been reported to show reduced levels of total cholesterol,
apolipoprotein A1 (ApoA1), and attenuated phospholipid transfer protein (PLTS) activity
by serum lipid analysis (Lyly et al., 2008). Reportedly PLTS is involved in the transfer
process of cholesterol to high density lipoprotein by the ATP-binding cassette transporter
1 (ABCA1)-mediated pathway (Oram et al., 2003). Furthermore, in Cln1-/- mice glial
cells and neurons an increased uptake of radio-labelled ApoA1 was observed (Lyly et al.,
2008).
The interaction of the protein cln1, palmitoyl-protein thioesterase 1 (PPT1), and the
protein cln5 with the mitochondrial F1-ATPase in in vitro assays was reported by Lyly
et al. (2008, 2009). Mitochondrial F1-ATPase was described to act as a receptor for
ApoA1 (Martinez et al., 2003). Abnormal molecular phospholipid species were found in
the cerebral cortex of CLN1 and CLN3 patients (Käkelä et al., 2003).
Other NCLs have been described to play a role in disturbed lipid metabolism as well.
The cln8 protein reportedly influences ceramide synthesis, lipid regulation, and protein
translocation in the endoplasmic reticulum (ER) (Haddad et al., 2012, Kuronen et al.,
2012, Winter and Ponting, 2002). Cathepsin D (CTSD), the cln10 protein, and cln6
deficient mice exhibited increased amounts of complex glycosphingolipids in neurons
and glial cells (Jabs et al., 2008). Haidar et al. (2006) described that CTSD influences
ABCA1-mediated efflux and cholesterol trafficking.
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4.2. CLN5
CLN5 disease is linked to the CLN5 gene located on chromosome 13, which encodes
a polypeptide of 407 amino acids (Savukoski et al., 1998). Early reports of CLN5
described it as late infantile NCL, but cases from early juvenile to adult onset have
been reported since. The encoded protein has an N-terminal signaling sequence that
is cleaved after localization to the ER. Furthermore, the lysosomal protein has eight
putative N-glycosylation sites that are utilized in vivo (Moharir et al., 2013). Further
background on the pathogenesis and clinical features of CLN5 are provided in Sections
C.1.2 and C.1.3, respectively.
4.2.1. Protein and modifications
The CLN5 gene was assigned to chromosome 13, 13p21–q32 (13q21.1-32)3 by linkage
analysis in Finnish families with common ancestors (Savukoski et al., 1994, Varilo et al.,
1996).
The gene contains four exons decoding the 407 amino acid long polypeptide, cln5
protein (cln5) (see Figure 4.1). The protein shows no sequence homology with any other
protein (Isosomppi et al., 2002, Savukoski et al., 1998). Cln5 is prevalent in vertebrae
and shows strong sequence conservation (see Figure 4.1).
Several potential methionine start sites are encoded in exon 1, holding four in-frame
initiation methionines. Initiator methionines are located at positions 1, 30, 50, and 62,
producing cln5 polypeptides with expected molecular masses of 40.3, 41.5, 43.4 and
46.3 kDa, respectively (Isosomppi et al., 2002, Savukoski et al., 1998). The longest
polypeptide encoded from the first methionine was reported to represent a membrane
bound form of the protein (Vesa et al., 2002). Schmiedt et al. (2010) reported that
proteolytic cleavage of cln5 produces polypeptides of identical size, independent from
the used initiation methionine.
According to ab initio prediction methods, the isoform 1 of cln5, starting with methionine
1, contains a signal peptide covering amino acids 1–42. Cln5 was additionally reported
to have a signal peptide which was cleaved at Ile96 (Schmiedt et al., 2010) or Val93
(Jules et al., 2017).
At first, cln5 was reported to be a transmembrane protein (Savukoski et al., 1998) or
to exist in either in soluble and transmembrane forms (Vesa et al., 2002). The protein
sequence contains two hydrophobic stretches at amino acids 76–91 and 353–373
3Genomic RefSeqGene NG_009064.1 (17594 bp) Transcript RefSeq NM_006493.3, NCBI RefSeq
NP_006484, EC nomenclature MIM# 256731.
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predicted to be transmembrane domains (Savukoski et al., 1998). However, prediction
programs SOSUI (Hirokawa et al., 1998) and TMHMM (Krogh et al., 2001) did not identify
any potential transmembrane helices. Today, cln5 is revealed to be a soluble glycoprotein
(Schmiedt et al., 2010). Also, soluble proteins with diverse apparent molecular weights
ranging from 39 kDa to 47 kDa were reported from CLN5 cDNA expression (Isosomppi
et al., 2002, Vesa and Peltonen, 2002).
Furthermore, cln5 has eight putative N-glycosylation sites with Asn-X-Thr/Ser con-
sensus sequence, for both high-mannose and complex sugar modifications (Isosomppi
et al., 2002, Vesa and Peltonen, 2002). N-glycosylation is covalently linked to asparagine
residues and has a pentasaccharide core consisting of two N-acetyl-D-glucosamine
(NAG) and three D-mannose (MAN) residues. After the pentasaccharide follow either
MAN residues in the high-mannose type or a mixture of sugar residues, e.g. galactose,
fucose, or others are used to modify the protein in the complex-type modification (Berg
et al., 2012). Glycosylation sites are located at amino acid positions 179, 192, 227, 252,
304, 320, 330, and 401 (Moharir et al., 2013). Glycosylated proteins expressed from
BHK-21 and COS-1 cells revealed apparent molecular weights ranging from 60–75 kDa
in sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) .
Endo-β-N-acetylglycosaminidase H (EndoH) treatment resulted in cln5 forms of
40 kDa or 47 kDa and PNGaseF treatment yielded cln5 of 38 kDa or 45 kDa (Isosomppi
et al., 2002). EndoH is an endoglycosidase that cleaves high-mannose glycosylation
from glycoproteins adjacent to the linkage with asparagine between two NAG residues
(Maley et al., 1989). PNGaseF is an endoglycosidase cleaving the protein-sugar bond
between asparagine and NAG of most N-linked glycoproteins (Tarentino et al., 1985).
Site directed mutagenesis studies revealed that N-glycosylation displays functional differ-
ences affecting folding, trafficking, or lysosomal function in cln5 (Isosomppi et al., 2002).
Mutating Asn179, Asn252, Asn304, and Asn320 affects the folding of the protein and
it is retained in the ER without glycosylation. The glycosylation at Asn401 is reported
to play a role in endosome/lysosome trafficking. The N-glycosylation sites Asn192 and
Asn227 are reportedly involved in lysosomal function (Qureshi et al., 2018). Also, cln5
contains other potential modification sites including myristoylation and phosphorylation
sites, which have not yet been experimentally analyzed (Savukoski et al., 1998).
4.2.2. Protein localization
Cln5 mainly localizes to the endosomal-lysosomal compartment as shown by studies
with confocal immunofluorescence microscopy in transiently transfected BHK-21 cells
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(Isosomppi et al., 2002). The polypeptide was reported to localize to the ER and has
been found in the axons of neuronal cells (Holmberg et al., 2004). Studies on embryonic
and postnatal mouse brains showed abundant mRNA expression in developing cerebral
cortex, cerebellum and in the ganglionic eminence (Holmberg et al., 2004). In the
adult mouse brain the most intense signal was reported in the Purkinje cell layer of the
cerebellum, in the cerebral cortex, as well as in the hippocampal principal cell layers.
Cln5 expression could also be found in a variety of tissues such as aorta, kidney, lung
and pancreas (Savukoski et al., 1998). Holmberg et al. (2004) reported that sub-cellular
cln5 localizes predominantly to the neuronal soma.
Most soluble lysosomal proteins contain specific carbohydrate modifications, espe-
cially mannose-6-phosphate (Man-6-P) glycosylation, for recognition by the mannose-6-
phosphate receptors (sMPRs). The glycosylation directs the targeting to the lysosomal
compartment (Pohlmann et al., 1995). Cln5 contains Man-6-P residues on high mannose-
type oligosaccharides linked to Asn320, Asn330, and Asn401. Thereby it has been
suggested that cln5 is trafficked by the MPR-dependent pathway (Kollmann et al., 2005,
Sleat et al., 2006). This supports a soluble cln5 variant (Sleat et al., 2006). Other studies
suggested cln5 may be transported on Man-6-P independent trafficking route (Schmiedt
et al., 2010), and other routes (Kollmann et al., 2005, Sleat et al., 2009).
Furthermore, cln5 may undergo a retrograde transport step from the Golgi to the ER
(Schmiedt et al., 2010). It has been suggested earlier that cln5 undergoes cleavage prior
to transport to the lysosome (Holmberg et al., 2004, Isosomppi et al., 2002, Vesa and
Peltonen, 2002).
4.2.3. Proposed functions of cln5
Schmiedt et al. (2012) described the developmental regulation of the Cln5 gene in mice.
A role of cln5 in regulating microglial function is suggested by the highest expression
observed in microglial cells within the brain combined with very early activation of
microglia in Cln5-/- mice. Indicating the involvement of cln5 in lipid metabolism, alterations
in serum lipid profiles, defective lipid transport and hypomyelination were observed in
Cln5-/- mice (Schmiedt et al., 2012).
Mamo et al. (2012) reported cln5 is essential for the recruitment of the multi-modular
protein assembly retromer, a protein complex responsible for the sorting and recycling of
lysosomal receptors (Bonifacino and Hurley, 2008). In HeLa cells over-expressing HA-
tagged cln5 and myc-tagged sortilin, a lysosomal enzyme transporter, co-immunopreci-
pitate. The stability of sortilin and cation-independent mannose-6-phosphate receptor
(CI-MPR) diminishes with cln5 depletion. Also CTSD levels increase upon cln5 depletion,
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which was interpreted as plausible by Markmann et al. (2015) since alternative lysosomal
targeting pathways for CTSD exist. The loss in function of CI-MPR transporter originates
in defects in the recruitment of the retromer due to less loaded Rab7, which is required
for this purpose (Mamo et al., 2012). Mamo et al. (2012) suggested “cln5 is part of an
endosomal switch that determines whether the lysosomal sorting receptors are recycled
to the Golgi compartment or degraded in lysosomes.“ This was discussed as beeing
inconsistent with cln5 properties as soluble lysosomal protein (Cárcel-Trullols et al.,
2015).
Very modest reduction in vacuolar protein sorting 26 (VPS26) and VPS35 was addi-
tionally reported. These proteins are part of the vacuolar protein sorting heterotrimer
with cargo binding function in the retromer (Mamo et al., 2012).
The retromer has been linked to the pathogenesis of late-onset Alzheimer’s disease
(Muhammad et al., 2008). Recently, a study reported that the mutant Asn320Ser of
cln5 protein might mediate Alzheimer’s disease associated toxicity by affecting retromer
function in microglia (Qureshi et al., 2018). HeLa cells and mouse N2a cells expressing
the mutated CLN5 variant displayed a decrease of full-length amyloid precursor protein
(APP). This was interpreted as a possible defect in retromer-dependent trafficking.
Furthermore, cln5 may function as modulator of dihydroceramide synthase (CerS), of
cell growth, and apoptosis. One study in fibroblasts from cln5 deficient patients found
that sphingolipids downstream of CerS, ceramide and dihydroceramide, were diminished
(Haddad et al., 2012). It was proposed that cln5 and cln8 are functionally related, as cln8
corrects the cln5 defect and altogether modulates CerS 1 and 2 (Haddad et al., 2012).
No proof like, e.g. co-immunoprecipitation of cln5 and CerS or cln5 and cln8, neither in
normal fibroblasts nor fibroblasts of cln5 deficient patients, was given.
Huber and Mathavarajah (2018) proposed that cln5 is a glycoside hydrolase based on
studies of dictyostelium discoideum cln5 with a glycoside hydrolase activity assay (see
chapter 4.2.5). Furthermore, the study names 61 proteins cln5 shows interaction with
based on dictyostelium cln5-green fluorescent protein (GFP) immunoprecipitation and
subsequent LC-MS/MS analysis.
Still, the exact function of cln5 remains unknown. The high relative expression level
of cln5 in central nervous system neurons and microglial cells as well as defective
myelination in the brain of Cln5-/- mice and late infantile CLN5 disease patients (Schmiedt
et al., 2012) points towards a distinct importance of cln5 function in the brain.
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Interactions with other NCL proteins
The protein cln5 locates to the lysosomes, although it may also function elsewhere in the
cell (Holmberg et al., 2004, Schmiedt et al., 2010). First reports of interactions with other
NCL proteins by Sleat (1997) described altered tripeptidyl-peptidase 1 (TPP1) (cln2)
levels in cln5 patients.
Based on co-immunoprecipitation and in vitro binding assays, Vesa and Peltonen
(2002) reported direct interactions of cln5 with cln2 and cln3 proteins. While interactions
of cln5 and cln3 persist with the ’Fin major’ and ’European’ variant mutations of cln5,
they are abolished with cln2 for these mutations consistently (see Chapter 4.2.4). These
results are suggesting the cln2 interaction domain is located N-terminal from amino acid
224, were the cln5 European mutation is located.
Lyly et al. (2009) could confirm interactions between the proteins cln1, cln2, and
cln3 with cln5 via co-immunoprecipitation assays. The same study reported additional
interactions between cln5 and cln6 as well as cln8. Over-expression of PPT1 (cln1)
rescues the lysosomal trafficking defect of cln5 (vLINCLFinMajor) in HeLa cells and human
neuroblastoma (SH-SY5Y) cells. Normally retained in the ER and Golgi, although this
mutant cln5 protein is ER exit-competent, it now co-localizes with PPT1 to the lysosomes
(Lyly et al., 2009). This suggests the interaction occurs in the ER, where the interactions
with the ER resident NCL proteins cln6 and cln8 would occur. The same study reported
that cln5 interacts with subunits of F1-ATPase as does PPT1 (Lyly et al., 2008).
Recently a CLN7 defect was reported to lead to depletion of mature cln5 due to
increased proteolytic degradation by cysteine proteases (Danyukova et al., 2018). Also
an Alzheimer’s disease associated CLN5 mutation was reported to hinder the maturation
of proCathepsin D to mature CTSD (Qureshi et al., 2018).
The interaction of cln5 with other proteins associated with NCLs suggests a common
pathway in neuronal cell metabolism. Nonetheless the manner and function of the
interactions is not yet understood.
4.2.4. Mutations
Thirty-seven different mutations and nine sequence variations in CLN5 are identified in
patients of Finnish and non-Finnish origin as of September 2018 recorded in the NCL
mutation database4 (Bessa et al., 2006, Cismondi et al., 2008, Holmberg et al., 2000,
Lebrun et al., 2009, Pineda-Trujillo et al., 2005, Savukoski et al., 1998, Sleat et al., 2009,
Xin et al., 2010). These consist of nineteen missense mutations, twelve small deletions
4University College London, https://www.ucl.ac.uk/ncl-disease/mutation-and-patient-database.
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or insertions causing frame-shift, one large deletion, and nine nonsense mutations.
Seven cDNA point mutations are known that do not cause an amino acid change. Tables
4.2 and 4.3 provide an overview of all disease causing mutations while mutations with
no effect on the amino acid sequence are not listed (known by the identifiers cln5.x with
x = 019, 023, 028, 025, 026, 037). Also heterozygote mutations are not included in the
tables.
Table 4.2.: NCL mutation database excerpt for known pathogenic CLN5 mutations involving a
frame shift (insertion or deletion) or premature stop codon.
identifier cDNA exchange amino acid change NCL phenotype
cln5.001 c.1175_1176delAT p.(Tyr392X) late infantile
cln5.002 c.225G>A p.(Trp75X) late infatile
cln5.005 c.669dupC p.(Trp224LeufsX30) juvenile
cln5.007 c.565C>T p.(Gln189X) late infantile
cln5.014 c.1072_1073delTT p.(Leu358AlafsX4) juvenile
cln5.016 c.1026C>A p.(Tyr342X) late infantile
cln5.017 c.1054G>T p.(Glu352X) late infantile
cln5.019 c.291dupC p.(Ser98LeufsX13) late infantile
cln5.020 c.1103_1106delAACA p.(Lys368SerfsX15) late infantile
cln5.027 c.527_528insA p.(Gly177TrpfsX10) late infantile
cln5.033 c.919delA p.(Arg307GlufsX29) juvenile
cln5.035 c.1038delT p.(Phe361LeufsX4) juvenile
cln5.048 c.741_747delinsTT p.(Trp247CysfsX5) late infantile
The most common mutation is the ’Fin major’ mutation, a 2 base pair deletion in
exon 4 (cln5.001, c.1175delAT) resulting in the change p.Tyr392X and a truncated
polypeptide of 391 amino acids. This is the only mutation exclusively identified in families
of Finnish descent. All other mutations have been found in families of diverse descent in
many different countries including Finland, UK, Afghanistan, Argentina, Canada, China,
Colombia, the Czech Republic, Egypt, Italy, the Netherlands, Portugal, Pakistan, Sweden,
and USA (Bessa et al., 2006, Cannelli et al., 2007, Cismondi et al., 2008, Holmberg
et al., 2004, Kousi et al., 2009, Lebrun et al., 2009, Pineda-Trujillo et al., 2005, Sleat
et al., 2009, Xin et al., 2010). Today, mutations in the CLN5 gene are reported in families
of diverse origin such as Asian, Hispanic and Arabian origin, rendering the naming as
Finnish variant obsolete.
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Second most common mutation is "Fin minor’, where a G to A transversion in exon
1 (cln5.002, c.225G>A) causes the substitution p.Tyr75X, resulting in a polypeptide of
only 74 amino acids. It was also found in a Swedish family with an additional C insertion
at amino acid 223 (cln5.005, c.669insC) causing a frameshift and premature stop codon
at position 253 (predicted) (Holmberg et al., 2000).
Table 4.3.: NCL mutation database excerpt for known pathogenic CLN5 mutations
involving a point mutation resulting in a changed residue.
identifier cDNA exchange amino acid change NCL phenotype
cln5.003 c.835G>A p.(Asp279Asn) late infantile
cln5.006 c.335G>A p.(Arg112His) juvenile
cln5.011 c.772T>G p.(Tyr258Asp) juvenile
cln5.012 c.4C>T p.(Arg2Cys) late infantile
cln5.018 c.1137G>T p.(Trp379Cys) late infantile
cln5.021 c.377G>A p.(Cys126Tyr) adult
cln5.022 c.1121A>G p.(Tyr374Cys) adult
cln5.029 c.575A>G p.(Asn192Ser) juvenile
cln5.030 c.620G>C p.(Trp207Ser) juvenile
cln5.044 c.613C>T p.(Pro205Ser) late infantile
Several polymorphisms, genetic variants at a locus within the population, are known
so far. One mutation in exon 4, (c.1103A>G, cln5.004), leading to a mutation of the
polypeptide of p.Lys368Arg, has a carrier frequency of 20% in the Finnish population
and about 10% in USA (Kousi et al., 2012, Savukoski et al., 1998, Xin et al., 2010). Also
displaying a carrier frequency of 10% in the USA is the mutation cln5.012 in exon 1
(c.4G>T, p.(Arg2Cys)). The mutation cln5.008 (c.335G>C, p.(Arg112Pro)) might also
be a polymorphism as it was only found on allele carrying c.835G>A, p.(Asp279Asn)
(cln5.003).
4.2.5. Protein structure prediction
Cln5 was reported as a soluble protein in studies using Triton X-114 solubility assays on
transfected COS-1 cells. These were consistent with predictions using TMHMM2.0 and
SOSUI software (Holmberg et al., 2004, Schmiedt et al., 2010).
Earlier, cln5 was reported to have two transmembrane domains predicted with BCM
transmembrane prediction program (Savukoski et al., 1998) or to exist in either soluble
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and transmembrane forms depending on the starting methionine used during expression
(Vesa and Peltonen, 2002).
While comparing dictoystelium cln5 and human cln5 sequences, Huber and Math-
avarajah (2018) proposed that cln5 may function as glycoside hydrolase (see Figure 4.2).
Based on the results of the online web server RaptorX, a three-dimensional structure
model was predicted to have a putative binding site for N-acetylglucosamine thiazoline
(NGT). This substrate also binds to β-hexosaminidase, a glycoside hydrolase linked to
Tay-Sachs and Sandhoff disease (Mark et al., 2003).
Figure 4.2.: Secondary structure prediction and consequently reported NGT binding pocket for cln5, picture
taken from Huber and Mathavarajah (2018).
4.3. Aim of this work
The function and interaction of NCLs proteins is currently the focus of intensive research.
The crystal structure and function of most of the proteins involved is already known,
e.g. TPP1, PPT1, CLN3 TM protein or CTSD. Nonetheless, the role of the proteins in
neurodegeneration and the interaction with other proteins remains elusive. The protein
associated with the CLN5 gene has not been characterized functionally before and
no conclusive structural information was available. Interactions of cln5 with the NCL
proteins TPP1, PPT1, or CLN3 TM protein have been reported (Lyly et al., 2009, Sleat,
1997, Vesa and Peltonen, 2002). In addition, various studies reported an influence of
cln5 in regulation of microglial function (Schmiedt et al., 2012), lipid metabolism, or
lysosomal sorting (Bonifacino and Hurley, 2008). The exact role of cln5 has not been
unambiguously identified.
The aim of this work is the study of cln5 structure and interactions. Initial analytical
studies of the protein by CD spectroscopy in solution are presented. Moreover, the
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analysis of the protein sequence for secondary and tertiary structure prediction with
various web services is discussed. Additionally, interaction studies are introduced, giving
insight to possible interactions of cln5 with other NCL proteins and proteins associated
with cell apoptosis.
In this work the crystal structure of cln5 is presented for the first time. Furthermore, a
structural relationship of cln5 with proteins of the NlcP/P60 superfamily (Xu et al., 2011)
can be established based on the study of the crystal structure. The structural similarity
of cln5 to the protein PPPDE1 is a valuable clue to function, as the central 3D fold,
including a reactive center, remains conserved. PPPDE1 was reported to function as
deSUMOylating protein (Shin et al., 2012) and deubiquitinating protein (Iyer et al., 2004,
Xie et al., 2017). The implications of this structural relationship for cln5 are discussed.
The structure can be the crucial factor to determine the function of cln5 and can help to
finally understand the role of cln5 in neurodegeneration. Based on this structure, more
focused studies of the function of cln5 are possible and are carried out at the moment.
The here presented work can be the key to finally assigning a function to cln5 and to
place it in the greater context of NCL diseases and apoptosis.
4.4. Materials and Methods
4.4.1. Protein structure prediction
At the beginning of the crystallization studies web services for secondary structure
prediction were used to better understand cln5. Some prior knowledge of a possible
structure or structure elements can help in the choice of crystallization methods and
screens. The web based services of the structure prediction servers I-TASSER (Yang
et al., 2015, Yang and Zhang, 2015), BLAST (Altschul et al., 1990), Swiss Model
(Waterhouse et al., 2018), HHPred (Soding et al., 2005) and RaptorX (Wang et al., 2011)
were employed with the protein sequence of cln5.
Two main approaches to protein structure prediction find wide application: template
based modeling (TBM) (homology modeling) and ab initio prediction.
Homology modeling is possible when likely homologues of the protein exist and is
based on database searches of known structures for sequence similarity with the query
sequence. The best match is picked as template, establishing the basis to build a model.
For different parts of the protein different templates can be used and refined. This
procedure is called TBM (Karplus et al., 1998, Šali and Blundell, 1993). Sequence
similarity can be measured via sequence identity, amino acids matching exactly in both
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sequences, or in similarity, amino acids having the analogous properties, such as polarity
or functional groups. Profiles of the sequence can be created, describing for example
the probability of mutation of each amino acid, and used to compare two sequences.
This can be implemented by using hidden Markov models (sHMMs).
Ab initio modeling is used when no structural homologues can be identified and
employs knowledge based energy functions (Klepeis et al., 2004). A model must be
built from scratch by understanding the physiochemical principles of how proteins fold
in nature. The modeling algorithms have three key concepts: energy function design,
conformational search and model selection.
I-TASSER uses a hierarchical approach, identifying structural templates from the PDB
using LOMETS, a meta-threading server for target-to-templates assignment. Functional
insights of the target are derived using the database BioLiP for function prediction (Yang
et al., 2015, Yang and Zhang, 2015).
BLAST compares protein or nucleotide sequences to sequence databases and reports
statistically significant matches (Altschul et al., 1990). Statistical significant results can
be used to infer functional or evolutionary relationships.
Swiss Model Homology web service builds protein homology structures relying on
ProMod3, extracting structural information from templates (Waterhouse et al., 2018).
HHPred is a server for protein homology detection, structure and function prediction
using HMMs. Various databases are searched for local or global alignment based on the
query sequence and can produce 3D structural model from the search result (Soding
et al., 2005).
RaptorX is a template-based prediction server for proteins without sequence homo-
logues in the protein database (PDB). It predicts secondary and tertiary structures and
from these structures contacts, solvent accessibility, disordered regions and binding
sites (Wang et al., 2011).
Furthermore, preliminary circular dichroism measurements were used to determine
secondary structure elements and protein integrity (see Section 4.4.3).
4.4.2. Protein preparation
All protein samples were obtained from the laboratory of Prof. R. Steinfeld, Department of
Paediatrics and Paediatric Neurology, UMG Georg-August University Göttingen, provided
by Dr. R. Krätzner, K. Schreiber and M. Ziegenbein. To facilitate purification, human
cln5 was modified with a short linker and a HIS6-tag (RSHHHHHH) at the C-terminus.
Transfection of the modified CLN5 and selection of stable HEK293 cell lines were
performed as described before by Steinfeld et al. (2004).
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Additionally, kifunensine was added to inhibit α-mannosidase, resulting in hyper-
mannosylation of the glycosylation sites (cln5-k). Afterwards, cln5-k was treated with
EndoH to cleave the hybrid oligosaccharides from N-linked glycosylation sites leaving
one N-acetyl-D-glucosamine (cln5-e). In a separate cell culture HEK293 cells, in addition
to kifunensine, were treated with selenomethionine (SeMet) (MSE in 3-letter amino
acid nomenclature) replacing all methionine residues (cln5-k-Se). Recombinant protein
samples were purified from the cell-culture supernatant, which was kept frozen until
purification.
After thawing, the supernatant was filtered through a membrane (pore size 0.22 µm
Corning PES filter) under water-jet vacuum. After addition of 20 mM K2HPO4 pH 7.5,
0.5 M NaCl and 40 mM imidazole the crude solution was loaded onto a 5 mL HisTrapTM
FF Ni affinity column (flow rate 1 mL/min, GE Healthcare). Protein elution with a step-
wise gradient resulted in two peaks (see Figure C.1). The fractions of the two peaks were
separately pooled and concentrated in centrifugal filters (Amicon Ultra, size exclusion
10 000) at 4 ◦C, 3000x rpm. The protein was exchanged into 10 mM K2HPO4 pH 7.2,
50 mM NaCl and concentrated to a final concentration of approximately 10 mg/mL. The
final concentration was determined via bicinchoninic acid (BCA) assay from a theoretical
extinction coefficient, 99320 M-1cm-1, based on the protein sequence. Purified protein
was kept on ice and protein purity and integrity was confirmed via SDS-PAGE according
to Laemmli (Laemmli, 1970) on aliquots from before and after purification and buffer
exchange. Successful purification resulted in a band in SDS-PAGE of 60 kDa, 55 kDa,
and 37 kDa for cln5, cln5-k/cln5-k-Se, and cln5-e, respectively (see Section C.2).
Interaction of cln5 with other NCL proteins
All interaction studies were performed in the lab of Prof. R. Steinfeld at the UMG
Göttingen. The cln5 over-expression in stable HEK293 cells showed an influence on
cln10 (CTSD) and LC3-I/II (studies performed by A. Wolf5).
Here the influence of cln5 depletion on NCL proteins and autophagy markers, LC3-II
and p62 is evaluated. LC3 in the lipidated form, LC3-II, has been shown to be an
autophagosomal marker acting in autophagosome formation. LC3-I represents the
cytosylic form and LC3-II is the membrane-bound form of LC3 (Kabeya, 2000). It is
therefore used to study autophagy in neurodegenerative disorders (Tanida et al., 2004).
The autophagy substrate p62 can bind LC-3 and is degraded by autophagy (Eskelinen
and Saftig, 2009).
5Department of Paediatrics and Paediatric Neurology, UMG Georg-August University Göttingen.
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The cell lysate from stable HeLa CLN5-/- cells was separated by 10%, 12% or 18%
SDS polyacrylamide gel electrophoresis (40 µg protein per lane) and transferred by
electroblotting to nitrocellulose membranes (Protran, Schleicher and Schüll, Germany)
according to standard protocols. The blot was blocked with phosphate-buffered saline
(PBS) containing 5% milk powder and incubated with rabbit or mouse anti-antibodies
(1:1000 in blocking solution). The blot was then washed twice in PBS containing
0.05% Tween 20, incubated with a horseradish peroxidase-conjugated anti-rabbit or anti-
mouse IgG (1:10000 in blocking solution; Dianova, Hamburg, Germany) and washed
as before. Signals were visualized using the enhanced chemiluminescence (ECL)
technique. Detection of the control protein β-actin was performed in the same manner
after removal of the anti-bodies with 200 MM glycin/HCl pH2.2, 3.5 MM SDS), 1% Tween
20. All western blot studies were repeated twice.
Investigation of cln5 processing by CathepsinD
CTSD, the protein of CLN10 disease, is an aspartyl endopeptidase with numerous
substrates in the lysosome (Benes et al., 2008). Additionally to protein degradation,
CTSD has been linked with apoptosis and lipid homeostasis (Getty and Pearce, 2011).
The role of CTSD in the NCL pathways is not clear and interactions with other NCL
proteins are possible.
Here, the potential processing of cln5 by CTSD is studied.
Frozen CTSD stored in phosphate-buffered saline was taken up in 100 mM sodium
acetate buffer pH 3.8 to achieve a concentration of 1 µg/µL for activity studies and
3 µg/µL for all other studies. CTSD was incubated at 37 ◦C for ten minutes with 50 mM
sodium fumerate pH 3.0 or 100 mM sodium acetate buffer pH 3.8 to obtain activate
CTSD.
For kinetic studies, 0.5 µg of cellular lysates were incubated with 1.3, 2, 3.3, 6.7, 10,
13.3, 23.3, 33.3, and 45 µM of substrate peptide MOCAc-GKPIIFFRLK(Dnp)-R-NH2
(Yasuda et al., 1999). Reaction velocities were measured at defined time intervals with a
microplate reader (Synergy HT [BIO-TEK Instruments]). Linear phase velocities were
plotted against the substrate concentrations; Km and Vmax were calculated by nonlinear
regression using the equation
V = Vmax · [S]
Km + [S]
(4.1)
where V is linear phase velocity, Vmax is maximal enzyme velocity, [S] is the substrate
concentration, and Km is the Michaelis-Menten constant.
For interaction studies 50 µL reaction solutions were prepared containing 500 ng,
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1.25 µg or 2.5 µg active CTSD with 2.5 µg cln5, resulting in ratios of 1:5, 1:2 and 1:1
CTSD:cln5 concentrations in PBS buffer pH 4.5. At time intervals of 0 min, 10 min, 30 min,
and 1 h sample of the reaction solution were withdrawn and added to pre-prepared
SDS-PAGE solutions to stop any reaction. The reaction solutions were separated via
SDS-PAGE and analyzed by western blot.
4.4.3. Circular dichroism
Circular dichroism (CD) can be used to estimate the secondary structure of proteins or
peptides (Greenfield, 2006). It is characterized by the unequal absorption of left-handed
and right-handed circularly-polarized light. If the light is polarized by passing through
suitable prisms or filters, its electric field will oscillate sinusoidal in a single plane.
CD spectra were measured on a Jasco J-810A spectropolarimeter with temperature
control Jasco PTC423S. The sample chamber was flushed with a nitrogen stream.
Measurement parameters were employed as listed in Table 4.4.
Table 4.4.: CD measurement parameters.
data mode CD and absorption
absorption band width 1.0 nm
response 1.0 s
data pitch 0.1 nm
scanning speed 50 nm
cuvette length 0.1 cm
sensitivity high
The CD spectra were adjusted by blank measurement to correct for solvent influence.
Five measurements were measured in a wavelength range from 300 to 190 nm. The re-
sulting spectra were smoothed with the means movement method (convolution width 25).
With the formula 4.2, the measured ellipticity (Θabs [mdeg]) was converted to mean
residue ellipticity Θ [10−3 deg cm2 dmol−1].
Θ =
( Θabs [mdeg] · 0.001
c [mol/L] · l [cm] · n · 10
)
(4.2)
With: c [mol/L] = concentration of protein; l [cm] = length of cuvette; n = number of
amino acids in the peptide.
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4.4.4. Crystallization
A large variety of crystallization conditions were screened via sitting drop method on 96
well plates (Axygen, Corning Incorporated, Corning, USA). Reservoir solutions of 100 µL
were pipetted employing a TECAN Genesis Robot. The drops of 0.2 µL consisting of
1:1 (v:v) protein and reservoir solution were set by a TTP Labtech Mosquito. Hanging
drop experiments were set up in VDXm 24 well plates (Hampton Research, Aliso Vieji,
USA) containing 1 mL reservoir solution and 2-4 µL protein solution with varying well-
to-reservoir ratio. Commercially available crystallization screens were used for initial
screening (Hampton Research: Index Screen HT, Crystal Screen HT, PEG/Ion HT,
Natrix HT; Rigaku Reagents: Wizard™HT, Wizard™3+4; Qiagen®: MPD Suite, PEGs
Suite, JCSG+; Jena Bioscience: XP Screen, Pentaerythritol, Pi-Minimal HTS, Pact++).
The XP screen contains the additive Anderson-Evans polyoxotungstate [TeW6O24]6-
(TEW), allegedly not only promoting protein crystallization but also diffraction quality
(Bijelic and Rompel, 2017). This screen was employed to facilitate anomalous phasing
using the intrinsic tellurium without additional HA soaking experiments. In addition,
variation of temperature (4, 10 and 20 ◦C), protein-to-reservoir ratios (1:1, 2:1, 1:2 (v:v)),
and protein concentration (4 to 12 mg/mL) were implemented. Furthermore, under-oil
crystallization, streak seeding, micro-seed seeding with serial dilution and micro-seed
matrix screening (MMS) were carried out (D’Arcy et al., 2014). Co-crystallization with
Polyvalan Crystallophore No 1 (Tb-Xo4) (Molecular Dimensions, Suffolk, UK) was
attempted by addition of 10 mM Tb-Xo4 to the protein solution before crystallization.
The compound allows convenient phasing using the anomalous signal of the lanthanide
terbium (Engilberge et al., 2017). Initial findings were reproduced on 96 and 24 well
plates using both sitting and hanging drop methods as well as seeding methods. In-drop
validation of the latest crystals was performed using an Jansi UVEX UV microscope.
4.4.5. Crystals
cln5 native
One single crystal could be obtained from 20% (w/v) polyethylene glycol (PEG) 3350,
0.2 M potassium chloride at 20 ◦C after eight months. The crystal was transferred in a
step-wise manner into a crystallization solution containing additionally up to 12% glycerol
as cryoprotectant and flash cooled in liquid nitrogen for storage. All attempts to obtain
more crystals from this condition employing grid screening and seeding methods were
unsuccessful.
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cln5-kifunensine
First screenings resulted in a single crystal from 30% (v/v) pentaerythritol ethoxylate (PE)
15/4, 50 mM BisTris pH 6.5, 50 mM ammonium sulfate (condition A) after seven weeks at
20 ◦C. Attempts at reproducing the crystallization were successful with reservoir solutions
from 25-31% (v/v) PE 15/4, 50 mM BisTris pH 6.1-6.5, 50 mM ammonium sulfate, resulting
in multiple crystals of different quality and sizes (Table 4.5). Furthermore, individual
crystals could be obtained, but not reproduced, from the following conditions:
• 20% PEG 3350 (w/v), 200 mM magnesium nitrate at 20 ◦C after six months
(condition B).
• 20% PEG 6000 (w/v), 100 mM HEPES pH 7.0, 200 mM magnesium chloride at
20 ◦C after seven months (condition C).
• 20% PEG monomethylether (PEG MME) 5000 (v/v), 0.1 mM BisTris pH 6.5 at
20 ◦C after four months (condition D).
In general the crystal size was 20-30 µm with some exceptions showing a size in one
direction of up to 70-80 µm. Crystals displayed various shapes, from diamond-shaped to
needles, plates and ingot-like. The precipitant from condition A, PE 15/4, was reported to
be sufficient for cryo-protection, starting with a concentration of 25% (v/v) (Gulick et al.,
2002). Crystals from condition B were transferred into cryoprotectant solution containing
13% glycerol (v/v) in addition to 20% PEG 3350 (w/v). Crystallization solutions of 20%
PEG 6000 and 20% PEG MME were prepared with an additional 20% glycerol for cryo-
protection. Transfer to the final cryoprotectant solution was performed in a step-wise
manner. All crystals were stored in liquid nitrogen until measurement.
All attempts to grown crystals of better quality or larger size using various seeding
techniques in addition to optimization were unsuccessful except for one single crystal
(see Figure 4.3b). Random sparse matrix MMS yielded one crystal from 20% PEG 1000
(v/v), 200 mM calcium acetate, 100 mM imidazole pH 8.0 with seeds originating from
condition A.
Heavy atom soaking experiments Multiple soaking experiments were conducted to
facilitate anomalous phasing for structure solution. Soaking solutions were prepared
by recreating the crystallization condition with the heavy atom compound added. Four
crystals were soaked in 100 µM Polyvalan for 2–5 min. Five crystals each were trans-
ferred to 500 mM sodium iodide or sodium bromide, respectively, and soaked for time
ranges from 30 sec to 7 min. Also, 20 µM 4-bromopyrazole soaks were performed with
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(a) picture from light microscope. (b) picture from UV microscope, fluorescence 0.1 s.
Figure 4.3.: Crystal of cln5-kifunensine after 135 days obtained from optimization of condition A.
two crystals for 30 min and 1:30 h. Finally, cln5-k-Se crystals were soaked in 1 mM
methylmercury chloride (MMCl), 1 mM p-chloromercuribenzene sulphonate (PCMBS),
10 µM ethylmercurithiosalicylate (EMTS, Thiomersal) and 10 mM trimethyllead acetate
(TMLA) for 1 to 5 d. All crystals were transferred to cryoprotectant, flash-cooled and
stored in liquid nitrogen until measurement.
cln5-kifunensine-EndoH
No crystals could be obtained from the cln5 protein variant that was treated with kifunen-
sine and subsequently de-glycosylated with EndoH (cln5-e).
cln5-kifunensine-Se-methionine
Due to the low amount of the SeMet-labeled protein available, the protein was used in
sparse matrix screens and in grid screen conditions derived from previous successes
with the native kifunensine variant (conditions A – D). After 12 weeks crystals were
observed in conditions ranging from 22.3 – 25.0% PEG 3350 (w/v), 0.179 – 0.193 M
magnesium nitrate (grid screen from condition B) (see Figure 4.4b). These crystals
were transferred in a step-wise manner to a cryoprotectant solution containing either 5%
glycerol in addition to the crystallization solution or an increased concentration of the
precipitant, 35% PEG 3350 (w/v). The crystals were flash-frozen and stored in liquid
nitrogen until measurement.
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(a) picture from light microscope. (b) picture from UV microscope, fluorescence 0.1 s.
Figure 4.4.: Crystals of cln5-kifunensine-SeMet after 85 days in condition B.
4.4.6. Data collection and processing
cln5-kifunensine
X-ray diffraction (XRD) data sets from all crystals were collected on a Dectris Pilatus
6M detector at the Swiss Light Source (SLS) undulator beamline PXII (X10SA) using
monochromatic radiation. Native data collection wavelength was 1.00 Å for non-derivate
crystals. Single-wavelength anomalous diffraction (SAD) data from derivate crystals
were collected at the peak (peak of f”) or inflection (negative peak of f’) wavelength
of the anomalous signal obtained from the plot of the anomalous scattering factors
against the wavelength with an SLS in-house beamline software tool. An on-beamline
fluorescence scan was conducted to verify the presence of anomalous signal before
each measurement.
Overall only 5% of all crystals selected for XRD diffraction showed any signal beyond
4 Å (see Table 4.5 and Figure 4.6a). None of the soaking experiments yielded any
significant anomalous diffraction. The data sets displayed high anisotropy upon merging.
Four data sets were collected from crystal cln5k-79. Two of those were collected at low
energy wavelength to facilitate S-SAD phasing. No sufficient anomalous signal could be
collected.
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Table 4.5.: List of best diffracting crystals obtained from cln5-kifunensine.
crystal cryst. space unit cell diffraction ISab notes
number cond. group [Å] limita [Å]
cln5k-6 A 80 (97) a=129, c=52 3.25 16.34 4-bromopyrazole
soak
cln5k-26 A 80 (97) a=128, c=50 4.60 10.34 NaI soak
cln5k-31 A (97) a=129, c=52 3.85 8.80 NaBr soak
cln5k-79 A 16 a=65, b=68, 2.75 15.97 four data sets
c=82 were collected
cln5k-83 A 97 a=128, c=148 3.60 15.74 TbXo4 soak
a diffraction limit given by I/σ(I) ≥ 2.
b calculated by XDS.
cln5-kifunensine-SeMet
XRD data sets from all crystals were collected on a Dectris Pilatus 6M detector at
the Swiss Light Source (SLS) undulator beamline PXII (X10SA) using monochromatic
radiation. An on-beamline fluorescence scan was performed to verify the presence of Se
anomalous signal (see Section C.5) and data were collected at the inflection wavelength
(Figure 4.5).
Four data sets were collected each from the two best diffracting crystals (cln5k-Se-8
and cln5k-Se-11) and processed individually. Data collection statistics for all individual
scans are summarized in Tables C.2 and C.3 (Appendix Section C.5) and for the merged
data set, from which the structure was solved, are given in Table 4.6. Due to erroneous
calculations of expected radiation damage while planing the experiment on beamline6,
the initial data set of each crystal was only measured with a 90 degree rotation about phi.
Fortunately, the protein crystallized in the high symmetry space group P 3221 and only
1/12 coverage of R* was required for a full set of unique reflections. Data were reduced
and integrated using the XDS software suite by Kabsch (2010) as described in Section
1.3.
6The on-beamline software GUI DA+ and its the extension for MAD data collection is capable of
calculating the expected radiation exposure. From this exposure a maximum radiation dose is calculated
and experimental parameters are suggested.
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Figure 4.5.: On-beamline fluorescence analysis to identify the inflection point of the selenium signal. Only
the region of interest as determined by the fluorescence scan, displayed in Figure C.5, is
depicted. The anomalous scattering factors f’ and f” are shown in blue and yellow, respectively.
(a) Diffraction image of a cln5-k crystal with reflections
visible up to a resolution of 2.6 Å.
(b) Diffraction image of a cln5k-SeMet crystal with reflec-
tions visible up to a resolution of 3.3 Å.
Figure 4.6.: Diffraction images of cln5 crystals measured at the PSI SLS beamline PII X10SA at 100 K.
Data collection with Pilatus 6M detector at 1.00 Å for the crystal in Figure 4.6a and Se inflection
wavelength for the crystal in Figure 4.6b.
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Table 4.6.: Statistics for merged data set used for data solution and re-
finement.
data statistics cln5k-Se-merged
X-ray source PSI SLS PII-X10SA
detector Pilatus 6M (25 Hz)
wavelength [Å] 0.97898
space group P3221 (SG 154)
unit cell [Å] a = 58.42
c = 179.05
resolution rangea [Å] 48.59–2.70 (2.79–2.70)
number of observations 540369
number of unique reflectionsa 10352 (1013)
redundancya 52.2 (19.0)
completenessa all [%] 99.94 (100)
completenessa anomalous [%] 100 (100)
mean I/σ(I)a 19.08 (2.35)
CC1/2 a 99.9 (83.9)
CC*a 100 (95.5)
Rmergea 0.2343 (1.255)
Rpima 0.0305 (0.2873)
a highest resolution shell in parenthesis.
The crystals showed nearly no anisotropy, the resolution limits along the reciprocal
space axis displayed a maximum difference of 0.069 Å (along a* 2.666 Å, along b*
2.666 Å, along c* 2.597 Å). Neither L-test nor the multivariate Z-score show signs of
twinning in the CCP4 suite program TRUNCATE (Winn et al., 2011) or PHENIX_xtriage
(Adams et al., 2010).
Enhancing the anomalous signal Further processing was accomplished using PHE-
NIX_scale_and_merge (Adams et al., 2010), XPREP7 and XSCALE (Kabsch, 2010).
Additionally, an experimental version of SHELXC (Sheldrick, 2010) was used to combine
all data sets. This experimental version is capable of merging multiple data sets applying
a weight to each scan to achieve the best possible anomalous signal and overall data set.
7G.M. Sheldrick, Bruker AXS Inc., Madison, Wisconsin, USA, 2003.
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A more detailed account of the techniques used is available in Section 1.4 and Chapter
2.
XSCALE was employed making use of the option for zero dose extrapolation assessing
and correcting for radiation damage. The output file provides a wealth of information to
evaluate the quality of the data set combination. Parameters such as ISa for the whole
data set and CC1/2, mean I/σ(I), CCanom, R-value or anomalous density by resolution
were reviewed. Special care had to be taken to assure all data sets were integrated
without influence of indexing ambiguity, since XSCALE cannot recognize or resolve the
ambiguity.
PHENIX_scale_and_merge accepts a reference data set or can use the best data
set as reference. The later was used for all files. The graphical interface of Phenix
displayed a single table as result for the merged file. As suggested by the developers,
the criteria CCcumulative at the lowest listed resolution in the statistics was used as initial
quality indicator (see Graph C.6).
XPREP displays multiple quality indicators for merged and unmerged data sets,
including CC1/2 graphs, all common R-factors, and general data statistics (e.g. number
of reflections, mean I/σ(I)). Futhermore d”/σ(d”) statistics for anomalous data were
evaluated.
Multiple combinations of the eight scans from two crystals were tested to obtain a
merged data set with the best anomalous signal. The CFOM (combined figure of merit)
value of a successful scan of the data set with SHELXD (Schneider and Sheldrick, 2002)
and the averaged anomalous signal calculated from ANODE (Thorn and Sheldrick, 2011)
were used to evaluate the quality of a merged data set.
Data quality
All data integration was repeated to optimize the resulting data quality and anomalous
signal as discussed in Chapter 2.
All diffraction images were integrated to reach a CC1/2 of 10%, a cutoff was employed
in consecutive steps of data merging, solution and integration according to quality
indicators. Typical resolution limits for all collected data sets is listed in Table C.4. The
data statistics are presented for all single data sets to a CC1/2 of 50% generated with
PHENIX. ISa for the data sets as calculated by XDS and the results are displayed in
Figure 4.7.
Since the collected data were rather weak and the crystals diffracted only to a resolu-
tion of 2.5–2.9 Å, special care was taken in further processing of the integrated data. As
only a total of eight data sets from two crystals were available, multiple combinations
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Figure 4.7.: The data quality of all individual data sets was evaluated after integration with XDS. The
resolution limits for the commonly used indicators are listed as well as the ISa limit.
were scaled and merged individually resulting in 13 reflection files of different size and
quality. For scaling and merging the programs XSCALE, PHENIX_scale_and_merge
and XPREP were used in addition to an experimental version of SHELXC. The resulting
reflections files could comprise from two to all eight scans and were evaluated based on
different criteria.
Since the structure contains seven selenium atoms in SeMet residues per molecule,
the anomalous signal was used for SAD phasing. Additionally, the strength of the
anomalous data could serve as quality indicator for the merged files and give some idea
whether the structure could be solved using the resulting merged data set. Evaluating
all merged files originating from different merging and scaling programs with the same
quality indicators in the same program increases the comparability. The anomalous
signal was therefore examined with SHELXD and ANODE.
Evaluation of the merged data sets
SHELXD is a commonly used program for structure solution. The program is capable
of locating the anomalous scatterers from SAD, MAD, SIR or SIRAS data to yield a
substructure solution based on direct methods. A likely solution is indicated by the best
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CFOM value achieved in all tries and should be above 35. CFOM is the combination of
CCweak and CCall, which should be above 15 and 25, respectively. The best CFOM in a
fixed number of tries can serve as a quality indicator when comparing the merged data
sets (see Figure 4.8).
Structure solution should be possible with all data set combinations presented in
Figure 4.8 but the overall quality of the substructure solution can differ considerably.
Using two scans (scan 1+2) from cln5k-Se-8 or cln5k-Se-11 results in the lowest CFOM
values and the value increases if more scans (scan 1+2+3 or all scans) are used instead.
It is clearly visible that the combination of multiple scans from one crystal increases the
CFOM independently from the merging program used.
The best overall CFOM was achieved with seven out of the eight data sets using the
experimental version of SHELXC. Leaving out cln5k-Se-8 scan3 improved the overall
CFOM when using the programs XSCALE and SHELXC. XPREP and PHENIX produced
their best result from all eight data sets, but the CFOM was not the best achieved overall
when compared with other programs.
ANODE was used to calculate the anomalous density at the positions of the specified
heavy atom. With the known substructure and approximate phases the program calcu-
lates the averaged density for each heavy atom position. A log file gives the anomalous
density for each heavy atom position as well as the strongest anomalous peaks which
can be used as quality indicator. The strength of the anomalous signal specific for
selenium atoms can be evaluated (see Figure 4.9).
In general it is assumed that the averaged anomalous signal for the anomalous
scatterer has to be above 10 to allow a substructure solution. Using only the first two
scans of cln5k-Se-11 would fail to produce enough anomalous signal strength to solve
the structure. When adding more scans to the merged file, the averaged anomalous
density increases for data sets from both cln5k-Se-8 and cln5k-Se-11. This effect was
observed in SHELXD as well.
Interestingly, the best overall result and individual results were obtained using XSCALE.
The best overall averaged anomalous density was obtained from using all eight data sets
– closely followed by leaving out only cln5k-Se-8 scan3. The increase in signal compared
from all scans of cln5k-Se-8 to including scans from cln5k-Se-11 is surprisingly small.
The same effect is also visible in the SHELXD statistics.
With both SHELXD and ANODE the use of all eight data sets or seven of all excluding
cln5k-Se-8 scan3 resulted in the best anomalous signal. While using the scans from
cln5k-Se-11 resulted only in a small increase in the anomalous signal strength in total,
they were used nonetheless to improve the overall data accuracy and quality.
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Figure 4.8.: SHELXD results for selected combinations of cln5-k-Se data sets. The results obtained from
the files merged by the programs PHENIX, SHELXC, XPREP, and XSCALE are presented.
Lines serve as visual guides only.
Figure 4.9.: ANODE results for selected combinations of cln5-k-Se data sets. The averaged anomalous
density for the selenium atoms obtained from the files merged by the programs PHENIX,
SHELXC, XPREP, and XSCALE are presented. Lines serve as visual guides only.
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Considering all data quality indicators, the final merged data set used for structure
solution and refinement was created using XSCALE using all scans from cln5k-Se-8 and
cln5k-Se-11, except cln5k-Se-8 scan3.
4.4.7. Structure solution and refinement
All data sets were evaluated for their quality and from the best data sets an averaged
file with the best anomalous signal was created (see Chapter 4.4.6). The merged data
set could be used to find a solution using SHELXC/D/E and the initial Cα-trace was
extended using ARP/wARP (Langer et al., 2008). The solution was improved by iterative
manual model revision in COOT (Emsley et al., 2010) and refinement with REFMAC5
(Vagin et al., 2004) using the CCP4i2 GUI (Potterton et al., 2018). The manual model
revision was performed by inspecting the agreement of the model with electron density
maps: a map with model bias correction (2mF0-DFc) and a difference electron density
map (mF0-DFc).
Additionally, the SHELXC experimental version automatically recognized and resolved
the indexing ambiguity, creating a merged file from all scans of one crystal. This file
was sufficient to solve the selenium substructure in SHELXD and a good alpha-traced
solution in SHELXE was found, using the initial solution as a reference file.
Glycosylation was present, as visible in the difference electron density map (see Figure
4.17). Therefore the Carbohydrate module in COOT was used to model high-mannose
sugar modification (Agirre et al., 2017). The sugar moieties were only modeled into the
visible difference electron density and when justified by the fit and B-factors. Privateer
(Agirre et al., 2015) was used to generate restraints for NAG and β-D-mannose (BMA)
and conformation validation.
A model could be built for the amino acid residues 99 to 399 of the cln5 sequence
and high-mannose sugar modifications at four positions (Asn179, Asn192, Asn252, and
Asn304). Two gaps in the chain from amino acids 151–160 and 347–352 remained in
the final model. The overall B-factor was above 50. All residues refining to a B-factor
over 100 were removed from the model.
Model validation was performed using the PDBredo (Joosten et al., 2014), MolProbity
(Chen et al., 2010) and FitMunk (Porebski et al., 2016) services. The last refinement
steps were conducted using PHENIX_refine (Adams et al., 2010), which yielded a
structure model with a final R/Rfree of 22.1/24.7, respectively. The final refinement results
were deposited with the PDB under assertion code 6r99.
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4.4.8. Model quality
An overview of the model and refinement statistics are listed in Table 4.7.
Table 4.7.: Refinement statistics for cln5k-Se-merged data set.
Refinement statistics Cln5K-Se-merged
resolution rangea 38.56–2.70 (2.79–2.70)
reflections used in refinementa 10352 (1013)
reflections used for R-freea 522 (45)
R-factora 0.2207 (0.2983)
Rfree
a 0.2472 (0.3741)
CC(work) 49.2
CC(free) 52.4
r.m.s. deviations from ideal geometry:
bonds [Å] 0.004
bond angles [◦] 0.74
No of non-hydrogen atoms 2441
No of residues 284
No of sugar moieties 7
No of water molecules 35
Ramachandran plot [%]:
residues in preferred regions 94.62
residues in allowed regions 4.66
residues in disallowed regions 0.72
rotamer outliers [%] 0
clashscore (Molprobity) 4.30
average B-factor [Å2]:
overall 57.05
macromolecule 56.93
ligands 61.21
solvent 53.54
a highest resolution shell in parenthesis.
The initial refinement was performed using REFMAC5 via the CCP4i2 GUI. During
model validation the R/R-free gap increased to 5 and no improvement in the amino acid
geometry was achievable. The manual adjustment of the weighting scheme did not result
106
4.4. MATERIALS AND METHODS
in the recommended root mean square (r.m.s.) deviation of bonds around 0.02 Å but
remained significantly higher. Therefore PHENIX_refine was employed for the final steps
of refinement during model validation. The R/Rfree gap decreased significantly owing
to lower Rfree values. Both the MolPobity score and the clashscore decreased from
2.24 to 1.58 and from 7.08 to 4.3, respectively, indicating a better overall model quality.
Furthermore, the r.m.s. bond deviation decreased and the protein geometry improved
resulting in more favored rotamers and more residues in Ramachandran favored regions.
The overall data resulted in a good model considering the resolution limit of 2.7 Å.
The limited resolution is reflected in multiple close contacts remaining and the lack of
reasonably modeled solvent molecules. Only a few water molecules with close distance
to other residues are kept in the final model and some regions of un-modeled electron
density remain.
The final model contains two regions where side chains of the amino acids were not
modeled, because no electron density was visible to support any sensible conformation.
This manifested in unusually high B-factors which were physically unreasonable. A
depiction of the structure colored by the B-factor of the main chain atoms is presented
in Chapter C.7. It is conceivable that these regions of the protein are more flexible and
exist in multiple conformations. In a structure based on XRD data to a higher resolution
these might be visible and could be modeled.
Overall, the final model quality statistics are in the expected ranges for a structure
solved at a resolution of 2.7 Å. Compared to other models produced from a similar
resolution – the cln5 structure model is of good quality.
SHELXL refinement
While the resolution of the acquired data does not justify a SHELXL (Sheldrick, 2015)
least-squares refinement, the program can help refining the occupation of the selenium
atoms in the structure. Since the modification with SeMet was achieved by starvation and
changing of the available medium, it can not be expected that all methionine residues
are completely exchanged. Therefore PDB2INS (see Chapter 3) was used to convert
the pdb file to the input format ins required by SHELXL and the structure factor file
was produced from the initial merged file with XPREP. Since the Rfree flags were not
present in the original merged file, a new set was generated in XPREP. While restraints
for all common amino acids and the most frequent ligands are automatically added to
the instruction file by PDB2INS, the restraints for the residue SeMet, MSE, were initially
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missing. Restraints for MSE were generated by GRADE server8 and added manually.
First, the refinement of the Se occupancy was attempted by assigning each individual
Se atom to a separate part. Since the same site could be occupied by either selenium or
sulfur, one atom of both types was placed at each site. The sum of occupancies of both
atoms of the site was restrained to be one, but the distribution of occupancy between
the two element types was refined freely with one free variable for each residue. The
occupancy of all positions was not refined at once. The positions were added step-wise
with ten refinement cycles (conjugate gradient least squares) in between, starting at the
position with the lowest expected occupancy reported by ANODE. This strategy lead to
no meaningful result, evident e.g in residue 202 which initially refined to an occupancy
for selenium of around 73% but rose to (over) 100% when all selenium positions were
refined at the same time (see Table C.5).
Next, SHELXL was instructed only to refine the occupation of all selenium atoms
with one free variable shared by all residues, leading to an overall occupancy of 82%.
Standard deviations were calculated with one cycle of least squares refinement while
allowing no shifts in the atom’s positional parameters. Occupation and displacement
parameters were refined separate from the coordinates.
Phenix_refine and REFMAC5 are capable of refining the occupancy of selenium sites
by simply reducing the occupancy of the site. The resulting occupancies are listed in
Table 4.8.
Table 4.8.: Occupancies of selenium atoms as refined by PHENIX_refine and REFMAC5.
SeMet residue 135 165 182 202 240 244 383 mean
PHENIX_refine 0.73 0.77 0.75 0.68 0.88 0.78 0.82 0.77
REFMAC5 0.95 0.96 0.99 0.97 0.97 0.98 1.00 0.97
The resulting mean occupancy from PHENIX_refine with 77% is close to the result
obtained from SHELXL. In contrast, REFMAC5 refined the occupancies to an average
of 97%, contrary to general expectations. In conclusion, the Met residues were mostly
replaced with SeMet, in all probability to about 80%. This is the ratio of exchange
reported before (Barton et al., 2006).
4.4.9. Molecular replacement
Structure solution via molecular replacement was attempted using the data sets cln5k-79
(single scans and merged data sets) and the model refined against the final merged
8http://grade.globalphasing.org, Global Phasing Ltd.
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data set cln5k-Se-merged. The full model was used as well as a model containing only
the Cα main chain. The programs MolREP (Vagin and Teplyakov, 2010), Buccaneer
(Cowtan, 2006), SIMBAD (Simpkin et al., 2018), and PHASER_MR as implemented in
PHENIX (McCoy, 2007) and CCP4i2 were tested. Furthermore, Arcimboldo_Shredder
(Sammito et al., 2014) was employed.
No program yielded any acceptable solutions. The XRD data of the cln5k crystals all
show anisotropy and difficulties during space group assignment. A closer look at the
quality of these data sets might result in a structure solution in the future.
4.4.10. Structure similarity studies
Protein structure comparison can expose distant evolutionary relationships not detected
by sequence identity. The three-dimensional fold is believed to have a major impact on
the stability, protein behavior, and the ability of a protein to bind ligands or other proteins.
Therefore, similarity analysis of a protein structure is a valuable tool in understanding
the proteins function or role.
Most common structure comparison programs and web services use different tech-
niques such as geometrical positions resemblance or secondary structure elements to
find local alignment. The qualification of structure similarity is often based on functions
very specific for the given server, as reviewed in Hasegawa and Holm (2009). With
the final model of the structure of cln5 different structure similarity search servers were
employed to find a homologous structure. The web services Dali (Holm et al., 2008,
Holm and Laakso, 2016) and PDBeFold (Krissinel and Henrick, 2004) were used.
PDBeFold parameters
Analyzing structure similarity with PDBeFold, the following parameters were used to
quantify the result. PDBeFOLD reports the quality of a result by the parameters Q-score,
P-value, P-score, and Z-score (Krissinel and Henrick, 2004). The following definitions
were taken from the official PDBeFold website9.
The Q-score represents the quality function of the Cα alignment, maximized by the
secondary structure matching (SSM) alignment algorithm. The Q-score reaches 1 for
perfect alignment and drops with increasing r.m.s. deviation or decreasing alignment
length.
The negative logarithm of the P-value is the P-score. The P-value measures the
probability of achieving the same or better quality of match at chance. A P-score lower
9http://www.ebi.ac.uk/msd-srv/ssm/
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than 3 indicates a statistical insignificant match. Z-score is statistical significant in terms
of Gaussian statistics, the higher the Z-score the higher the statistical significance.
Furthermore some general information on the matched secondary structure are
presented. Nres and Nalign state the number of residues and length of alignment as
number of matched residues, respectively. %seq represents a quality characteristic of
Cα-alignment as sequence identity in percent. NSSE and %SSE describe the number of
residues and percent of matched SSEs, respectively.
Dali parameters
The web server Dali evaluates structure similarity by a Z-score. Results yielding Z-scores
lower than 2 are considered spurious and should not be considered any further. Matches
with a Z-score above 2 show significant similarities. Furthermore, matches with an
Z-score above an empirical cutoff, depending in the size of the protein, or a sequence
identity above 20% are regarded as strong. The empirical cutoff is given by N/10− 4,
where N is the number of residues in the query structure.
4.5. Results and discussion
4.5.1. Interaction Studies
Influence of cln5 deficiency on other NCL proteins
Studies of cln5 deficiency on other NCL proteins and lysosomal proteins with a role
in autophagy were conducted. The influence on the expression of other NCLs and
autophagy proteins in knockdown CLN5 HeLa cells was analyzed (see Figure 4.10 and
Table 4.9). The results for cln11, cln12, cln13 and cln14 are not shown since the antibody
did not display adequate specificity. No visible or measurable staining could be achieved
with the cln2 antibody, therefore the results were excluded as well.
Table 4.9.: Analysis of influence of CLN5 knock-down on NCL and autophagy proteins by western blot.
cln5 cln1 cln3 cln4 cln6 cln10 p62 LCI/II
control 1 1 1 1 1 1 1 1
CLN5-/-
0.07 0.99 0.68 1.25 0.85 0.94 2.99 1.77
- 0.34 0.45 0.35 0.01 0.27 1.07 1.30
- 0.45 0.87 0.45 1.84 0.76 0.98 0.52
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Figure 4.10.: Interaction studies by western blot on un-transfected cells expressing cln5 (shRNA, control)
and CLN5 knockdown Hela cells (CLN5#1 shRNA).
The deficiency of cln5 displayed an influence on other NCL proteins and autophagy
associated proteins p62 and LCI/II. Overall the results did not display a clear trend, since
large variations are present in the results. For example, the first measurement showed
an up-regulation of the proteins p62 and LCI/II. This result could not be confirmed by the
subsequent measurements, where p62 showed no change in comparison to the control
and LCI/II even showed a decrease.
The NCL proteins cln1, cln3, cln6, and cln10 displayed no change in expression level
compared to the control.
Next, an increase of cln10 with cln5 depletion as expected from the results by Mark-
mann et al. (2015) could not be verified. Also an influence of cln5 deficiency on cln3 could
be reported here. The amount of cln3 was depleted slightly with cln5 deficiency. Vesa
et al. (2002) reported that cln5 and cln3 show interaction via co-immunoprecipitation
assay. Furthermore, the proposed interaction between cln5 and cln6, as suggested by
Lyly et al. (2009) could not be conclusively confirmed. Further studies will be necessary
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to determine the influence of cln5 deficiency on NCLs proteins or proteins linked to
autophagy.
Investigation of cln5 processing by CathepsinD (cln10)
The interaction between cln5 and active CTSD was researched by SDS-PAGE studies.
To determine whether cln5 is processed by CTSD, cln5 was incubated with different
ratios of active CTSD for various time periods. To simulate lysosomal acidity, the studies
were performed in 100 mM sodium acetate puffer pH 4.5. Firstly, CTSD activity was
verified at lysosomal pH (see Table C.1).
Next, the reaction solution containing active CTSD and cln5 was analyzed. Samples
of the reaction solution were removed at given time intervals and SDS-PAGE used to
separate the components (see Figure 4.11). The cln5 band remains stable and without
any visible decay. SDS-gels were analyzed with ImageJ to obtain a first impression of
cln5 concentration in presence of active CTSD (Table 4.10). These preliminary studies
can be quantified by further investigation using other experimental techniques.
Table 4.10.: SDS-PAGE-based analysis of the CTSD processing of cln5. The ratio of CTSD to cln5 was
varied and the amount of cln5 remaining after a certain time period was analyzed. The results
are displayed as cln5 amount in contrast to the control.
time control ratio CTSD:cln5
1:10 1:5 1:2 1:1
0 min
1 27.30 8.61
1 0.98 0.96 0.93
1 0.90 1.03 0.87
10 min
1 0.70 0.23
1 0.98 0.93 0.73
1 0.88 0.85 0.73
30 min
1 1.29 0.57
1 0.85 0.91 0.98
1 0.87 0.91 0.79
1 h
1 0.92 0.48
1 1.04 1.01 0.99
1 0.82 2.56 0.84
No decrease of cln5 can be found in the presence of active CTSD at lysosomal pH. A
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processing of cln5 by CTSD within the time scope of the experiment was not measurable.
It is possible that further studies with a longer exposure of cln5 to active CTSD can find
evidence of cln5 processing by CTSD. Also a different experimental setup might yield a
more precise analysis of an interaction between cln5 and CTSD.
(a) Before interaction (left) and after an incubation time of 10 minutes (right).
(b) Incubation time 30 minutes (left) and 60 minutes (right).
Figure 4.11.: SDS-PAGE of cln5 interaction with active CTSD to evaluate possible cln5 processing.
4.5.2. Circular dichroism
Circular dichroism (CD) was used to investigate the secondary structure of cln5 in
solution. First, the difference between the two peaks eluted by Ni-affinity chromatography
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is evaluated (see Section C.4). The resulting CD spectra show no variation and a further
discrimination of the eluted protein is not considered necessary. It is assumed that this
is a purely self-made distinction due to the step-wise gradient used during Ni-affinity
chromatography, since neither SDS-PAGE nor CD analysis show a significant variation.
Next, different concentrations of the protein are measured to determine the likely
secondary structure elements (see Figure 4.12).
Figure 4.12.: Circular dichroism spectra calculated from circular dichroism of cln5 protein at different
concentrations. Concentrations in µg/mL.
The CD analysis shows no dependence of the secondary structure on the concen-
tration or the temperature at which the data was collected or the concentration. The
temperatures of 4 ◦C and 20 ◦C are typical temperatures for the crystallization of pro-
teins. No change in the secondary structure in the temperature range is favorable for
crystallization.
The spectra clearly indicate that antiparallel β-sheets could be present in the structure
of cln5 when compared to spectra as discussed in Greenfield (2006). But the intensity of
the peaks is not as high as expected for a tertiary structure containing only this structure
element. It can be ruled out that the protein is disordered or denatured.
In conclusion, the CD analysis confirms that a secondary and tertiary structure is
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present in solution. Additionally, there is no measurable structural difference between
the two peak fractions obtained from purification.
4.5.3. Structure description
One molecule of cln5 is observed in the asymmetric unit. The crystal structure reveals
cln5 to be a globular protein with two domains consisting of α-helices and anti-parallel
β-sheets (see Figure 4.13 and, for other viewpoints, Figure 4.14). A schematic overview
of the structure is displayed in Figure C.7, Section C.7. In Figure 4.14 the structure
is colored by regions depicting grouped secondary structure elements that can be
considered as folds.
Figure 4.13.: Structure of cln5, colored by sequence, from blue at N-terminus to red at C-terminus. Sec-
ondary structure elements are labeled consecutively.
Starting from the N-terminus, the first 40 amino acids form an extended strand
covering nearly one complete flank of the molecule. Two disulfide bridges, from Cys119
to Cys208 and from Cys126 to Cys214 keep the first region in place between two sugar
modifications at Asn192 and Asn252 (see Figure 4.19). The strand proceeds into an
antiparallel β-sheet consisting of five β-strands (β1–5). The sheet is intermitted by a
long β-hairpin reaching over to the other side of the structure with a short α-helical
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element (α1) between the third and fourth strand, and by a short α-helix (α2) between
the fourth and fifth strand. While the helix α2 is lying across the sheet on one side,
the region is completed by two prominent α-helices (α3 and α4) on the opposite side
forming an αα motif (see 4.15, blue fold).
Figure 4.15.: Structure of cln5, colored by fold. The first fold, colored in blue, consists of the antiparrallel
β-sheet (strands β1–5) and two α helices ( α1–2). The second fold, colored in yellow, is a
short antiparrallel β-sheet (strands β6, 8, and 12.). The last structure fold, colored in green,
consists of a small antiparrallel β-sheet (strands β9, 10, and 11.) and three α helices ( α5–7).
In the middle, a short antiparallel β-sheet consisting of three strands (β6, β8 and β12)
is located (see 4.15, yellow fold). The first strand of the β-sheet is sequencially located
between α3 and α4.
Between the strands β8 and β12 an adjoining antiparallel β-sheet (β9 – 11) is located
(see 4.15, green fold). Also, two more α-helices (α6 and α7), forming another αα motif,
and a short α-helical element ( α5) are part of the region. The strand β12 is the last
structural element before the C-terminus, which is located next to helix α4.
The crystal structure shows electron density for the amino acids 99 to 399 with
two gaps of ten and six amino acids between Val150–His161 and Pro346–Phe353,
respectively (see Figure 4.16). Furthermore, significant electron density is present at
four glycosylation sites, Asn179, Asn192, Asn252, and Asn304 (see Section 4.5.3).
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Figure 4.16.: Sequence of cln5 annotated with secondary structure elements. Secondary structure elements
are visualized as helix in red and strands in green, numbered consecutively as α and β,
respectively. β hairpins are illustrated with red lines. Furthermore, disulfide bridges are
marked and numbered in yellow and residues with contacts to ligands are tagged with a red
dot.
Comparison with protein structure predictions from literature
The structure of cln5 is a globular, soluble protein. Larkin et al. (2013) predicted a
putative transmembrane helix reaching from amino acid 76 to 91 and an amphipathic
helix located at amino acids 353–392. While the first transmembrane helix is in front
of the reported signal peptide cleavage site at Ile96, the mature protein retains the
amphipathic anchor region. Indeed, an α-helix is present from amino acids 353 to 364
(α7) in the region of the predicted second transmembrane helix (see Figure 4.16). This
secondary structure element is only eleven residues long instead of the anticipated 39
residues and directly followed by two β-strands (β10 and β11), that form an antiparallel
β-sheet. The structure prediction by Savukoski et al. (1998) appears more accurate,
since here a hydrophobic region was predicted from amino acids 353 to 373. Both
topology studies are based on bioinformatic analysis of the cln5 sequence but were
conducted 15 years apart (Larkin et al., 2013, Savukoski et al., 1998). It is not clear why
the deployed prediction tools reported different results.
Since only the residues from amino acids 99 to 399 are resolved in the crystal structure
of cln5, the signal peptide cleavage position at Val93 or Ile96 is more probable than
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at an earlier residue. But a conclusive statement based solely on the crystal structure
presented here cannot be made here, of course.
Glycosylation sites
The N-glycosylation sites at Asn179, Asn192, Asn252 and Asn304 show excellent
electron density for carbohydrate modification. Here high-mannose modification was
modeled with up to three residues (see Figure 4.17). An overview of all sugar modi-
fications and their immediate surroundings is presented in Figure 4.18 and in Figure
C.9.
Figure 4.17.: The sugar modification at Asn252 could be modeled with three sugar molecules. The electron
density from the final refinement is contoured at 1σ around the residues NAG701–702 and
BMA703.
Asn179 is located at the start of strand β3 and the first sugar residue, NAG501,
can form hydrogen bonds with the nearby side-chain of Asp221 at helix α2 (Figure
4.18a). Two sugar residues can be found at Asn192, NAG601 and NAG602 (Figure
4.18b). Hydrogen bonds connect NAG601 and the protein backbone at Gln120 as well
as Tyr118. These interactions can hold the extanded strand in the first part of the protein
in place, in addition to the disulfide bridges (see Figure 4.19).
At Asn252 three sugar residues could be modeled, NAG701, NAG702, and BMA703
(Figure 4.18c). Hydrogen bonds to the protein backbone at Pro127 and Ala213 may
contribute to the stability of the structure. The interaction of Pro127 with BMA703 is
located to the other side of the N-terminal, extended strand in comparison to NAG601.
This indicates a contribution to a stabilized overall motif at this position, visualized in
Figure 4.19. The sugar residues around the peptide chain at amino acids 117 to 121
and the extended strand is further stabilized by disulfide bridges to the sides at Cys119
and Cys126.
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(a) Sugar modification at Asn179 (NAG 501). (b) Sugar modification at Asn192 (NAG 601-602).
(c) Sugar modification at Asn252 (NAG 701-
BMA703).
(d) Sugar modification at Asn304 (NAG 801).
Figure 4.18.: The sugar modification at the amino acids Asn179 (a), Asn192 (b), Asn252 (c), and Asn320
(d) are displayed with the nearest contact and the surrounding residues.
Figure 4.19.: Two disulfide bridges Cys119 to Cys208 and Cys126 to Cys214 are visualized and the nearby
sugar modifications at Asn192 and Asn252 flanking the N-terminal extended strand are
displayed.
120
4.5. RESULTS AND DISCUSSION
One sugar molecule, NAG801, was modeled at Asn304 and displays hydrogen bonds
to Glu302 and the amino acid backbone at strand β11 (Figure 4.18d). An overview of
the nearest residues for all sugar modification is also given in Chapter C.7.1.
4.5.4. Structure homology
Structure prediction
At the very beginning of this study several secondary structure prediction web-based
servers were employed. An idea of the secondary structure elements that can be
expected might help modify crystallization conditions and, in the best case, a binding
partner could be identified. The web based services of the structure prediction servers
I-TASSER, BLAST, Swiss Model, HHPred and RaptorX were employed with the protein
sequence of cln5. None of the programs resulted in a prediction that gave further insights
into the structure of cln5, possible homologues or interaction partners (see Chapter
C.8.1).
The final structure solution achieved in this thesis can be compared with past struc-
ture predictions. Huber and Mathavarajah (2018) published a binding prediction that
anticipated a putative NGT binding side involving the residues Gln147, Pro148, Val101,
Lys154, Gln243, Tyr311, Gly313, Glu314, Tyr317, Phe37310. This putative binding side
was based on a predicted secondary structure from the RaptorX web server (see Figure
4.2). Figure 4.20 displays the XRD structure of cln5 with all predicted binding residues
from the publication by Huber and Mathavarajah (2018) marked in green. All residues
predicted to bind NGT are located widely apart in the structure of cln5. The difference
between the predicted cln5 structure and the actual crystal structure reported in this
thesis is quite prominent.
10The original publication numbered the residues starting from 1 for the first residue in the shortened
sequence corresponding to Leu49 in the full sequence. Therefore the residue numbers were corrected to
be consistent with the numbering used in this work.
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Figure 4.20.: Structure of cln5 with predicted ’binding residues’ as discussed by Huber and Mathavarajah
(2018) based on a secondary structure prediction from RaptorX server.
An attempt to reproduce the reported structure prediction was not successful (see
Chapter C.8.1). Furthermore, no putative binding site could be predicted from the models
obtained with the RaptorX web service. The secondary structure prediction results from
I-TASSER, Swiss Model and HHPred are reported in section C.8.1. BLAST did not
report any sequence matches outside of the cln5 orthologues.
In conclusion, the secondary structure prediction calculated by the RaptorX web server
was not helpful in predicting the secondary structure in advance of the crystallization
studies. Furthermore, no additional information was gained and results reported from
other groups could not be reproduced. The additionally employed structure prediction
methods resulted in poor or incomplete models of low confidence scores and were
not regarded any further. Since most of the algorithms employed by this programs
are based on a search for sequence similarity or homologies, none could predict a
sensible structure of cln5. Even sophisticated programs like RaptorX cannot replace
XRD structure solution for proteins with no known homologues.
4.5.5. Structure similarity
Initial structure similarity matches were found using the Dali web service. Dali sorts
results by Dali Z-score, a measure for similarity. The structure similarity between cln5
and the two top matches found with Dali is weak but significant (see Table 4.11).
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Table 4.11.: Structure similarity matches using Dali web service (Holm et al., 2008, Holm and Laakso,
2016).
PDB-ID chain Z-score RMSDa [Å] lalib Nres %ID protein description
3ebq A 6.8 3.2 109 144 11 PPPDE1
2wp7 A 6.7 3.3 111 158 12 PPPDE2
a RMSD = root mean square deviation.
b lali = length of the alignment.
PPPDE1 (permuted papain fold peptidase of DsRNA viruses and eukaryotes 1) (Xie
et al., 2017) and PPPDE2 (Suh et al., 2012), also known as DeSI2 (deSUMOylating
isopeptidase 2) and DeSI1, respectively, show structural similarity with cln5 in the same
region. While the Z-score is clearly above 2, indicating a significant similarity, the
comparably low sequence identity of 11% and 12% does not support a strong match.
PDBeFold allows structure alignment via the identification of residues occupying
equivalent geometrical positions. It is based on secondary structure matching (SSM)
and can perform pairwise or multiple three-dimensional alignment (Krissinel and Henrick,
2004). The significance of a match is measured by Q-score, P-score, Z-score, r.m.s.
deviation (RMSD) and percentage of sequence identity (%SSE) (see Chapter C.9).
Table 4.12.: Alignment statistics CLN5 and PPPDE1 from PDBeFold (Krissinel and
Henrick, 2004).
cln5 Alignment PPPDE1
Nres %res Q P RMSD [Å] Nalign Nres %res
285 35 0.159 1.54 2.119 99 144 69
NSSE %SSE %seq Z NSSE Ngaps NSSE %SSE
18 39 12.1 6.63 7 9 12 58
When using the result from Dali as search query in PDBeFold, the result gave a poor
Q-score and a sequence alignment of only 12% (Table 4.12). A sequence alignment of
99 residues is found, which corresponds to 69% of the PPPDE1 protein. Nonetheless,
the match could describe a significant part of the cln5 protein structure – 35% of all
modelled residues – and may help to assign a probable function. The match was
therefore investigated further.
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Next, the structure overlay of cln5 and PPPDE1 was visualized in a graphics program
for visual inspection. The rotation-translation overlay was produced with PDBeFold,
which also provides a table with the results of the 3D Cα alignment. In this alignment
table the distance is rated as well as the amino acid similarity (see Figure 4.21). Several
regions display a close distance match and better superposition. Some amino acids are
identical and occupy the same position. These regions of interest were analyzed further.
Permuted papain fold peptidase of dsRNA viruses and eukaryotes 1
PPPDE1 was reported to have a deubiquitinating function (Iyer et al., 2004, Xie et al.,
2017) and deSUMOylation activity (Shin et al., 2012). It was suggested that PPPDE1
is part of the NlpC/P60 superfamily of papain-like enzymes due to its similar fold (see
Figure 4.22) (Xu et al., 2011). Embedded in this fold lies an arrangement of catalytic
residues, including a Cys/His-containing dyad with an additional tyrosine.
The NlpC/P60 superfamily belongs to the cysteine peptidases, proteolytic enzymes
that hydrolyze a peptide bond. The thiol group of a cysteine acts as a nucleophile and
cysteine peptidases are often active at acidic pH. The superfamily is characterized by
a papain-like fold consisting of a bundle of α-helices on one side and a β-barrel motif
on the other side. The cysteine is here part of a catalytic triad consisting of a cysteine,
a histidine, and an asparagine (aspartic acid). The NlpC/P60 superfamily consists
of four main families, as suggested by sequence analysis (Xu et al., 2011). P60-like,
AcmB/LytN-like, Yaef/Yiif-like, and LRAT-like enzyme families are ubiquitous papain-like
cysteine peptidases or other functionally related enzymes (Anantharaman and Aravind,
2003, Aramini et al., 2008, Pai et al., 2006, Xu et al., 2010, 2009).
The families within the superfamily are sub-grouped. The canonical papain-like
NlpC/P60 enzymes (CPNEs) contain the families of P60-like and AcmB/LytN-like en-
zymes. These are hydrolases with specificity for amide linkages in cell-wall components
and have a catalytic core similar to that of papain (Xu et al., 2011).
The permuted papain-like NlpC/P60 enzymes (PPNEs) consist of the families AcmB/-
LytN-like and Yaef/Yiif-like enzymes. These were predicted to have a circularly permuted
catalytic domain consisting of a conserved catalytic triad (Cys, His and a polar third
residue). Bioinformatic studies have suggested that PPNEs are related to the PPPDE
superfamily (Iyer et al., 2004).
An overview of the structural folds associated with the NlpC/P60 super family is given
in Figure 4.23, (b) and (c), respectively. The depicted protein structure folds are drawn
similarly to the predicted topology diagrams by Iyer et al. (2004).
The structure of PPPDE1 was solved by the Structural Genomics Consortium (PDB-ID
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Figure 4.22.: Structural analysis of the papain-like proteins of the NlpC/P60 superfamily taken from Xu et al.
(2011). a) depicts a structure comparisson between BcPPNE (left) and CPNE BcYkfC (right)
with subdomains colored and catalytic residues as ball-and-sticks. b) The conservation of the
core structure within the NlpC/P60 superfamily is visualized by superposition of conserved
residues. c) Sequence alignment of PPNEs (BcPPNE, YiiX, PPPDE1, G6R and LRAT) and
CPNE BcYkfC.
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(a) Papain-like fold. (b) Papain-like fold as present in the structure papain
(1PPN).
(c) Predicted permuted papain-like fold in NlpC/P60.
(d) Permuted papain-like fold as present in the structure
PPPDE1 (3EBQ).
(e) The topology diagram of the structure fold in cln5 is
depicted. The fold is similar to the permuted papain-
like fold in PPPDE1. The catalytic residues identified
as catalytic triad in PPPDE1 can be found in cln5 in
the same spatial arrangement.
Figure 4.23.: Topology diagrams of the NlpC/P60 super family protein folds (a–d) (Iyer et al., 2004). The
predicted permuted papain-like fold is derived from Anantharaman and Aravind (2003). In
comparison the preserved structure fold found in cln5 is depicted in (e).
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3ebq, unpublished results). The PPPDE family proteins have a conserved cysteine and
histidine dyad for protease or acyltransferase activity in a circularly permuted papain-like
fold. An overlay of the fold region and a sequence analysis was presented by Xu et al.
(2011), see Figure 4.22. The dyad with an additional tyrosine forms a reactive triad
consisting of the amino acids Cys108, His38, and Tyr101 in PPPDE1 (see Figure 4.23d).
Cln5 displays the circularly permuted papain-like fold
Taking a closer look at the reactive triad and the associated fold of the PPPDE proteins
reveals that cln5 and PPPDE1 overlap and show conserved residues. Cln5 displays the
triad of Cys, His and Tyr as present in PPPDE1. Furthermore, the complete structural
fold of the circularly permuted papain-like fold around the reactive triad is present in the
structure of cln5. The complete overlay was generated using PDBeFold, see Figure 4.24.
In general, the structure fold involving α3 and α4 as well as β1–5 is arranged in a similar
manner as in PPPDE1.
Figure 4.24.: Overlay of permuted papain-like fold with cln5 in dark gray and PPPDE1 in light grey, the
similarity is colored as calculated by PDBeFold (red/green or light red/light green, respectively).
Secondary structure numbering as in Figure 4.13, orientation 	 180◦.
The reactive triad present in PPPDE1 is located to the side of the conserved structure
fold, consisting of Cys108, His38 and Tyr101. As typical in the whole NlpC/P60 super-
family, the reactive center is located in between an α-helix bundle and β-sheet. These
amino acids are visualized in Figure 4.25b. The cln5 structure displayed in Figure 4.25a
in the same orientation shows a similar positioning for the residues Cys280, His166 and
Tyr258. The triad is depicted in Figure 4.26.
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(a) The triad in cln5 consisting of the amino acids Cys280,
His166, and Tyr258.
(b) The triad in PPPDE1 consisting of amino acids
Cys108, His38, and Tyr101.
Figure 4.25.: Structural overlay of the conserved secondary structure of cln5 and PPPDE1: Similarity
marked in green (β-sheet) and red (α-helix). Orientation of structure in (a)/(b) as in Figure
4.13 and in 4.25a/4.25b, horizontal  by 90◦. The PPPDE1 structure displays residue Cys108
as disordered, both positions of the sulfur atom are displayed in (b).
Figure 4.26.: The triad present in PPPDE1 is depicted as overlay with cln5. In PPPDE1 the triad consists
of the residues Cys108, His38, and Tyr101. In cln5 the corresponding residues are Cys280,
His166, and Tyr258. The residue His38 in PPPDE1 was reported disordered in two conforma-
tions, both are depicted here. The overlay of permuted papain-like fold is colored as in 4.25,
the secondary structure numbering is given as in Figure 4.13, and the orientation is depicted
as in the topology diagrams in Figure 4.23.
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In conclusion, cln5 shows a strong structure similarity to PPPDE1 in the putative
catalytic domain. While the function of cln5 remains unknown, the similarity to PPPDE1
with a conserved reactive triad gives a strong indication that cln5 might have an enzymatic
function. The triad in PPPDE1 is the reactive center for the protein’s deSUMOylation
activity (Gillies and Hochstrasser, 2012, Shin et al., 2012). Cln5 displays a circularly
permuted papain-like fold in one of its domains, the triad is present in a conserved form
at the edge of this fold. This is a strong indicator that the residues Cys280, His166,
Tyr258 may have a catalytic function in cln5 as well.
Recently, PPPDE1 was reported to be a deubiquitinating peptidase (DUB) (Xie et al.,
2017) in addition to the deSUMOylating function associated with the cysteine peptidase
(Iyer et al., 2004). Neither function has been attributed to cln5 before. Nonetheless, as
demonstrated here, the structure of cln5 could contain valuable clues to function. Further
enzyme activity studies with a focus on a possible cysteine peptidase function should be
conducted in addition to testing for a deSUMOylation activity.
4.5.6. CLN5 mutation analysis
Since several dozen mutations of CLN5 are known to date, the focus will be on point
mutations leading to disease onset as depicted in Figure 4.27. A loss of function can be
expected if no mature protein is expressed, as it is the case in missense mutations. With
point mutations, it may be interesting to study why such small changes also lead to a
loss of function.
Mutation cln5.003 transforms Asp279 to an asparagine residue, a change from acidic
to polar amino acid. This residue is situated in the midst of the preserved catalytic triad
(see Figure 4.28a) but is not part of it. Even small changes in a catalytic center could
lead to total loss of function.
Another mutation affects the triad directly, cln5.011 describes a change of Tyr258
to asparagine. This tyrosine residue is part of the conserved triad as it is found in
the PPPDE family. Since the mutation leads to disease onset and the amino acid is
associated with catalytic function in other proteins, it it may point to the role of this
residue in the function of cln5.
The mutation cln5.029 results in a change of Asn192 to a serine amino acid and
thereby in the removal of a glycosylation site. In the XRD structure glycosylation at
this residue was well ordered as indicated by the observed electron density. More
interestingly, the sugar modification frames a part of the N-terminus of the protein with
an extended strand (see Figure 4.19). Nonetheless, that part is held in place by two
disulfide bridges and flanked by two sugar residues at either side, suggesting a well
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Figure 4.27.: Structure of cln5 is displayed and the currently known missense mutations are highlighted. All
point mutations leading to symptoms of late infantile NCL are marked in red and orange for
adult onset causing mutations.
ordered region (see Figure C.9b). The elimination of this glycosylation site might not
only destabilize the pH-resilience but also the secondary structure itself.
The mutation cln5.021 transforms Cys126 into a tyrosine residue resulting in the loss
of a disulfide bridge. The disulfide bridge binds Cys126 to Cys214, part of the β-sheet in
a structure motif. This disulfide bridge is in the middle of the aforementioned part of the
N-terminus framed by sugar modifications at Asn192 and Asn252.
Likewise located in this region is Arg112, which is changed to histidine by mutation
cln5.006. A change from the basic arginine to histidine represents a very significant
change in space requirement and distance for possible contacts. This residue is located
at the edge of both the conserved triad region as well as the sugar moiety at Asn252
(see Figure 4.28b). Mutations in this part of the protein might not only disturb the folding
and stability of the secondary structure but also result in loss of function, should the
conserved core, as in the NlpC/P60 superfamily of papain-like enzymes, be a catalytic
center.
Interestingly, the premature stop codon of Fin major mutation results in only a slightly
shorted protein with a termination at Tyr392. The termination occurs shortly before
the glycosylation site at Asn401. This part of the protein is not part of the conserved
structure fold, therefore it is not possible to evaluate if the mutation affects the structure.
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(a) Mutation site cln5.003. (b) Mutation site cln5.006
Figure 4.28.: Mutation of Asp279 (4.28a) and Arg112 (4.28b) leads to disease onset in patients. Asp279 is
directly neighboring the preserved reactive triad consisting of Cys108, His166 and Tyr258.
Localization studies showed that the mutation of Asn401 (N401Q), the glycosylation site
itself, most likely resulted in a correctly folded protein that was mis-localized to the Golgi.
This N-glycosylation site might be important for cln5 trafficking to the lysosome (Moharir
et al., 2013).
Further studies are mandatory to ascertain the function and interactions of cln5 and to
understand the grave effect of mutations in patients.
4.6. Conclusion and outlook
In this work the protein cln5 was successfully crystallized in two different variants. XRD
experiments were conducted on multiple crystals and structure solution was possible
from crystals with the intrinsic anomalous scatterer selenium. The crystal structure of
cln5 was measured to an average resolution for protein crystals. The structure gave vital
insights into structural relationships not discovered until now.
The cln5 crystal structure shows three folds, the largest one of which can be found in
a similar configuration in the protein PPPDE1. This relationship could not be discovered
by bioinformatic analysis. PPPDE1 was reported to have a deSUMOylating function and
a deubiquitinating function. The main structural fold of PPPDE1 is conserved within the
family of permuted papain-like NlpC/P60 enzymes. The motif of the permuted papain-like
fold is present in cln5 and reveals the structural relationship of cln5 to the PPPDE family.
The conserved reactive center of PPPDE1, consisting of a cysteine, a histidine, and a
tyrosine residue, is present in cln5. This suggest that a putative catalytic site is present
in cln5 as well. The reactive center is typical for cysteine peptidases with a papain-like
fold. Most cysteine peptidases are active at acidic pH, as it can be found in the animal
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lysosome were cln5 is located.
So far only one of the folds in the structure of cln5 could be associated with known
folds. In the future it might be possible to find a structural relationship for the other part
of the protein as well.
With a lack of mechanism-based therapies, the study of the protein structure can
give insights into the function of cln5 and offer prospects for further therapies. A more
fundamental understanding of the molecular mechanism and interactions is desirable.
As only part of the secondary structure of cln5 could be identified as a known fold, it is
reasonable that cln5 may display other functions as well. An additional function remains
elusive and further studies have to be conducted. Due to the structural similarity to the
permuted papain-like NlpC/P60 enzymes, activity studies with their substrates should
be considered. Studies to reveal a possible cysteine peptidase activity of cln5 might be
sensible. It is essential to further establish biochemically the proposed function of cln5
based on the structure.
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A. Appendix Poly(rA)
A.1. Single crystal data
All X-ray diffraction (XRD) measurements of Poly(rA) crystals are listed in the tables
in this chapter. Overall 37 scans were collected from seven crystals at three different
beamlines. The data is presented in the order of measurement number (#) and not by
crystal name. At first, the three crystals measured at the DESY synchrotron PetraIII
PX11 undulator beamline are listed. Next, all crystals and their scans measured at the
SLS synchrotron beamlines are given. Here crystals were measured at the undulator
beamlines PXII X10SA and PXI X06SA. The measurements are listed in this order.
Furthermore all data in this chapter is presented ordered by measurement number, from
1 to 37.
In Table A.1 addition information of the data collection are presented. An overview
of different data quality indicators for each scan is given in Table A.2. The calculation
of the data quality indicators was performed by PHENIX_xtriage. During the course of
the investigation, data quality indicators were also collected from the programs XDS,
XSCALE, and XPREP.
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Table A.1.: Overview of the data collection from Poly(rA) crystals.
# crystal scan beamline rotation slicing exposure transmission No of
[◦] [◦] [sec] [%] frames
1 A1 1 P11 90 0.2 0.1 1 450
2 2 P11 180 0.2 0.1 1 900
3 3 P11 180 0.2 0.1 1 900
4 4 P11 180 0.2 0.1 90 900
5 5 P11 180 0.2 0.1 1 900
6 A3 1 P11 180 0.2 0.1 2 900
7 2 P11 180 0.2 0.1 20 900
8 3 P11 180 0.2 0.1 50 900
9 A4 1 P11 180 0.2 0.1 5 900
10 2 P11 180 0.2 0.1 5 900
11 3 P11 180 0.2 0.1 5 900
12 4 P11 180 0.2 0.1 5 900
13 5 P11 180 0.2 0.1 50 900
14 6 P11 180 0.2 0.1 20 900
15 B3 1 X10SA 360 0.1 0.1 20 3 600
16 2 X10SA 180 0.1 0.1 10 1 800
17 3 X10SA 180 0.1 0.1 70 1 800
18 B4 1 X10SA 180 0.1 0.1 25 1 800
19 2 X10SA 180 0.1 0.1 50 1 800
20 3 X10SA 180 0.1 0.1 80 1 800
21 C3 1 X10SA 180 0.1 0.1 15 1 800
22 2 X10SA 360 0.1 0.1 15 3 600
23 3 X10SA 180 0.1 0.1 40 1 800
24 4 X10SA 180 0.1 0.1 50 1 800
25 5 X10SA 180 0.1 0.1 75 1 800
26 6 X10SA 180 0.1 0.1 90 1 800
27 C2 1 X10SA 180 0.1 0.1 10 1 800
28 2 X10SA 360 0.1 0.1 50 3 600
29 3 X10SA 180 0.1 0.1 30 1 800
30 4 X06SA 180 0.1 0.1 20 1 800
31 5 X06SA 180 0.1 0.1 50 1 800
32 6 X06SA 180 0.1 0.1 90 1 800
33 C1 1 X06SA 180 0.1 0.1 20 1 800
34 2 X06SA 180 0.1 0.04 50 1 800
35 3 X06SA 180 0.1 0.1 50 1 800
36 4 X06SA 180 0.1 0.05 90 1 800
37 5 X06SA 180 0.1 0.1 90 1 800
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Table A.2.: Data Quality for each scan from the Poly(rA) measurements. Data quality
indicators calculated by PHENIX_xtriage.
# completeness redundancy mean I/σ(I) Rmeas Rpim Wilson B
[%] [Å2]
1 99.69 11.3 4.2 0.227 0.067 5.81
2 82.90 9.6 11.8 0.088 0.027 6.56
3 90.64 9.9 6.1 0.132 0.040 7.00
4 92.17 10.1 7.0 0.126 0.038 7.41
5 83.32 9.5 8.4 0.114 0.035 7.57
6 76.74 10.4 20.0 0.057 0.017 5.89
7 94.11 10.6 10.9 0.085 0.025 6.06
8 85.84 10.3 13.0 0.079 0.024 6.02
9 99.69 11.3 4.2 0.227 0.067 5.81
10 82.90 9.6 11.8 0.088 0.027 6.56
11 90.64 9.9 6.1 0.132 0.040 7.00
12 92.17 10.1 7.0 0.126 0.038 7.41
13 81.88 7.7 9.5 0.076 0.025 8.59
14 83.38 10.0 6.7 0.092 0.029 11.78
15 97.12 21.8 21.8 0.059 0.012 6.09
16 96.49 10.9 16.3 0.090 0.027 5.73
17 97.89 11.4 15.0 0.085 0.025 6.05
18 98.88 10.9 12.1 0.073 0.022 5.86
19 96.65 10.6 12.1 0.099 0.029 6.77
20 98.41 11.3 16.2 0.062 0.018 5.35
21 99.41 12.3 12.9 0.12 0.034 5.71
22 94.31 22.4 36.5 0.051 0.011 6.40
23 99.14 12.4 19.1 0.072 0.02 5.63
24 97.74 12.4 14.1 0.086 0.024 5.97
25 99.51 12.3 27.2 0.049 0.014 6.07
26 99.24 12.3 22.7 0.056 0.016 6.74
27 95.76 11.1 24.1 0.051 0.015 6.13
28 99.26 23.9 33.1 0.045 0.009 5.91
29 99.6 12.2 29.4 0.02 0.012 6.05
30 94.75 9.2 33.5 0.031 0.01 10.07
31 99.87 11.8 21.7 0.046 0.014 9.07
32 99.88 11.8 29.9 0.037 0.011 8.43
33 94.66 9.2 24.2 0.048 0.015 7.30
34 99.92 11.5 21.2 0.056 0.016 6.25
35 99.90 11.4 23.900 0.046 0.014 6.73
36 99.95 11.7 23.1 0.051 0.015 6.55
37 99.84 11.4 25.7 0.040 0.012 4.57
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A.1.1. Radiation damage
The possible change in the size of the unit cell due to radiation damage is evaluated for
cell axis a in Figure A.1.
Figure A.1.: Change of unit cell axis a in consecutive measurements.
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A.1.2. Overload correction
The influence of the overload correction on the parameter Ranom calculated by XPREP
is plotted against the data set number (#) in Figure A.2.
Figure A.2.: Detector parameter overload correction and it’s influence on Ranom.
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A.1.3. Absorption correction
The influence of the absorption correction employed during data reduction in XDS is
evaluated. The values with absorption correction and without for the quality indicators
ISa, CCanom, and d”/σ(d”) are listed in Table A.3. All quality indicators were calculated
with XDS. The values for CCanom and d”/σ(d”) are given for a specific resolution. The
values for ISa with and without absorption correction are plotted against the data set
number (#) in Figure A.3.
Figure A.3.: Influence of the strict absorption correction on CCanom during data reduction with XDS.
142
A.1. SINGLE CRYSTAL DATA
Table A.3.: Influence of absorption correction during data reduction on data
quality. The values for CCanom and d”/σ(d”) are given for a specific
resolution for each data set (#).
# ISa resolution CCanom d”/σ(d”)
without with [Å] without with without with
1 36.27 35.18 2.57 13 19 0.977 1.099
2 28.4 26.22 2.09 11 16 1.007 1.099
3 26.61 26.86 2.32 10 18 1.08 1.167
4 14.89 15.22 2.32 21 30 0.908 0.948
5 29.97 29.5 2.55 3 10 0.93 1.034
6 27.05 25.88 2.51 9 13 0.87 0.914
7 15.35 15.73 2.25 15 16 0.811 0.806
8 17.95 17.27 2.1 12 16 0.863 0.888
9 13.29 13.12 2.14 7 13 0.937 1.014
10 16.98 15.32 2.52 2 0 0.901 0.9
11 16.34 16.84 2.09 11 12 0.998 1.025
12 19.03 17.1 2.27 12 12 0.962 1.001
13 14.88 15.17 2.28 27 22 0.943 0.959
14 21.05 22.16 2.84 27 29 1.059 0.971
15 21.3 20.73 2.18 18 17 1.007 1.029
16 12.17 12.16 3.41 16 11 1.076 1.026
17 10.91 11.06 2.46 19 22 1.123 1.142
18 14.93 14.58 2.1 24 25 1.041 1.076
19 20.3 20.33 3.41 0 3 0.93 0.954
20 17.96 17.78 2.19 13 15 0.949 0.984
21 37.02 36.21 2.69 8 7 0.944 0.977
22 43.32 43.52 3.44 4 15 0.883 0.901
23 38.88 38.65 2.4 13 17 1.044 1.049
24 35.26 35.49 2.51 5 15 0.941 1.036
25 38.17 36.69 2.4 24 28 0.96 1.035
26 35.62 34.49 2.4 20 26 1.009 1.053
27 56.22 56 3.1 18 19 0.929 0.946
28 44.15 40.88 2.2 31 33 1.108 1.142
29 48.64 45.76 2.09 19 26 1.015 1.048
30 42.8 38.94 3.73 28 14 0.915 0.915
31 41.5 36.18 2.37 27 33 1.034 1.203
32 33.98 30.08 2.37 24 28 0.93 0.999
33 21.59 19.43 3.76 10 1 0.786 0.879
34 21.74 20.23 2.33 14 14 0.944 0.959
35 25.7 24.34 2.33 27 30 0.992 1.041
36 22.09 20.85 2.37 11 19 0.927 0.997
37 27.86 25.47 2.33 40 38 0.998 1.07 143
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A.1.4. Correlation of quality indicators
The correlation between the quality indicators Isa (XDS) and I /σ(I) with the anomalous
signal specific indicator Ranom is evaluated. Furthermore their significance for the result-
ing averaged anomalous density at the positions of the phosphor atoms is discussed.
In this section an overview of the indicators for all data sets is presented in Table A.4.
A possible correlation is visualized in the Figures A.4, A.5, A.6, and A.7 by plotting the
quality indicators against one another.
Figure A.4.: The mean I/σ(I) is plotted against the Ranom. The mean I/σ(I) was calculated for each data set
by XPREP and the Ranom was calculated by Phenix_xtriage.
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Table A.4.: Data quality for each scan from the Poly(rA) data sets (#).
Data quality indicators are compared for correlation.
# Isa mean I/σ(I) Ranom averaged anomalous
(XDS) (XPREP) (PHENIX) density (ANODE)
1 35.18 1.47 0.0975 1.37
2 26.22 4.65 0.0555 2.88
3 26.86 2.86 0.067 2.45
4 15.22 2.68 0.0634 2.39
5 30.38 3.25 0.061 2.35
6 25.97 7.3 0.0379 3.74
7 15.73 3.93 0.0433 3.79
8 17.27 4.76 0.0409 3.86
9 13.12 1.52 0.0894 1.55
10 15.32 4.65 0.0555 2.17
11 16.48 2.32 0.0616 2.07
12 17.1 2.68 0.0634 1.95
13 15.27 3.25 0.061 1.72
14 22.16 2.56 0.0401 2.1
15 20.73 3.67 0.101 0
16 12.16 5.34 0.0637 1.95
17 11.06 4.74 0.0558 1.65
18 14.64 4.26 0.0439 2.68
19 20.33 4.34 0.0683 1.51
20 17.78 5.55 0.0365 3.46
21 36.21 3.9 0.0646 1.59
22 43.51 7.81 0.0266 3.73
23 39.46 5.89 0.0403 2.74
24 35.49 4.42 0.0464 2.89
25 38.37 8.54 0.0274 4.06
26 35.33 7.19 0.0299 3.54
27 56.26 8.05 0.0374 2.88
28 41.27 7.75 0.0192 6.32
29 47.52 9.11 0.0266 4.29
30 38.94 13.12 0.0232 4.56
31 36.18 7 0.0309 4.8
32 30.08 9.65 0.0218 6.08
33 19.43 9.48 0.0335 3.14
34 20.23 7.01 0.0368 4.33
35 24.34 7.99 0.0268 5.51
36 20.85 7.58 0.0295 4.85
37 25.47 8.6 0.0253 5.97
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Figure A.5.: Ranom is plotted against the averaged anomalous density. The Ranom was calculated for each
data set by PHENIX_xtriage and the averaged anomalous density of the phosphorus atom
positions was calculated by ANODE.
Figure A.6.: The mean I/σ(I) is plotted against the limit of the asymptotic signal-to-noise ratio (ISa). The
mean I/σ(I) was calculated for each data set by XPREP and the ISa was calculated by XDS.
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Figure A.7.: The Ranom is plotted against the limit of the asymptotic signal-to-noise ratio (ISa). The Ranom
was calculated for each data set by Phenix_xtriage and the ISa was calculated by XDS.
A.1.5. Averaging statistics
The programs XRPEP, XSCALE, and PHENIX_scale_and_merge were used to prepare
averaged data set combinations of varying content. Data sets for averaging were
selected by various criteria. The resulting averaged combined files were analyzed for
the strength of the anomalous signal. For this purpose the averaged anomalous density
of the selenium atoms was calculated. The results are listed in Table A.5.
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Table A.5.: For selected merged data sets the average anoma-
lous density calculated by ANODE is listed. The
data sets were merged with the programs XPREP,
XSCALE or PHENIX_scale_and_merge.
data seta XPREP XSCALE PHENIX
crystal-A1 3.24 3.12 3.49
crystal-A3 5.29 5.43 5.65
crystal-A4 3.32 3.15 4.01
crystal-B3 5.37 5.24 5.04
crystal-B4 4.34 4.27 4.37
crystal-C3 5.62 5.64 5.92
crystal-C2 5.44 7.69 8.68
crystal-C1 7.64 7.75 7.98
PetraIII-P11 3.18 3.38 5.78
SLS2015-PX10 6.31 6.32 6.37
SLS2016-PX10 7.57 7.38 8.36
SLS2016-PX06SA 6.02 7.04 9.49
All SLS 9.03 9.09 10.23
Best5MeanIs 5.55 6.15 8.53
Best10MeanIs 7.93 8.60 9.68
Best15MeanIs 8.63 9.41 10.46
Best20MeanIs 9.21 9.48 10.62
Best25MeanIs 8.91 8.88 10.70
All37 8.09 8.88 10.61
a The single data sets are merged by crystal (crystal-A1–
C1), by beamline (PetraIII or SLS), or by the highest mean
I/σ(I) value (Best5MeanIs–Best25MeanIs). The averaged
data sets contain from 3–37 single data sets.
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B.1. PDB file format
The protein database (PDB) consists of record types, which can be divided into ten
sections.
• title section
• primary structure section
• heterogen section
• secondary structure section
• connectivity annotation section
• miscellaneous features section
• crystallographic and coordinate transformation section
• coordinate section
• connectivity section
• bookkeeping section
Record entries can be mandatory or optional and have to appear in a specific order.
Mandatory records, by record type, are listed and have to appear in a defined order. All
mandatory record types are listed in Table B.1 with a short description.
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Table B.1.: Keywords used in the pdb file format as defined and described in the PDB format guide.
record type descriptiona
HEADER first line in file, contains PDB ID code, classification and date of deposi-
tion.
TITLE description of the experiment.
COMPND description of macromolecular contents.
SOURCE biological source of the macromolecule.
KEYWDS list of keywords describing the macromolecule.
EXPDTA experimental technique used for structure determination.
AUTHOR list of contributors.
REVDAT revision data and related information.
REMARK general remarks, subdivided by number.
SEQRES primary sequence of backbone residues.
CRYST1 unit cell parameters, space group, and Z.
ORIGXn (n = 1, 2, or 3) transformation from the orthogonal coordinates to the
submitted coordinates.
SCALEn (n = 1, 2, or 3) transformation from orthogonal to fractional coordinates.
MASTER control record for book keeping.
END last record in file.
a http://www.wwpdb.org/documentation/file-format-content/format32/v3.2.html, Worldwide Protein Data
Bank Foundation, Piscataway, USA.
B.2. PDB test results
A total of 23974 data sets from the PDB were used to identify issues with the data
conversion program PDB2INS or SHELXL. Of this test collection, 964 data sets resulted
in an issue and did not finish a refinement with SHELXL when used in an automated
fashion. Of all issues tables characterizing the issue are presented, based on rate
of occurrence (Table B.2 and B.3). In the description a short form of the keywords
appearing as error message are displayed in bold font. For most problems a work
around is available while using PDB2INS in the interactive mode or by manual editing.
Some issues require special attention.
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Table B.2.: Overview of issues reported while using PDB2INS, sorted by frequency. The error keyword is
given in bold font.
%E %T description
10.37 0.42 no structure factor found The inquiry file -sf.cif did not contain a
complete set of reflection keywords. PDB2INS only converts a reflection
file if a keyword set is complete. Accepted keyword sets are listed in
Table 3.2.
4.67 0.19 model error It is legal to deposit more than one model in one pdb file.
PDB2INS cannot handle those files and will terminate without writing
a new file. Removing all but one model from the input file will enable
PDB2INS to convert the file.
1.36 0.05 Syntax error A numerical parameter contains a non-digit character. This
can occur in structure factor files when a reflection or standard deviation
contains e.g. a question mark.
1.24 0.05 Illegal atom name For all atoms in natural amino acids a specific nam-
ing scheme is standard (Markley et al., 1998). When one or more
atoms are not named correctly, the program will write a warning and will
mention the problematic residue.
1.14 0.05 residue renumbering PDB2INS is capable of renumbering residues
when an insertion code is used. This is necessary since no specific
method of handling insertion codes is available. When this renumbering
is affected by complications, the residue that could not be renumbered
is included in the error message.
0.93 0.04 other
%E percent in error.
%T percent in all test sets.
Both programs, PDB2INS and SHELXL, give extensive error messages and display
the problematic section of the file. Following these hints and instructions nearly all issues
can be solved with little time and effort.
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Table B.3.: Overview of issues reported while using SHELXL, sorted by frequency. The error keyword is given
in bold font.
%E %T description
31.74 1.28 bad resi SHELXL terminated without refinement when one of the
residues has a residue name containing only digits. This is allowed
in pdb files. PDB2INS will prompt the user to change this residue
names when run in interactive mode. However, in an automated mode,
PDB2INS only writes a warning but continues without renaming.
22.41 0.90 reflection format One reflection does not adhere to the hkl format as
specified in section 3.3.2.
11.20 0.45 wrong element The pdb file contains an element name in the SFAC
instruction line that does not correspond to the first 98 elements of the
periodic table. Most commonly, one of the elements is specified as ’X’,
an unknown element, which does not correspond to any structure factors
in SHELXL.
10.68 0.43 wrong restraint One or more atoms do not have the appropriate re-
straints specifying them. The user can check if the mentioned residues
are named correctly.
5.30 0.20 other
%E percent in error.
%T percent in all test sets.
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C.1. Background
C.1.1. Pathogenesis of neuronal ceroid lipofuscinoses
Since the identification of the first genes causing neuronal ceroid lipofuscinoses (NCLs)
a great number of mutations have been identified. With large heterogeneity the encoded
proteins were identified as soluble lysosomal proteins and putative transmembrane
proteins, nonetheless NCLs demonstrate a consistent morphological phenotype.
In spite of their genetic heterogeneity the NCLs share two archetypal features:
1. the accumulation of auto-fluorescent, electron dense material, containing sph-
ingolipid activator proteins (ssaposins) A and D or subunit c of mitochondrial
adenosine triphosphate synthase (ATPase), in the lysosomes of nerve cells and
even many other cell types.
2. mental, motor, and visual problems caused by selective and progressive loss of
neurons.
The neuronal and extra-neuronal pigment accumulations in NCLs are found in the
lysosomes, the diseases are considered lysosomal storage disease (LSD). While many
of the NCL proteins are present in the lysosomes, the NCLs display characteristics
not typical for LSD (Mink, 2010) as cited in (Nita et al., 2016). The periodic acid-Schiff
(PAS)- and Sudan black B-positive accumulated material is not disease specific and takes
different form when viewed under the electron microscope. Granular osmiophilic deposits
(GROD), rectilinear complex (RLC), fingerprint profiles (FPP), as well as curvilinear
profiles (CLP) or ’condensed forms’ have been reported.
In almost all cases the disease is inherited in a recessive manner when mutations
are present on both gene alleles. Exceptions occur in adult-onset NCL via CLN4 gene
mutations, were a dominant inheritance is described (Nosková et al., 2011), and in a
patient with complete isodisomy of chromosome 8 giving rise to homozygosity of deletion
in CLN8 (Vantaggiato et al., 2009).
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C.1.2. Pathogenesis of cln5
Earliest cases were almost exclusively found in Finland, giving rise to the name Finnish
variant late infantile NCL (vLINCLFin) disease next to variant Janský-Bielschowsky
disease. Beginning with slight motor mis-coordination and muscular hypotonia, the
typical age of onset is 3 to 7 years for late infantile phenotype CLN5 in patients with
CLN5 ’Fin major’ (Santavuori et al., 1991, Xin et al., 2010). To this day, there have been
reports of an age of onset as early as 18 months and as late as 17 years, the later is
classified as adult disease (Xin et al., 2010). Most patients present at first with motor
impairment or regression while, with some patients, visual loss or seizures were the
first presenting symptom (Xin et al., 2010). In 2017, a study reported a high number of
patients with language decline as presenting symptom in line with decline of cognitive
abilities (Simonati et al., 2017).
Within 1-9 years of first clinical presentation the patients developed seizures, visual
loss, motor difficulty, and cognitive regression. The disease shows rapid progression
of symptoms in patients with CLN5 ’Fin major’ between the ages of 9 to 11 years. Also
behavior disturbances were reported, such as hyperactivity, aggression, intolerance
and motor stereotypes as early features in child patients (Simonati et al., 2017). With
disease progression anxiety, obsessive activities, hallucinations, and autistic features
were observed.
Early symptoms are followed by impaired concentration, learning problems and mental
retardation (Haltia, 2003). Onset of epileptic seizures in patients manifest by 7 to 8 years
of age, followed by myoclonia. Some patients reported optical illusions that may be
caused by seizures but are difficult to differentiate from symptoms related to declining
vision. Visual deficiency can be apparent from the beginning of the disease and macular
dystrophy can be found in an early stage. Progressive optic atrophy with functional
blindness is found after the age of 7 to 9 years (Haltia, 2003).
While cognitive decline is an early sign, it also progresses rapidly (Santavuori et al.,
1991). Patients loose their ability to walk and become bedridden by the age of 9 to
13 years (Haltia, 2003, Simonati et al., 2017). Later, spastic contractures develop and
speech impairment leads to the inability to produce speech by the age of 11 years. Better
retained is the understanding of speech, which is preserved with some patients till the
age of 14 or 15 years (Mole et al., 2012).
Feeding difficulties appear at the age of 9 to 13 years and can lead to weight loss
due to swallowing difficulties and slow eating when the disease progresses (Mole et al.,
2012). The disease leads to premature death between 12 to 23 years and shows a delay
of at least 6 to 8 years with adult onset between early and subsequent major symptoms
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(Haltia, 2003).
The phenotype classification should be used with caution, since publications differ
in the definition of ’late infantile’ and ’juvenile’ when referring to the age of onset. The
mutation database1 adheres to the following age classification: infantile from 6 to 18
month, late infantile from 2 to 4 years, juvenile from 5 to 10 years and adult afterwards.
There are some publications classifying patients up to the age of 3, 4 or 5 as late-
infantile, the early nomenclature as variant late infantile NCL is reminiscent of this. Other
publications do not use the age of onset when describing the phenotype, a patient with
cln5.014 mutation and age of onset of 3 years is still classified as the juvenile NCL
phenotype (Kousi et al., 2012, Xin et al., 2010). Conflicting is the listing of a patient
described with an age of onset of 5 years and listed as late infantile phenotype in the
mutation database but referred to as juvenile NCL by Kousi et al. (2012).
C.1.3. Clinical features of CLN5
Magnetic resonance imaging (MRI) displays abnormalities at time of diagnosis and
reveals severe cerebellar atrophy. Brain imaging studies revealed pronounced atrophy
of the cerebellum and more generalized effects upon the cortical mantle (Haltia, 2003,
Savukoski et al., 1998). T2-weighted images show a low thalamic signal intensity when
compared to caudate nuclei signal. Also, an increased signal intensity is observed in
periventricular white matter and posterior limbs of internal capsules.
Electroretinogram (ERG) presents abnormalities at an early stage of disease and is
abolished by 8 to 9.5 years (Lebrun et al., 2009). Giant visual evoked potentials (VEPs)
can be seen 8 – 9.5 years and the macula becomes sharply outlined.
Electroencephalogram (EEG) displays posterior spikes to low frequency photic stimu-
lation in patients between 7 to 13 years of age (Holmberg et al., 2000). Giant somatosen-
sory evoked potentials (SEPs) were reported by the age of 7.5 to 9.5 years and often
reported in patients with myoclonus (Berkovic et al., 1991).
C.2. Protein purification
The chromatogram of the purification of cln5 with Ni affinity chromatography is given
in Figure C.1. The step-wise gradient is depicted as green line and the UV absorption
spectra of the protein at 280 nm and 254 nm are given as blue and red line, respectively.
During eluation, two peaks were obtained and pooled separately.
1http://www.ucl.ac.uk/ncl/mutation.shtml, hosted by the MRC Laboratory for Molecular Cell Biology,
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Figure C.1.: Chromatogram of cln5 purification via Ni affinity chromatography. The UV absorption at
wavelength 280 nm and 254 nm is depicted.
Figure C.2.: SDS-PAGE gels depicting cln5 native protein (left), cln5-kifunensine (middle), and cln5-
kifunense-SeMet (right).
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Figure C.3.: SDS-PAGE gel depicting deglycosylation of cln5 with EndoH. cln5 kifunensine protein (right)
and treated with EndoH (left).
C.3. Interaction Studies
Table C.1.: Measurement of CTSD activity at different pH levels.
activity [nmol g-1 h-1] inactive pH 3.0 pH 4.5
10 ng 419.1 3078.5 2700.4
ratio 1 0.88
10 ng 23097 195550 154410
ratio 1 0.79
10 ng 23097 195550 166301
ratio 1 0.85
University College London, Gower Street, London. WC1E 6BT. United Kingdom.
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C.4. Circular dichroism
The circular dichroism spectra obtained from the different peaks (see Section C.2) is
depicted in Figure C.4.
Figure C.4.: Circular dichroism spectra calculated from circular dichroism of cln5 protein at 0.1 µg/mL
concentration. The two peaks obtained from Ni affinity chromatography are compared.
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C.5. Data collection
the results of the on-beamline fluorescence scan is depicted in Figure C.5.
Figure C.5.: On-beamline fluorescence scan to verify the presence of significant selenium signal. The
region of interest is marked.
Various resolution limits used to define the cutoff during data integration are presented
for the scans of cln5k-Se crystals in Table C.4.
Table C.4.: Approximate resolution limits according to various commonly used criteria.
resolution [Å] c8-1 c8-2 c8-3 c8-4 c11-1 c11-2 c11-3 c11-4 merged
Rmeas≤80% 2.70 2.78 2.98 2.82 3.19 3.12 3.26 3.35 3.25
mean I/σ(I)≥2.0 2.79 2.90 3.00 2.68 3.37 3.18 3.25 3.13 2.64
CC1/2 ≥30% <2.50 2.58 2.75 2.38 3.04 2.87 <2.92 2.84 <2.50
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C.6. Data merging and refinement
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Figure C.6.: Value of CCcumulative at 6.00 Å for various combinations of cln5Se data collected from two
crystals. The value at highest resolution should give a good indicator of the quality of the
merged file. All values above 0.5 are considered a good match.
Table C.5.: Refinement of the occupancy of the selenium/sulfur sides by step-wise addition of
refined residues in SHELXL. The occupancy for the selenium containing residues
is listed per refinement cycle. No number was given for residues with an occupancy
of one that was not refined.
occupancy [%] MET residue number
cycle 202 383 135 165 240 182 244
1 73.37
2 79.43 96.12
3 78.73 95.93 106.5
4 79.41 100.5 - 98.22
5 97.38 - - 91.83 68.01 89.01
6 107.4 - - 89.00 65.00 95.09 89.36
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C.7. Structure
Figure C.7.: Topology diagram of the cln5 structure (from PDBsum (Laskowski, 2001)).
The average B-factor of the structure is 57 Å2. Some regions of the structure have a
significantly higher B-factor. A B-factor of 79 Å2 corresponds to a thermal displacement
of around 1 Å but a high value can also indicate disorder. The B-factor of the main chain
is displayed in Figure C.8.
163
APPENDIX C. APPENDIX CLN5
Figure C.8.: The main chain of cln5 is colored by B-factor from blue (40 Å2) to red (80 Å2).
C.7.1. Sugar modifications
The following diagrams (Figure C.9) of the sugar modification have been created with
the web service PDBsum2 (Laskowski, 2001). The nearest residues for the sugar
modifications at Asn179 (C.9a), Asn192 (C.9b), Asn252 (C.9c), and Asn179 (C.9d) are
depicted.
2http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=index.html.
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(a) Sugar modification NAG501 at Asn179.
(b) Sugar modification NAG601 at Asn192.
(c) Sugar modification NAG701 at Asn252.
(d) Sugar modification NAG801 at Asn304.
Figure C.9.: An overview of the sugar modifications in the structure of cln5 and their surrounding residues,
generated with PDBsum LigPlot (Laskowski, 2001).
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(a) Model 1 predicted from the full cln5 sequence (amino
acids 1–407).
(b) Model 2 predicted from the full cln5 sequence (amino
acids 1–407).
(c) Model 3 predicted from the shortened cln5 sequence
(amino acids 49–407).
(d) Model 4 predicted from the shortened cln5 sequence
(amino acids 93–407).
Figure C.10.: RaptorX predictions of cln5 protein structure calculated from different sequence ranges. The
secondary structure elements are highlighted.
C.8. Structure prediction
C.8.1. Structure prediction methods
Huber and Mathavarajah (2018) reported an analysis of the predicted secondary struc-
ture of cln5 with amino acids 49 to 407, the ’pre-processed form’ of cln53. Based on
this work the RaptorX server was used here on the full sequence (407 amino acids), the
shortened sequence used by Huber and Mathavarajah (2018) (amino acids 49–407) and
the even shorter mature protein reported by Jules et al. (2017) (amino acids 93–407).
The secondary structure predictions obtained from the RaptorX web server in this work
were visually evaluated and compared to the published prediction (see Figures 4.2 and
C.10). None of the various predictions showed a visual match to the published prediction
of the secondary structure.
3UniProt accession number O75503.
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The calculated models displayed an unordered secondary structure for the larger part
of the protein sequence. For the remaining part mostly a mixture of short α helices
and small antiparallel β sheets was predicted. This stands in contrast to the results
reported before (Huber and Mathavarajah, 2018). A search for binding pockets was not
successful with the calculated models.
The secondary structure prediction tool based on the sequence, HHPred was em-
ployed with the full sequence of cln54. HHPred reported the first match PPPDE2
(2wq7_A) with an identity of 15% and a similarity of 0.113 giving a sum probability of
53.4 (see Table C.6). The second hit Lmo2511 protein (3k2t_A) was calculated with
an identity of 19% and a similarity of 0.425 leading to a sum probability of 21.3. These
probability scores are far below the recommended 95% for a nearly certain homology.
The E-value, as a measure of statistical significance, evaluates how many chance hits in
the database better than the present one could be obtained. Only a match with a high
probability and an E-value below one should be considered, therefore the results were
categorized as not significant.
Table C.6.: Statistics for the homology based secondary structure prediction reported by HHPred (Soding
et al., 2005).
PDB-ID Prob E-value P-value Score SS Aligned Query Template
Cols HMM
2wq7_A 53.4 84 0.0015 28.2 6.7 115 50-208 3-119 (168)
3k2t_A 21.3 0.022 0.0039 21.3 3.1 26 263-293 11-36 (57)
I-Tasser generates secondary and tertiary structure models based on the calculated
alignments5. The models generated on the template alignment matches to cln5 are
displayed in Figure C.11. The quality of the prediction is measured by a confidence
score (C-score) ranging from -5 to 2, with higher values signifying a model with a high
confidence. The template modeling (TM) score is a scale of measure for the similarity
between two structures and a TM-score of ≥ 0.5 indicates a model of correct topology.
All obtained models displayed a low confidence score and a low score on parameters
describing the accuracy of the modeling. These results were not considered further.
Results obtained from SWISS-MODEL are depicted in Figure C.12 (Waterhouse et al.,
2018).
4The search was conducted on the 28th November 2017.
5The search was conducted on 24th January 2016.
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(a) Model 1, C-score -4.56. (b) Model 2, C-score -3.70.
(c) Model 3, C-score -4.20. (d) Model 4, C-score -4.02.
Figure C.11.: Models based on the secondary structure prediction by I-TASSER. The TM score for the first
model was reported as 0.24.
C.9. Structure similarity
C.9.1. Three dimensional structural overlay of cln5 with NlpC/P60
superfamily proteins
Additional structural overlays based on the structure similarity are depicted in this section.
Figure C.13 shows the structural overlay of cln5 with selected proteins of the NlpC/P60
super family.
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Figure C.12.: Secondary structure prediction by SWISS-MODEL. Only for part of the sequence was a target
found and a secondary structure predicted.
(a) Overlay of cln5 and BcPPNE (ekw0). (b) Overlay of cln5 and Yiix (2if6).
(c) Overlay of cln5 and BcYkfC (3h41). (d) Overlay of cln5 and BcYkfC (3h41).
Figure C.13.: Conserved secondary structure across NlpC/P60 superfamily: similarity as calculated by
PDBeFold is marked. cln5 in dark gray/red/green, PPNE protein in light grey/light red/light
green. PDB codes are given in parantheses.
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C.10. Graphics Software
Table C.7.: Graphics software used for processing and picture generation.
software usage distributor /reference
ChemDraw 2D molecule figures PerkinElmer, Waltham, USA.
Coot molecule visualization (Emsley et al., 2010).
GIMP graphic editing The GIMP Team, https://www.gimp.org/.
HKL2MAP quality indicator plots
(SHELXC/D/E)
(Pape and Schneider, 2004).
ImageJ SDS-gel and western
blot analysis
MRC Laboratory of Molecular Biology, Cam-
bridge, England and University of York, York,
England.
Inkscape topology diagrams The Inkscape Project, https://inkscape.org.
Origin plots from data OriginLab, Northampton, USA.
PyMol molecule rendering DeLano Scientific LLC, Schrödinger , Cam-
bridge, USA.
Xprep quality indicator plots Bruker AXS, Madison, USA.
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